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Abstract 
Nearly all humans experience acute pain during their lives.  Generally, acute pain is short lived, 
however, up to 20% of adults globally suffer from persistent pain. This prevalence increases with 
age with up to 50% of elderly people in the community setting and 80% in aged care facilities 
(ACFs) experiencing persistent pain.  Pain, whether acute or persistent can create a significant 
burden and cost to the patient and society as a whole, through reduced work productivity and 
health care costs.  
In the financial year ending June 2014 analgesics (excluding anti-inflammatories) were the fifth 
most commonly dispensed class of drug on the Pharmaceutical Benefits Scheme (PBS) in 
Australia.  Six of the top 50 medications on the PBS, by volume, were analgesics or anti-
inflammatories.  The most frequently dispensed analgesics were paracetamol (with over 6.4 
million prescription), followed by paracetamol and codeine (with approximately 3.8 million 
prescriptions) and then oxycodone (with approximately 3.7 million prescriptions). These figures 
parallel research findings in Australia and other countries that have found that the consumption 
of analgesics, particularly opioids, for persistent pain has increased dramatically over the past 
decades, as a consequence of significant societal reliance on the pharmacological management of 
pain. 
With pain being so prevalent in today’s society, evaluating the way in which pain is managed 
pharmacologically, as well as identifying quality use of medicine (QUM) issues related to its 
management is paramount to ensure optimal patient outcomes. In addition, increased research 
activity in pain management has been recommended by the National Pain Strategy [Australia] 
and the Royal Australasian College of Physician’s Opioid Policy, with a focus on assessing 
attitudes to pain, risk factors for persistent pain conditions and reducing the harms associated 
with pain management, particularly opioids.   
The overarching aim of this thesis was to identify barriers to pain management and make 
recommendations as to how these could be overcome.  Specifically, the research objectives were 
to:  
 Observe how pain is managed pharmacologically in Australian clinical practice;
 Identify predictors for persistent postoperative pain (PPP);
 Identify QUM issues related to the management of pain; and
 Identify barriers to pain management.
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These research objectives were investigated through a number of complementary papers, which 
are described in Chapters Three to Ten.  This thesis initially describes the current literature 
surrounding the pathophysiology and management of pain, and then goes on to detail the eight 
studies completed as part of this thesis, which investigate the clinical management of pain and 
how pain management could be improved.  The thesis concludes with a discussion about the main 
areas where QUM issues exist in relation to the management of pain and how these issues and 
barriers could be overcome.   
 
The study presented in Chapter Three evaluates nearly 170 patients who underwent an operation 
at the Royal Hobart Hospital (RHH), the major teaching hospital in Southern Tasmania, and 
discusses the management of pain by patients following discharge from hospital, and the 
provision of advice regarding pain management provided during their admission. This study 
found that management of pain by patients was often characterised by underuse of analgesics 
despite a significant proportion of patients experiencing moderate-severe pain.  Additionally this 
study found that the content of the advice given to patients about pain management and 
consistency in personnel who provided this advice was highly variable. From this study, it is clear 
that there is the need for significant improvement in discharge counselling to ensure that patients 
have sufficient knowledge to safely and adequately self-manage their pain following a hospital 
separation. 
 
Chapters Four and Five follow patients who underwent orthopaedic surgery or a sternotomy at 
the RHH for a period of 12 months to evaluate how patients manage their pain throughout this 
post-surgical period, the effect the pain had on their physical function, the incidence of and 
potential predictors of PPP and ways to improve pain management.  These studies identified a 
number of patient factors associated with PPP, including pre-operative anxiety, pre-existing pain 
and younger age. Uncontrolled pain following discharge and symptoms consistent with 
neuropathic pain following discharge were also associated with PPP, and this is an area that could 
be addressed to potentially reduce PPP incidence and severity. 
 
Chapters Six and Seven retrospectively evaluated nearly 20,000 Australian patient medication 
reviews, to identify the prevalence of analgesic use, how analgesics were used in clinical practice 
and ways that pain management could be optimised. These studies found a lack of concordance 
between guideline recommendations and the management of pain; specifically maximum opioid 
doses being exceeded, concurrent use of opioids and benzodiazepines, low use of laxatives in 
combination with opioids and a failure to optimise use of non-opioid analgesics in patients 
prescribed opioids. 
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The final three studies report on the perspectives of general practitioners’ (GPs), anesthetists’ 
and nurses’ regarding enablers and barriers to optimal pain management and identify ways in 
which pain management could be improved. Through these complementary studies, a number of 
barriers to optimal pain management were identified, including:  
- Patient stoicism and reluctance to take analgesics;
- Inadequate understanding about pain and its management by patients and health care
practitioners;
- Poor and variable post-surgical discharge counselling and patient resources regarding
pain management;
- Poor access to pain clinics and allied health professionals;
- Slow hospital-GP communication following a surgical admission;
- A lack of involvement of pain specialists following surgery to manage pain;
- Difficulties in the identification of pain in patients with dementia in ACFs; and
- Poor GP-ACF communication regarding escalation of analgesic orders.
Based on this research a number of recommendations are suggested to improve the management 
of pain in Australia.  These include: 
- Increased education and training about pain and its management to undergraduate, graduate
and qualified health care practitioners working with patients who experience pain;
- Increased patient education regarding pain, analgesics and expectations of treatment;
- Improved involvement by pain specialists or the Acute Pain Service (APS) following a
surgical procedure and at discharge;
- Improved and consistent discharge counselling and post-discharge resources for patients
who have undergone a surgical procedure;
- Increased access for persistent pain patients to funded multidisciplinary services including
pain clinics, psychologists and physiotherapists; and
- Further research evaluating the effectiveness of the interventions suggested in this thesis,
including pharmacist education of patients in GP clinics, increased patient education on
surgical discharge, pain specific follow-up after surgery, and the development and validation
of a PPP assessment tool.
In summary, pain is currently not well managed in primary care settings by patients or GPs, and 
there is the need for improvement to optimise patient outcomes. Improved counselling, follow-
up and management of post-discharge pain have the potential to reduce the incidence of PPP, and 
at a minimum, improve the quality of life (QOL) and potential for patients to participate in 
rehabilitation following surgical discharge.  Additionally, improved GP concordance with 
xii 
guidelines and recommendations may allow for a reduction in harms associated with the use of 
opioids.  These small changes in practice have significant potential to improve patient outcomes 
and the management of pain in Australia without the need for substantial increases in funding or 
policy change.   
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Chapter 1: Introduction 
 
1.1 Background 
Pain is one of the most common reasons that patients present to a GP or seek medical assistance 
(1-3).  Nearly all persons in the world experience acute pain in their lifetime, with persistent pain 
(pain lasting for three months or more) (4) affecting nearly 20% of the world’s population (5-11). 
This prevalence increases with age, with up to 50% of elderly people living in the community and 
80% in aged care facilities (ACFs) experiencing persistent pain (12-17).   Pharmacological 
treatment strategies are relied upon predominantly, despite conflicting trial data and the lack of 
good quality evidence (18-20).   
 
It is difficult to generalise the international literature in relation to the patterns and quality of 
pain management to the Australian situation due to jurisdictional prescribing requirements and 
differences in the health care systems. Despite poor quality trial evidence supporting the use of 
opioid analgesics long-term, there has been a substantial increase in the utilisation of these 
products globally and in Australia (21-26) as well as treatment duration (22, 27). This increased 
use has been paralleled by an associated increase in the incidence of adverse events and 
accidental overdose (27-32). Additionally, pain has been reported to be both undertreated and 
overtreated (33).  These factors have led to concerns regarding the excessive use of opioids and 
the threat they pose to the public and individual health.  Subsequently there has been an attempt 
to try and optimise pain management and improve the targeting of analgesics.  Moreover, there 
have been an increasing number of organisations and Governments internationally as well as in 
Australia that have advocated for more research about pain and its management (34-38). 
 
In 2010, Pain Australia published the National Pain Strategy (36). The Pain Strategy’s sixth goal 
is to increase the amount of research being conducted in the field of pain and its management.  
Areas of research include: evaluation of interventions for persistent pain management, assessing 
attitudes towards pain and its management, and assessing the safety and efficacy of pain 
management in older patients (36).  Additionally, a policy paper (38)  published by the Royal 
Australasian College of Physicians also suggested further areas for research should include: 
identification of risk factors for the development of persistent pain conditions, improving the 
management of persistent pain, and reducing the harms around persistent pain management, 
specifically opioid use.  
 
The prevalence of pain in Australia is increasing, due in large part to an ageing population.  
However, pain in older people has many different etiologies.  With the prevalence of pain so high 
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it is important to assess current management of persistent pain irrespective of the indication. 
However, it is also important to assess how older populations manage acute, subacute and 
chronic pain to identify if older patients have different predictors of chronicity of pain than 
younger cohorts.  Post-operative pain is a common cause of acute, subacute and persistent pain 
in all age groups.  However, as we age surgical procedures become more commonly required due 
to an increased number of comorbidities; consequently, post-surgical pain is increasingly 
affecting older and very old Australians.  Surgical procedures provide a unique opportunity to 
review patients throughout the acute, subacute and persistent pain spectrum to assess predictors 
of pain and review the way older people self-manage pain during this period. If factors associated 
with the transition from acute to persistent pain in this older cohort could be identified, 
potentially it would allow for the development of interventions that will specifically assist older 
Australians from developing persistent pain. 
 
For these reasons, evaluation of the way in which patients and clinicians manage pain with 
analgesics and identification of how pain could be managed better are necessary in order to 
optimise patient outcomes and reduce the inherent risks that these medications have in the 
patient population as well as society as a whole.  This thesis aimed to address these gaps in the 
literature by conducting a number of inter-related studies with the following objectives: 
 To evaluate how pain is managed pharmacologically by patients, nurses, GPs, surgeons 
and anaesthetists; 
 To identify what factors are associated with the development of persistent post-operative 
pain (PPP); 
 To identify quality use of medicine (QUM) issues related to the management of pain; and 
 To identify the barriers and enablers to pain management. 
 
1.2 Methodology  
A number of related studies were conducted using primarily quantitative methods to 
retrospectively and prospectively review the management of pain. Additionally, opinions in 
relation to pain management were obtained from GPs, anaesthetists and nurses, allowing for a 
diverse perspective of the enablers and barriers to optimal pain management.  The patient 
perspective of pain management was also included in Chapter Three and to a lesser extent in 
Chapters Four and Five.   
 
To investigate how post-surgical pain is managed pharmacologically by older Australians in the 
short, medium and longer term, as well as identify predictors of PPP a number of studies were 
conducted. Chapters Three, Four and Five were prospective studies undertaken at the Royal 
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Hobart Hospital (RHH).  For the study conducted in Chapter Three, patients were recruited 
through hospital discharge lists following any type of surgery requiring an incision, and then 
mailed a survey to complete in the week following discharge, regarding their pain management 
after surgery.  Chapters Four and Five involved recruiting and interviewing patients on surgical 
wards of the RHH who had undergone orthopaedic surgery or a sternotomy, two common 
procedures older Australians undergo (41, 42, 43, 44) .  These patients were then followed over 
the next 12 months via telephone call interviews conducted at ten days, six weeks, three months 
and 12 months.  Predictors of PPP were identified, as well as recording analgesic use, physical 
function and pain intensity across the study time period.  These studies were conducted in 
accordance with the STROBE statement for cohort studies (39).   
 
Chapters Six and Seven were retrospective studies of 20,000 Australian medication reviews.  
Home Medicines Reviews (HMRs) and Residential Medication Management Reviews (RMMRs) 
are conducted by accredited pharmacists and as part of the process of writing the report to the 
GPs, data are often entered into various software packages.  All patient records entered in one of 
these packages, Medscope™, was used to assess the patients’ medications, medical conditions, and 
demographics.  The data were then analysed to determine the prevalence of analgesic use, 
characteristics of patients with a documented diagnosis of pain and the quality of pain 
management.   
 
To better inform recommendations regarding the management of pain in older Australians, we 
conducted additional studies to incorporate the perspectives of patients, and a range of health 
care professionals, including GPs, anaesthetists and nursing staff in ACFs.  Chapters Eight and 
Nine were undertaken using online surveys. Anaesthetists practising in both the public and 
private sectors throughout Australia were emailed an electronic link to the survey.  Participants 
were asked about patient factors associated with acute postoperative pain and PPP, their 
opinions of the barriers to optimal acute pain management and how their management differed 
depending on particular patient attributes.  GPs in Tasmania were also contacted via the Primary 
Health Network newsletter and direct emails to general practice clinics to ask them to complete 
a similar survey.  The GPs were asked about their management of pain, which guidelines they use, 
barriers to pain management and how these could be overcome.  Chapter Ten describes a study 
involving semi-structured interviews conducted with 23 staff at five ACFs in southern Tasmania 
to explore their views regarding the barriers and enablers to pain management in their context. 
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Table 1 provides an overview of the thematic structure of this thesis, and identifies the 
relationship between individual studies and the overall objectives.   
Table 1 Thesis objectives and where they are addressed within the text 
Objective Chapters where these objectives are 
addressed  
Observe how pain is managed pharmacologically by 
patients, nurses, surgeons, GPs and anaesthetists 
Patients: Chapters 3, 4, 5 
Nurses: Chapters 6, 7, 10 
Surgeons: Chapters 3, 4, 5 
GPs: Chapters 3, 4, 5, 6, 7, 8, 10 
Anaesthetist: Chapters 4, 5, 9 
Identify what factors are associated with the 
development of PPP 
Chapters 4 and 5 
Identify QUM issues related to the management of pain Chapters 3, 4, 5, 6, 7, 8, 9, 10 
Identify the barriers and enablers to pain management Chapters 3, 4, 5, 6, 7, 8, 9, 10 
 
1.3 Limitations 
These studies were designed to evaluate the management of pain using prescription and over-
the-counter analgesic medications in adults in Australia.  The use of complementary and 
alternative medicines, topical preparations and non-pharmacological management strategies 
were beyond the scope of this study.  The management of paediatric pain, end of life pain or pain 
management associated with active cancers were also beyond the scope of this study due to 
substantial differences in the management, duration, and drug dosing protocols with these types 
of pain.     
 
For some of the studies the data relied on patients’ recall over the previous week and were unable 
to be cross-matched with discharge information, which is liable to some inaccuracies, although 
these were likely to be relatively minimal. For the data reported in Chapters Six and Seven, there 
were potential limitations associated with the accuracy of pain diagnoses, and the recording of 
‘as required’ analgesics; however, due to the number of participants in these studies, these 
limitations were unlikely to affect the overall findings.  In addition, non-pharmacological 
management strategies were not recorded in this data set; consequently, this may have 
overestimated the proportion of patients being suggested as inadequately managed.  There was 
the potential of self-selection bias in Chapters Three, Eight and Nine, which may have been biased 
towards prescribers or patients interested in the area of pain management, or those with specific 
or strong perspective that may affect the generalisability of the results.  However the results were 
consistent with other studies, further larger scale studies in these areas would be beneficial, 
particularly evaluating GP practice throughout Australia to improve the generalisability of the 
data.  The data presented in this thesis provide a comprehensive snapshot of the management of 
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pain in a number of situations with analgesics and allows for QUM issues to be identified and 
recommendations to be made to optimise the management of pain in Australia.  
 
1.4 Ethics 
The research contained within this thesis abides by all Australian and International guidance 
surrounding human research ethics.  Each study within this thesis was approved by the 
University of Tasmania’s Health and Medical Human Research Ethics Committee (approval 
reference numbers: H0012833; H0015044; H0014453; H0015249) or the University of 
Tasmania’s Social Sciences Human Research Ethics Committee (approval reference number: 
H0012404). 
 
1.5 Funding 
The research contained in Chapters Four and Five was supported by a grant from the Royal 
Hobart Hospital Research Fund (RHHRF) (no 13-012). 
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Chapter 2: Pathophysiology and management of pain 
 
2.1 Pain 
Pain, although experienced by most people throughout history, has varying individual or cultural 
significance. The perceived causes of, and treatments for pain have also varied significantly 
throughout the ages, based on the knowledge, understanding and societal beliefs at that time 
(45). Traditionally, pain was often thought to be associated with the effect of evil spirits, a 
punishment for sins or as a trial to strengthen one’s faith or resolve (45). However, as more 
scientific research has been undertaken a greater understanding of the pathophysiology of pain, 
has resulted in a greater emphasis on a biomedical model and more recently the biopsychosocial 
approach to pain management (46).  Despite an increased understanding of the pathophysiology 
of pain there are many aspects of pain that remain unclear, including the transition from acute to 
persistent pain (47).   
 
Pain is defined as “an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” (4).  This definition emphasises 
the importance of the biopsychosocial model of health in noting pain is also an emotional 
experience and thus should not be managed solely using a biomedical approach. This is because 
pain perception, predisposition to persistent pain and analgesic efficacy are influenced by many 
factors, including a person’s biology and psychology, together with environmental and social 
factors (46, 48, 49).  Factors influencing pain perception and progression will be discussed 
further in section 2.1.3 of this literature review. 
 
Pain is a significant issue within modern society.  Persistent pain is often considered a public 
health priority or challenge (50, 51) and musculoskeletal conditions are one of the Australian 
Government’s priority health areas (52).  Additionally, there is also a National Pain Strategy in 
Australia, which is currently in the process of being updated (36). With an estimated one in five 
adults experiencing persistent pain (5-11), it is not surprising that the economic burden within 
society is large (53-56).  There is substantial disability associated with persistent pain, resulting 
in increased absenteeism from work, increased health care utilisation and increased risk of 
hospitalisation and mortality (9, 55-58).  As recognition of the significant patient and societal 
burden that pain creates, pain was also included as the “fifth vital sign” in 1998 by the United 
States Veteran’s Health Administration, which required it to be recorded at all clinical encounters 
in this population (59). This has since been adopted more widely by the medical profession (48, 
60, 61).  
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2.1.1 Classifications, definitions and assessment of pain 
2.1.1.1 Classification and definitions of pain 
There are a number of different ways in which pain can be classified. Generally, more than one of 
the classifications will be used to describe a person’s pain. This may be a description of the 
underlying cause of pain, for example osteoarthritis, gout or rheumatoid arthritis (RA).  
Alternatively it can be classified based on the location, for example, lower back pain, abdominal 
pain or headache; or based on duration and frequency.  Acute pain is defined as “pain of recent 
onset and probable limited duration. It usually has an identifiable temporal and causal 
relationship to injury or disease” (62). Whereas persistent pain (or chronic pain) is defined as 
pain lasting more than three months (62).  Persistent pain can either be chronic or intermittent 
in nature (47).   
 
Pain can also be categorised based on the underlying pathology, for example, nociceptive pain 
which is pain associated with actual or potential damage to non-neural tissues, or neuropathic 
pain which is due to damage to the somatosensory nervous system (63). Patients can also 
experience mixed pain, including both neuropathic and nociceptive characteristics.  Nociceptive 
pain can be further divided into either somatic pain, which relates to the musculoskeletal system, 
which will be mainly discussed in this thesis, and visceral pain, which is where pain originates 
from internal organs and can result in symptoms such as angina or gastric cramping (64). The 
way in which pain is classified can affect the choice of drugs as well as the way in which the 
condition is treated.  The management of pain shall be discussed more in section 2.2. 
 
Table 2 Disease states and pain type, duration and pattern 
Disease state Type of pain Likely duration/pattern of pain 
Angina Nociceptive – visceral Acute; chronic intermittent 
Migraine Nociceptive – visceral Acute; chronic intermittent; chronic continuous 
Dysmenorrhoea Nociceptive – visceral Acute 
Gastric cramping 
(associated with irritable 
bowel syndrome) 
Nociceptive – visceral Acute; chronic intermittent; chronic continuous 
Osteoarthritis Nociceptive – somatic Chronic continuous or chronic intermittent (ie 
activity induced) 
Bone metastasis Nociceptive – somatic Persistent, continuous 
Back pain Mixed – somatic Acute, chronic continuous or chronic intermittent 
(ie activity induced) 
Persistent post-
operative pain 
Mixed – somatic Acute, chronic continuous or chronic intermittent 
(ie activity induced) 
Rheumatoid arthritis Nociceptive – somatic Acute, chronic continuous or chronic intermittent 
(ie activity induced) 
Peripheral neuropathy Neuropathic  Acute, chronic continuous or chronic intermittent 
(ie activity induced) 
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2.1.1.2 Assessment of pain 
Pain is subjective, and thus a way to measure it objectively is necessary to assist in clinical 
decision making regarding the appropriateness of the pharmacological management strategies 
employed. There are numerous scales that can be used to assess pain severity or nature (65), 
including the Numerical Rating Scale (NRS), The McGill pain questionnaire and the Abbey Pain 
Scale.  There are also assessment measures to ascertain the characteristics of the pain such as the 
Douleur Neuropathique 4 (DN4) or the painDETECT assessment tools to assess whether the pain 
is of neuropathic origin (66, 67).  Pain tools have also been developed to assess pain in specific 
pain conditions, such as the West Ontario and McMaster Universities Osteoarthritis Index (68) 
and the Rheumatoid Arthritis Pain Scale (69). Pain can also be assessed by reviewing its impact 
on quality of life measures, such as and the Short Form-36 Bodily Pain Scale (65) or the Arthritis 
Impact Measurement Scales (70). 
 
The NRS is one of the most commonly used pain assessment tools; it assesses pain by asking 
patients to rate their pain using a numerical scale of zero (no pain) to 10 (the worst pain they 
could imagine). A more comprehensive measure often used is the McGill Short Form pain 
assessment (71), which includes a number of pain assessments including a the Visual Analogue 
Scale (VAS) which assesses pain based on a patient indicating on a drawn 10cm line the level of 
their pain; a patient’s current intensity of pain is assessed using the Present Pain Intensity Index 
and a number of descriptors regarding the pain characteristics are also included. Another 
assessment tool, often used, particularly, although not exclusively in children is the Wong-Baker 
FACES assessment (72), which assesses pain by showing patients faces demonstrating different 
levels of pain and asking which one reflects their pain.  Pain can also be assessed descriptively, 
for example none, mild, moderate and severe. For patients who are unable to communicate their 
pain, other scales such as the Abbey Pain Scale (73), Pain Assessment in Advance Dementia Scale 
(PAINAD) (74) or the Critical-Care Pain Observation Tool (75) can be used, which assess non-
verbal pain descriptors.  
 
Self-rated pain assessments tools such as the NRS, VAS, verbal rating scale and a face scale have 
been demonstrated to be valid methods to detect pain intensity (76). Selecting the correct tool to 
use in a given situation is important. Some tools are very simple to use - for example the NRS, that 
captures intensity only but are simple to administer, whereas other more in depth 
questionnaires, such as the McGill Pain Questionnaire, provide additional information about the 
characteristics of pain, but require trained health care professionals to administer them. 
However, assessment tools are not without the problems.  By far, the greatest flaw with these 
self-assessment tools is that there is no way to objectively quantify what the patient has reported; 
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this could potentially result in both under and over estimation of pain severity. Patients who are 
over stating their pain, may be doing so with the objective of receiving opioids for aberrant drug 
use, which has been noted as a concern for GPs when prescribing opioids (77).  Whereas 
underestimation, due to patient stoicism in older patients in particular, may result in 
inadequately managed pain.  Both of these can have poor patient outcomes. Similarly, assessment 
tools that are based on observation, for those patients unable to verbalise their pain, are reliant 
on medical staff identifying facial expression, vocalisation, changes in behaviour and body 
language to indicate pain.  These observation tools require time to assess the patient and also 
knowledge about how a person would normally behave in order to make a decision regarding 
their pain.  Overall, the assessment of pain is challenging, but necessary in order to assist in the 
clinical decision making process and provide the best patient care.  
 
2.1.2 Pain pathophysiology 
Acute pain is a necessary protective mechanism of the body, to prevent us from undertaking 
behaviours that will result in further damage (48, 78) and allow the body to heal,  prevent 
infection and commence recovery at the injury site (3). Acute pain has an identifiable cause, and 
should be managed as a symptom of this other condition (4, 63).  Acute pain will generally subside 
after the cause of the pain has been resolved or the area has healed (for example, a scar has 
formed or a bone has been re-aligned and the limb set in plaster).   
 
Figure 1 represents the pain pathophysiology for acute nociceptive pain.  Acute pain occurs when 
a noxious stimulus, something that causes or has the potential to cause tissue damage, acts on 
sensory receptors, known as nociceptors in the peripheral nervous system. This is a process 
referred to as nociception (47, 48).  The signal is then transduced and encoded to an action 
potential which is subsequently conducted to the central nervous system (CNS) (4, 48, 63).  From 
there, the pain signal results in second order neurone activation in the dorsal horn of the spinal 
cord (47).  This results in the pain signal being transmitted to the thalamus, and then, via third-
order neurones, the signal is transmitted to the cerebral cortex where the brain perceives the 
pain signal (3).    
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Figure 1 Nociceptive acute pain pathophysiology (79) 
 
The stimulation of the nociceptors results in an influx of inflammatory mediators at the site of 
injury (49, 80) including cytokines, chemokines, and neurotrophins (3, 48). This slew of 
inflammatory mediators leads to the sensitisation of nociceptors, resulting in the receptors 
having a lower stimulation threshold and also eliciting an increased response to the noxious 
stimuli (3, 4, 63).  Consequently, a patient may demonstrate a hypersensitivity reaction where 
they feel more pain from the same stimulus (hyperalgesia) and/or they can experience a lower 
threshold for pain, meaning they feel pain from a stimulus that would previously not have caused 
any pain (allodynia) (48, 63) as demonstrated in Figure 2.  Generally, this sensitisation is a short-
lived protective mechanism (4, 63).   
 
Figure 2 Pain sensitisation (79) 
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If the inflammation associated with pain is short in duration, then the nociceptors return to their 
normal function and no secondary changes occur.  If, however, the sensitisation is prolonged, 
secondary changes can occur that increase the activation of nociceptors, increasing the number 
of pain signals reaching the CNS (3, 49, 80) and subsequently increasing the excitability of the 
dorsal root ganglia and then the dorsal horn (48, 80).  This has the potential to result in peripheral 
sensitisation and then subsequently central sensitisation, where nociceptors in the CNS 
demonstrate heightened sensitivity to pain stimulus (4, 63).  Prolonged acute pain and the 
resultant central sensitisation can cause changes to the way the CNS pathways operate, through 
the process of neural plasticity (3, 47) which can then result in the transition from acute to 
persistent or chronic pain.  By definition, all cases of persistent pain start out as acute pain, one 
of the common causes of which are surgical procedures.  This area has received significant 
attention and it has been identified that high levels of acute postoperative pain increases the 
likelihood of developing PPP (81, 82), in part due to peripheral and central sensitisation.   
 
This transition from acute to persistent pain occurs during the subacute period. Although there 
is no standard definition for subacute pain, it generally describes the period following an acute 
pain episode, up to approximately three months, after which point in time the person would be 
deemed to have persistent pain (83).  Despite acute pain being a precursor to persistent pain, it 
is inappropriate to simply regard persistent pain as acute pain that continues for a prolonged 
period of time.  Persistent pain has a very different pathophysiology (84). For example, patients 
with chronic pain conditions can also have changes to endogenous pain pathways, such as diffuse 
noxious inhibitory controls (DNIC). DNIC is a pain pathway where one painful stimulus inhibits 
the pain of another pain stimulus (85, 86).  Diminished function of this pathway has been 
associated with a number of persistent pain conditions including osteoarthritis, RA and 
fibromyalgia (85, 86). However, pathophysiology alone does not explain why pain transitions 
from being acute to chronic. A number of factors have been associated with an increased 
likelihood of experiencing pain and these shall be discussed more in section 2.1.3. 
 
Previously, persistent pain was managed based on the likely underlying disease or site (87) and 
as a symptom of another disease.  However, this strategy may be ineffective, for example, disease-
modifying treatments for RA improve the underlying disease but do not necessarily improve the 
pain (87). In these circumstances, where the pain persists despite the initial injury or disease 
having improved or resolved, changes in pathophysiology result in pain persisting (88). 
Consequently, persistent pain is often classified as a disease state in its own right (36, 80, 89) and 
requires different management strategies, to that for acute pain.  Further to this, the goals of 
management also change.  In acute pain, the goal of management is reduction of pain intensity 
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preferably to no or minimal pain intensity; whereas the goal in persistent pain is to improve 
function rather as eliminating pain, which is generally unachievable (90-95) due to the 
underlying physiological changes.  
 
2.1.3 Diagnosis, perception, experience and predictors of pain 
Pain is a subjective and variable process, with each person experiencing pain differently (96).  It 
is heterogeneous with different aetiologies resulting in the same symptoms as well as the same 
aetiology presenting with a number of different symptoms (87). This is because the stimuli are 
not the only determinants of the pain experienced; the perception of pain is governed by 
biological, psychological and social factors (Figure 3).  Generally, it is thought that these factors 
interact and thus all aspects should be considered when managing pain.  This section shall discuss 
the factors associated with differences in development or perception of pain. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 The biopsychosocial model of pain 
 
2.1.3.1 Biology 
An individual person’s biology generally cannot be changed.  Factors, such as age, sex, ethnicity 
and genetics influence the likelihood of an individual developing pain. These biological factors 
also interact with psychological and social factors and thus alone are not the sole determinant of 
a person being diagnosed with a pain-causing condition.  
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2.1.3.1.1 Age 
The prevalence of persistent pain increases with age (6, 7), with people over the age of 50 years 
being twice as likely to be diagnosed with a pain-causing condition, than people aged less than 50 
(46).  This is because a number of conditions that cause pain are more likely to occur with 
increasing age, including osteoarthritis, fractures (often associated with falls), cancer, diabetes 
mellitus, stroke, post herpetic neuralgia and neurodegenerative diseases such as Parkinson’s 
disease. The level of disability associated with persistent pain also increases with age (97).  
However, younger patients have been found to be at higher risk of certain types of persistent pain, 
including PPP (82) and pain caused by trauma (98), which is likely associated with people under 
the age of 65 being at greater risk of injury and trauma (99).  
 
Age-related physiological changes affect how the elderly perceive and experience pain, including 
a reduced production of endogenous analgesic substances and changes in pain perception, which 
can complicate the presentation and diagnosis (100-105). It is important to note, however, that 
chronological age does not necessarily reflect a patient’s QOL, level of frailty or physical function 
(106, 107); for this reason, patients should be assessed and treated on a case-by-case basis.  Older 
people also demonstrate greater heterogeneity in the way they respond to medications, including 
analgesics (16), which is in part attributable to changes in pharmacokinetics and 
pharmacodynamics  (108), higher number of comorbidities (109) and prescribed medications, 
increasing the risk of drug interactions and adverse effects (110).  
 
2.1.3.1.2 Sex differences 
Differences between the sexes in pain prevalence and severity have been well documented (111-
113), with women consistently demonstrating a higher incidence of persistent pain (6, 8, 113). 
Some of these differences have been hypothesised to be due to variations in social and 
psychological conditioning between men and women (114-116).  However, a number of 
biological factors also influence pain perception and sensitivity (117) including the influence of 
testosterone in-utero, the effect of oestrogen as a pain modulator in women (116) and 
endogenous opioid production (114, 116).  Pain sensitivity also varies across a woman’s 
menstrual cycle (118-121), as well as her lifetime, including a reduction in certain types of pain 
following menopause and an increase in others (116).  Additionally, during active labour there is 
also an increase in the pain threshold, presumably as a protective mechanism (122).  
 
2.1.3.1.3 Ethnicity  
Differences have been demonstrated between ethnic groups, in relation to experimental pain. 
Studies have found a reduced pain tolerance for people of African-American or Hispanic descent 
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(123, 124) as well as a higher prevalence of persistent pain in clinical practice (125-127).  Studies 
from New Zealand (8, 9) found the prevalence of persistent pain was lower in people of Asian and 
Pacific Islander descent than those from European descent; however, a different study did find 
they experienced greater pain intensity (128). It is unclear if these differences in pain sensitivity 
and prevalence are related to social, cultural, psychological or genetic differences, or an 
interaction of some or all of these factors (127).   
 
2.1.3.1.4 Genetic polymorphisms 
Genetic polymorphism is where individuals exhibit differences in their DNA sequence. The 
association of genetic factors and persistent pain has been well documented (81, 82, 129, 130).  
These genetic changes have been shown to affect nociception (131), pain perception (132, 133), 
opioid receptor expression (134) and variations in levels of catecholamine-O-methyltransferase 
(COMT) causing changes in pain response and susceptibility to pain conditions (133, 135). Opioid 
analgesic efficacy can also be reduced with certain genetic polymorphisms, including cytochrome 
P450 2D6 polymorphism reducing the efficacy of codeine and multi-drug resistant gene 1 (MDR1) 
polymorphisms reducing the efficacy of opioids (136).  Other factors are also influenced by 
genetics, including susceptibility to pain catastrophising (137), which affects the way people 
think about, cope with and manage pain. In addition, other genetic polymorphisms can 
predispose people to certain painful conditions such as migraine (138), fibromyalgia (139) and 
RA (140).  It has been suggested that one difference alone is probably unlikely to affect overall 
pain perception; however, the interaction of multiple genetic differences may result in variations 
in how pain is experienced (131, 132).   
 
2.1.3.1.5 Comorbidities 
Obviously pain-causing comorbidities increase the risk of patients experiencing pain.  However, 
pre-existing persistent pain has also been associated with the development of new persistent pain 
conditions (81, 82, 141).  The mechanism behind this is thought to be related to allodynia and 
hyperalgesia causing a heightened pain response. Psychological comorbidities including 
depression, anxiety (9, 56, 81, 82, 142-147) and substance abuse (148, 149) as well as 
cardiovascular disease have also been associated with persistent pain (150).   
 
2.1.3.2 Psychological factors 
The effect of one’s psychology (thoughts, feelings and behaviour), on both the likelihood of 
developing pain and the ability to cope with pain, has been extensively researched.  Anxiety, 
depression, pain catastrophising and stress have been associated with an increased likelihood of 
experiencing PPP (48). Pain, particularly persistent pain, has been found to be associated with 
15 
anxiety and depression, as well as other psychological conditions including post-traumatic stress 
disorder (9, 56, 81, 82, 142-147) with some studies finding that more than one psychological 
condition increases the risk of pain related disability (146).   In addition, a number of studies have 
also found an association between psychological comorbidities and the number of pain sites (151, 
152). 
 
2.1.3.2.1 Depression 
A number of studies (56, 145, 147, 153-155) have found an association between persistent pain 
and depression; with some studies also finding an association with acute pain (155, 156). A 
number of hypotheses have been proposed to explain the relationship between pain and 
depression (157). Firstly, that chronic pain decreases QOL and physical function, thus resulting 
in depression; secondly, that depression comes first and increases sensitisation to pain; or thirdly, 
that it is a bi-directional relationship, meaning that having depression can both cause and be 
caused by chronic pain (157), which is not unreasonable as they share a number of similar 
pathways in the body (145, 158).  Recent evidence has also indicated that opioids may increase 
the risk of depression; this does not appear to be dose-dependent (159). 
 
2.1.3.2.2 Anxiety 
Anxiety and pain may also have a bi-directional relationship. Patients who are anxious are more 
likely to report pain and have a greater number of painful sites than those patients without 
anxiety (146, 147, 160). This may also be associated with the patient’s coping strategies, with 
patients who are anxious or fearful of pain more likely to use avoidance strategies to prevent 
further pain and damage, which conversely results in greater levels of disability (161).   Lower 
levels of self-efficacy (the ability to continue “normal” behaviour despite the presence of pain) 
have been associated with increased levels of anxiety and increased levels of disability (162).  
Preoperative anxiety has also been associated with an increased risk of higher levels of 
postoperative pain and increased risk of PPP (82, 163). 
 
2.1.3.2.3 Pain catastrophising and fear of pain 
Pain catastrophising is defined as “an exaggerated negative mental set brought to bear during 
actual or anticipated painful experience” (164). Pain catastrophising has been found to increase 
pain intensity and disability associated with pain, as well as increase the risk of developing 
persistent pain (81, 82, 165-170). Fear of pain is closely related to pain catastrophising, with fear 
affecting the severity of the pain experienced (144). One study (171) found that children’s 
recollection of pain intensity was a more accurate indicator of pain intensity reported, 
demonstrating the effect that memory has on the anticipation and actual experience of 
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subsequent painful events. Avoidance behaviour due to fear of pain has also been found to be 
associated with an increased level of pain and disability (172, 173). Passive coping strategies, 
such as praying or hoping pain will get better, has also been associated with increased pain 
intensity and disability (174, 175). In comparison, active or enhanced coping strategies for pain 
have been associated with reduced disability, but not reduced pain intensity (168, 176).  
Acceptance of pain and the associated limitations has also been associated with lower pain 
intensity and lower emotional distress (177).  These factors demonstrate the significant impact 
that the way one thinks about pain has on the ability to effectively cope with and manage in life 
with pain. 
 
2.1.3.2.4 Childhood   
Sexual and physical abuse during childhood has been found to be associated with persistent pain 
and disability in a number of studies (178-185). The majority of studies have evaluated the effect 
of abuse on women, although some studies have included men (181, 186). This area of research 
is complicated by the sensitive nature of sexual and physical abuse, reducing the likelihood of 
large population-based studies. Additionally, traumatic events during childhood, including the 
death of a mother, hospitalisation associated with a traumatic event (e.g. car accident), being 
placed in care or experiencing financial hardship have been found to increase the likelihood of 
developing persistent pain (187).  
 
A number of studies have suggested that the relationship between a child and their parents can 
also affect the likelihood of developing a persistent pain condition and how well the patient copes 
with a persistent pain condition (162).  It has been hypothesised that a child’s relationship with 
their parents can also indirectly influence the development of persistent pain conditions in later 
life, by affecting their subsequent relationships with others (including their parents and romantic 
relationships) (162, 188-190). 
 
2.1.3.3 Social and environmental factors 
A number of social and environment factors can influence pain development, associated 
disability, efficacy of pain management or coping strategies; and include cultural differences 
(191) and environmental factors (192).  People who are part of a lower socio-economic group (6-
8, 125, 126, 193) or have lower educational levels (6, 7) are more likely to experience pain and 
have higher levels of disability associated with that pain.  Some research also indicates that when 
people receive compensation for a work place injury they have a slower return to work, than 
those who do not (194, 195).  Perceived social support has been found to improve the ability to 
function when experiencing persistent pain (168, 196).  Epigenetic changes have also been 
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identified, where the environment in which one lives affects the genetic makeup (197, 198), 
resulting in changes to the way pain is experienced. 
 
2.1.3.4 Factors predicting the chronicity of pain 
“All chronic pain was once acute, but not all acute pain becomes chronic” (199).  As the above 
section has described, there are numerous factors associated with pain and pain-causing 
conditions, and it is likely that an interaction between multiple factors increases the likelihood of 
this transition occurring. In terms of identifying factors increasing the likelihood of pain 
transitioning from acute to persistent, most attention has been focused on the postoperative 
setting. Surgery presents a unique area to study where the cause of acute pain is known, often 
amenable to a greater degree of control and generally (although not always if surgery is related 
to persistent pain) does not exist prior to the surgical incision. Factors that have been identified 
as increasing the risk of PPP include a number of the aspects discussed above, such as pre-existing 
pain, younger age, female, pre-operative anxiety, depression, pain catastrophising, low income, 
low education level and poor self-rated health (81, 82, 199-203).  In addition, a number of other 
surgical related factors have been identified including, type or surgery, longer duration of 
surgery, low volume surgical unit, unrelieved postoperative pain, high postoperative analgesia 
consumption, stress, late return to work, infection, bleeding, compartment syndrome and organ 
rupture (81, 82, 199-203).  A small number of studies have also evaluated pain following 
discharge after surgery, which may also predict the chronicity of pain (204-208).   
 
The chronicity of back pain has also been extensively researched.  Studies have found that up to 
20% of patients who suffer an acute back injury will still be suffering from pain one year later 
(209).  A systematic review of the literature found a number of factors to be associated with an 
increased likelihood to transition to persistent lower back pain including: maladaptive behaviour, 
functional impairment, psychological vulnerability, poor health status and financial 
compensation (209).  Age, gender, smoking status, occupation dissatisfaction, high physical 
demand jobs and education level, however, have not been found to be consistently associated 
with the development of persistent back pain (209).   
 
The persistence of neuropathic pain has also been researched, with anxiety, depression, pain 
catastrophising and age all considered to predict persistent neuropathic pain by a panel of 
experts (210).  A systematic review found that fear of movement, passive coping strategies, 
psychological vulnerability, acute pain and increased body weight also increased the risk of pain 
persisting (211). Neuralgia following herpes zoster infection has also been found to be more 
common in patients who are older, male, smokers, experienced higher levels of acute pain, 
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experienced a shorter duration but more severe rash, those who did not use antiviral medication 
and those with a poorer health status prior to the infection (211, 212). 
 
In summary, although studies have found various factors to be associated with the way a person 
experiences pain or the likelihood of them developing a persistent pain condition, these factors 
often overlap. This allows for profiling of those people likely to experience pain conditions and 
may, in the future, allow for more targeted interventions to reduce the likelihood of patients 
developing persistent pain conditions.  Nonetheless, further research is needed as studies have 
provided conflicting results, often use variable definitions of persistent pain and including 
variable patient data.  Consequently, large-scale prospective studies would be very beneficial to 
aiding in the development of assessment tools for predicting those most at risk for persistent pain 
conditions. 
 
2.2 The pharmacological management of pain 
The field of pain management and the role of pain physicians are relatively new in medicine.   The 
treatment of persistent pain as part of a multidisciplinary team only commenced in the 1950s 
with Dr John Bonica opening the first multidisciplinary pain centre (213, 214).  The first textbook 
regarding the management of pain was published in 1953 (214).     
 
Pain is frequently managed using pharmacological treatment options. Numerous agents have 
analgesic properties and these include paracetamol, opioids, non-steroidal anti-inflammatory 
drugs (NSAIDs) including the cyclooxygenase (COX)-2 inhibitors, antidepressants, antiepileptic 
drugs (AEDs), corticosteroids and local anaesthetics. However, it is important to acknowledge the 
role that non-pharmacological strategies play in the management of pain, particularly persistent 
pain. These strategies include cognitive behavioural therapy (CBT), physiotherapy, acupuncture, 
osteopathy, transcutaneous electrical nerve stimulation (TENS), heat therapy, exercise and other 
forms of mechanical manipulation (215, 216). In addition, patients frequently employ 
complementary and alternative therapies to aid in managing pain, especially where pain is due 
to rheumatological conditions; these can include fish oil, glucosamine and chondroitin.  The use 
of non-pharmacological management strategies or complementary or alternative therapies, 
although frequently employed by patients and health care providers, is beyond the scope of this 
literature review, and will not be discussed further in this review.   
 
Decisions regarding pharmacological treatment options for pain are often chosen depending on 
the aetiology and likely duration of pain-related episodes. If pain is associated with an underlying 
condition such as autoimmune conditions, disease-modifying therapy may also be included in the 
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management strategies to reduce and prevent further damage or inflammation.  Similarly, if a 
patient suffers from visceral pain, treating and managing the underlying condition rather than 
relying on analgesics, is the mainstay of therapy, such as antispasmodics for gastric pain or 
glyceryl trinitrate for angina-related pain.  The management of underlying diseases is beyond the 
scope of this review, which will focus primarily on medications that exert analgesic properties. 
 
General guidance for the management of persistent pain suggests commencing analgesics in a 
step-wise fashion, starting with a non-opioid analgesic and building on this if pain is inadequately 
managed (16, 108, 217-220) (Figure 4). Medications should be commenced at a low dose and 
slowly titrated upwards to an effect, noting that adverse events can occur at doses below the level 
where patients receive adequate analgesic benefit (16, 108, 221). If a patient’s pain is 
inadequately managed using a non-opioid analgesic alone then opioid analgesics should be added 
to the patient’s therapy (108, 217, 222). This multimodal management of pain, where a 
combination of different classes of drugs with complementary modes of action, are used 
concomitantly (e.g. an opioid plus paracetamol, an NSAID, or an adjuvant analgesic drug) is 
recommended for both acute and persistent pain (48, 223-225).  This combination therapy may 
improve pain management and can also have an opioid-sparing effect (16, 108).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 World Health Organisation (WHO) Pain Ladder (217, 226) 
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However, pain management must also be tailored to the severity and duration of pain (108); for 
example, commencing paracetamol (a non-opioid analgesic used for the management of mild to 
moderate pain) for severe pain, without other pharmacological management strategies is 
unlikely to be effective or appropriate. Similarly, commencing a long-acting opioid for severe 
infrequent intermittent pain is less suitable than a short-acting, fast-onset agent.  
 
Patient factors and the needs of certain patient populations also should be considered before 
prescribing analgesics.  For example, older patients, particularly those who are frail, tend to have 
multiple comorbidities and multiple medications, increasing the likelihood of drug-drug or drug-
disease interactions. In addition, these patients tend to have a number of other factors affecting 
drug selection and dosing, including altered pharmacokinetics and pharmacodynamics as a 
consequence of physiological changes with ageing, and are at increased risk of adverse events 
(108, 227, 228). Patients with a history of substance or alcohol abuse, depression or anxiety are 
also more likely to experience aberrant drug use associated with opioid analgesics (148, 154, 
229), and further harm minimisations strategies and non-pharmacological treatment strategies 
should be employed (12, 15, 16, 219, 230).  
 
Evidence for the use of most analgesics, even prescription pharmaceutical agents, are often 
lacking in level one, randomised controlled trials evaluating long-term treatment outcomes (89, 
231). In addition, as with many conditions, there are also a lack of randomised controlled trials 
or head to head trials, of sufficient duration which include patients with multiple comorbidities, 
and frail or elderly patients to be able to adequately inform treatment practices (228, 231). Trials 
evaluating the effect of analgesics on persistent pain often last weeks or months, rather than years 
(18, 231, 232). Consequently, long-term efficacy, as well as adverse effect profiles, are often not 
identified and the actual risks in those population groups excluded from trials, such as the frail, 
elderly, those with a substance abuse history or those with comorbidities are relatively unknown. 
 
Numerous guidelines exist in different countries, for various pain-causing aetiologies and 
different patient groups (16, 108, 219, 222, 228, 233-237) to guide the management of persistent 
pain.  However, the vast majority of these guidelines are generally laborious to read and often 
provide minimal practical advice to clinicians about drug choice, dose or co-prescribed therapies. 
A significant issue with the production of guidelines for chronic pain is the dearth of published 
literature to evaluate outcomes and thus rely on expert opinion. In addition, most trials focus on 
a reduction in pain scores rather than an improvement in physical functioning; for this reason 
new guidelines have been developed describing six areas that should be evaluated in clinical trials 
about pain (238). Noting the diversity in the guidelines in this area, the WHO has commenced 
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writing evidence-based guidelines for the treatment of chronic pain in adults (239). It is likely to 
be a number of years before these guidelines are publically available and accepted by the medical 
community.  Table 3 summarises the most commonly used pharmacological treatment options 
for the management of pain.  These are discussed, in turn, in further detail below.   
 
 
Table 3 The primary pharmacological treatment options for the management of pain (220, 240) 
 
Drug class Pain Type Pain Duration Pain Severity Add on/ monotherapy 
Paracetamol Nociceptive and 
mixed  
Acute and 
persistent 
Mild-severe  Add on and 
monotherapy 
NSAIDs nociceptive and 
mixed 
Acute and 
persistent  
Mild-severe Add on and 
monotherapy 
Opioids Nociceptive and 
mixed 
Acute and 
persistent  
Moderate-
severe 
Add on  
Gabapentinoids Neuropathic and 
mixed 
Acute and 
persistent 
Mild-severe Add on and 
monotherapy 
AEDs Neuropathic and 
mixed 
Acute and 
persistent 
Mild-severe Add on and 
monotherapy 
Antidepressants Neuropathic and 
mixed 
Acute and 
persistent 
Mild-severe Add on and 
monotherapy 
Nerve blocks Nociceptive, 
neuropathic and 
mixed 
Acute (primarily) 
and persistent 
(refractory pain) 
Moderate-
severe 
Add on  
NSAIDS: non-steroidal anti-inflammatories; AED: anti-epileptic drugs 
 
2.2.1 Assessment of analgesic efficacy 
As noted previously, the evidence used to support the development of guidelines often relies on 
expert opinion as the clinical trials undertaken to assess the efficacy of analgesics are often 
methodologically poor, use variable trial methodology, drug dose, route of administration and are 
too short to be able to assess the true safety and efficacy of drugs in persistent pain; which make 
comparisons between studies extremely challenging. It is for these reasons that systematic 
literature reviews are often unable to conclude an effect size from the medications.  In addition, 
trials will frequently exclude patient populations such as elderly, frail and those with a history of 
substance abuse, which makes generalising the effect size to these populations nearly impossible.  
There are some published works such as the Oxford League table (241) which documents the 
number needed to treat for a 50% reduction from baseline with a stat dosing of an analgesic, 
which is useful in the acute, but not persistent, pain setting.  Nonetheless, these include only 
studies that compare the active treatment to placebo rather than another active comparator, and 
consequently cannot take into consideration the synergistic benefit of multimodal analgesia that 
is often used in the post-operative setting, making the applicability of this data to actual clinical 
practice still uncertain.  
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Further complicating the assessments of effect size is then determining what effect is clinically 
meaningful.  Some studies have found that a reduction of 30% or a reduction of two points on the 
NRS is clinically significant and corresponds to a clinically significant improvement (242).  
However, as noted previously, there are many assessment tools that can be used and how to 
amalgamate these scores in meta-analyses to identify an effect size is also challenging.  
Furthermore, a reduction of pain intensity as measured on a NRS is patient-dependent.  A number 
of studies have found that a reduction in pain intensity is not linear in its response to clinical 
significance, with greater pain intensity scores requiring a greater reduction in intensity to be 
clinically relevant (243, 244).  This means that the baseline score is required rather than 
aggregate scores to ascertain a clinically significant pain reduction.  It is in part for this reason 
that there is also increasing recognition of the need to assess quality of life improvements rather 
than reduction in pain intensity when managing persistent pain patients (90-95), although for 
acute pain, a reduction in pain intensity is still the primary goal. 
2.2.2 Non opioid analgesics 
2.2.2.1 Paracetamol effectiveness 
Paracetamol (or acetaminophen) can be used for mild pain as monotherapy, and in combination 
with other analgesics for the management of moderate to severe pain.  The mode of action of 
paracetamol is not fully understood.  A number of mechanisms have been proposed, including 
inhibition of prostaglandin H2 synthesis via COX-2, as well as the activation of descending 
serotonergic pathways (220, 245-247).  Paracetamol can be administered via oral, intravenous 
(IV) or rectal routes (245).     
 
Paracetamol is one of the most common medications used around the world and can be used from 
infancy to death (246).  It is generally recommended as baseline therapy for both acute and 
persistent pain (16, 108, 240, 248).  Following surgery or in conditions that cause persistent pain 
(that is not intermittent in nature) generally paracetamol should be taken regularly at the 
maximum tolerated dose (preferably four grams (g) per 24 hours for most adults). If pain is 
inadequately controlled by paracetamol alone, then paracetamol should be continued at the 
maximum tolerated dose and other medications should be used concomitantly (16, 219).  
 
Paracetamol has been used extensively in acute pain management with good effect in both stat 
dosing and repeated dosing across a range of different types of acute pain (48, 245, 248-254). IV 
paracetamol has been found to be an effective analgesic following surgery as well as reducing 
overall opioid consumption (48, 255, 256) although the optimal dosage range and the extent to 
which it is opioid-sparing require further investigation (245). Not all studies evaluating 
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paracetamol have demonstrated analgesic benefit (257), with others indicating no difference in 
recovery speed compared to placebo (258).  
 
Paracetamol in some studies appears to not be as effective as NSAIDs; however, it is better 
tolerated and is subject to fewer contraindications, and can therefore be used in a wider range of 
patients (246).  A number of studies have also suggested that paracetamol in combination with 
an NSAID may be more effective than the individual components alone (48, 259-262).  However, 
a recent study found that paracetamol, an NSAID and an adjuvant (gabapentin) was not superior 
to two non-opioid analgesics (256).  Additional research is required to determine the optimal 
multimodal analgesic regimens for acute pain and the role of paracetamol in these.   
 
Paracetamol has been used to good effective for persistent pain conditions (253).  However, as 
with most analgesics, the evidence to support its use in persistent pain is variable and trial 
durations are short (263-265). A recent meta-analysis (19) found that paracetamol was slightly 
more effective than placebo in the management of osteoarthritis of the knee and hip and as 
effective as placebo for lower back pain.  It is important to note that the placebo effect has a 
considerable influence in the management of pain (266).  As placebos are unavailable in clinical 
practice, the effect of paracetamol over no treatment is likely to result in an improvement in pain 
management over no treatment.  Additionally, there were some flaws in this meta-analysis, 
namely the use of multiple arms of a study with different doses of paracetamol (ranging it from 
500 milligram (mg) when required to 4g regularly).  The effect of these doses is not comparable 
and thus it is unreasonable for them to be assessed together and may contribute to an 
underestimation of the effect of paracetamol. A network met-analysis (267) was conducted 
comparing different doses of paracetamol  This study found that paracetamol, as well as other 
NSAIDs were superior to placebo for the management of osteoarthritis pain in relation to pooled 
effect size and physical function. However, the effect size was small (4mm on a 100mm visual 
analogue scale) for doses of less than 2g per day, although the effect size was greater at doses 
exceeding 2g per day, indicating there may be more benefit at higher doses.  
2.2.2.2 Paracetamol safety 
Adverse events are uncommon with paracetamol (within the recommended maximum dosage 4g 
daily) however, the safety and efficacy profile of paracetamol is increasingly being questioned 
(20).  Dosage adjustment is normally not required unless the person weighs less than 50kg or 
they are at high risk of liver failure, where a maximum daily dose of 2g is recommended (268-
270).  It was noted in a recent meta-analysis that the adverse event profile associated with 
paracetamol demonstrated no statistically significant difference to that of placebo, with the 
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exception that liver enzymes were more likely to be elevated in those taking paracetamol (19). 
However, a short course of therapeutic paracetamol did not result in increased liver function 
values or risk of toxicity in the frail elderly (271).  Thus the clinical relevance of asymptomatic, 
elevated liver enzymes is unclear.  In addition to raised liver function tests, a recent systematic 
review of observational studies was published which suggested paracetamol may increase the 
risk of a cardiovascular events, kidney impairment and gastrointestinal bleeding (270). Despite 
this finding, there remains a far greater body of evidence suggesting such harms are more 
prevalent with NSAIDs and, that on the basis of this current knowledge, paracetamol is generally 
considered to be a safer option at standard therapeutic doses (264).  
There is limited published evidence to determine the effect of frailty or age-related hepatic 
decline on paracetamol metabolism or the risk of overdose (272).  Additionally, whilst the draft 
version of British guidelines for osteoarthritis management suggested paracetamol may not be a 
safe choice in elderly patients, this recommendation was not included in the final report (237) 
and paracetamol is likely safer than the alternative options (264). As those patients most likely 
to use paracetamol are almost universally excluded from clinical trials, further research is needed 
to determine the adverse effect profile of paracetamol when taken chronically in these 
populations. 
 
The most concerning adverse event related to paracetamol is the risk of overdose.  Paracetamol 
toxicity is the leading cause of acute liver failure in the United States of America and Europe, with 
approximately 50% of these cases as a result of an unintentional overdose (269). Overdose of 
paracetamol can result in hepatotoxicity mediated through the production of a reactive 
metabolite, N-acetyl-p-benzo-quinone imine (NAPQI) (269).  Generally, NAPQI will be 
metabolised to a non-toxic metabolite by glutathione. However, if there is a deficiency of 
glutathione, or an overdose of paracetamol overwhelms hepatic capacity to safely detoxify 
NAPQI, there is potential for liver toxicity, the outcome of which is the requirement of a liver 
transplant or death (269).  
 
In addition to intentional overdose, patients may also unwittingly take excessive amounts of 
paracetamol.  Common reasons implicated in accidental overdose are: if pain is unrelieved with 
standard doses, or patients take multiple paracetamol containing products (particularly in 
combination with a narcotic) (273, 274). This increase in overdose rates led the United States of 
America’s Food and Drug Administration (FDA) to release a statement suggesting prescribers 
avoid using products containing more than 325mg of paracetamol in combination with a narcotic 
(275).  Significant care needs to be taken around the prescribing of multiple paracetamol 
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containing products and subsequent counselling about the maximum dosages of paracetamol to 
reduce the risk of unintentional overdose.   
 
2.2.2.3 NSAID effectiveness 
NSAIDs can be used for mild to moderate pain as monotherapy, and in combination with other 
analgesics for the management of pain.  NSAIDs act by preventing the synthesis of prostaglandins 
through the inhibition of COX 1 and COX 2; inhibition of COX2 results in a reduction in 
inflammation and subsequently pain (220). There are many NSAIDs available, including non-
selective NSAIDs (such as aspirin, diclofenac, ibuprofen and indomethacin) and COX-2 selective 
NSAIDs (celecoxib, etoricoxib, meloxicam, parecoxib). There is some evidence to suggest that the 
different NSAIDs vary in efficacy, with etoricoxib being most effective, followed by ibuprofen 600-
800mg, ketorolac and diclofenac 100mg (241).  It is important to note, however, these are 
determined against placebo and the efficacy in different medical conditions, or in combination 
with other analgesics may vary (276).   
 
The evidence to support the use of NSAIDs in acute pain is significant (48, 276) although trial 
quality is lacking (277-281). A number of recent Cochrane reviews have evaluated the efficacy of 
NSAIDs in a number of conditions including acute postoperative pain (48), acute gout (280), 
dysmenorrhoea (281), acute back pain (279),  strain, sprain or bruise (277) and have generally 
found to be supportive of NSAID use. However, as with other areas of research, the benefit of 
NSAIDs is not consistent; for example, although parecoxib has been found to be effective following 
some surgical procedures (257) other studies found that it does not result in a reduced intensity 
of acute pain (282). Other patient and condition related factors likely play a role in the efficacy of 
the different NSAIDs.   
There is evidence to support the use of NSAIDs for some chronic pain conditions such as 
spondyloarthritis (283), inflammatory arthritis (284) and chronic lower back pain (279). 
However there is also mounting evidence that in conditions not traditionally considered to be 
inflammatory, namely osteoarthritis, patients have a preference for NSAIDs finding them more 
effective the paracetamol (264, 276). Currently, the evidence to support the use of NSAIDs in 
neuropathic pain conditions is lacking (278).  
2.2.2.4 NSAID safety 
NSAIDs have a number of side effects with both acute and chronic use. They have a worse side 
effect profile than paracetamol (264) and for this reason it is recommended to use paracetamol 
preferentially (285). If NSAIDs are required, they are recommended to be used at the lowest 
effective dose for the shortest period of time (285), which is problematic in persistent pain 
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conditions where regular dosing is required.  Numerous studies have reported that NSAIDs, both 
selective and non-selective, are associated with cardiovascular harms and the Therapeutic Goods 
Administration (TGA) (286) recently advised that NSAIDs should not be used in patients with 
cardiovascular disease or significant renal or liver impairment.   
 
Whilst many of the potential adverse effects are common to all NSAIDs, there is some variation in 
the specific adverse effect profile of the different NSAIDs (285, 287, 288). Gastrointestinal 
irritation is common with NSAIDs and with prolonged use can cause gastrointestinal ulcers and 
subsequent gastrointestinal bleeding (288).  COX-2 selective NSAIDs are likely to cause less 
gastric irritation than non-selective agents; however the co-administration of gastric protective 
agents (such as proton pump inhibitors) with non-selective NSAIDs also reduces the incidence of 
gastrointestinal ulcers (288).  Similarly, there appears to be less risk associated with naproxen 
than other NSAIDs in relation to the risk of cardiovascular events (285, 289).  
 
Due to the side effect profile of NSAIDs, guidelines for elderly or frail patients recommend 
avoiding them (16, 108, 221) and topical NSAIDs are preferred (289). However, if an oral NSAID 
is required, it is recommended in the elderly to use ibuprofen or naproxen in preference to other 
NSAIDs, if there is no history of heart failure and the patient has sufficient renal function (289). 
Some studies (290, 291) have suggested that NSAIDs may be safer than opioids in the elderly, 
although there were a number of confounding aspects, including the lack of recording of use of 
over-the-counter NSAIDs in the opioid group, which make the results difficult to interpret (292). 
Based on the safety profile of NSAIDs, guidelines generally recommend low dose opioids to be 
considered a more suitable add-on therapy to paracetamol than NSAIDs (16, 108) if paracetamol 
alone is not adequately controlling pain in elderly or frail patients. 
 
2.2.3 Opioid analgesics  
Pharmacological opioids mimic endogenous opioids, such as beta-endorphins and encephalin, 
that act on μ receptors in the dorsal horn of the spinal cord and periaqueductal grey in the brain 
(220, 293, 294) to exert their analgesic effect. Opioids should not be used for the management of 
mild pain, but are frequently used in the management of moderate to severe pain (48). Some 
opioids, namely tapentadol and tramadol, have an additional mode of action involving inhibition 
of neuronal reuptake of noradrenaline and serotonin. These effects result in more noradrenaline 
being available in descending pathways which attenuates pronociceptive receptor-driven 
ascending signals, further reducing pain (15).  Potentially, tapentadol and serotonin and 
noradrenalin reuptake inhibitors (SNRIs), such as duloxetine also affect DNIC function and may 
increase DNIC function and subsequently improve persistent pain conditions (295, 296).      
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Some opioids are indicated only for use during surgical induction or maintenance of anaesthesia 
(remifentanil; alfentanil) and some (fentanyl; morphine) can be used intravenously during 
surgery as well as well as via other routes (transdermal patch, intranasal spray and orally) for 
acute or persistent pain (220). Opioids have different levels of potency and thus are often 
categorised as weak or strong opioids (297). Conversion tables are available to determine equi-
effective doses (298-301).  However variations in the patients’ pharmacodynamics and 
pharmacokinetics may affect the equi-effective dose in clinical practice. For this reason, opioid 
switching due to individual patient factors may allow for improved analgesic effect without the 
need for an increased (equivalent) dose or reduced adverse events profile (48, 301-303).  
 
2.2.3.1 Opioid Effectiveness 
Morphine and its derivatives have been used as analgesics for hundreds of years (304).  There is 
significant evidence to demonstrate the efficacy of opioids for the management of moderate to 
severe acute pain when given orally, IV, intramuscularly, or epidurally, as well as transdermally 
(48, 305-309).  A range of opioids are used in the management of acute pain; however, there does 
not appear to be one opioid that is generally more effective than others, yet patient variability 
may mean that one patient responds better to one opioid over another one (48). 
  
The evidence to support the use of opioids for persistent pain however is poor (94). Despite this, 
opioid analgesics are increasingly prescribed for the management of persistent pain, 
demonstrated by the dramatic increase in their use (21-25) and treatment duration (22, 27).  The 
trials evaluating opioids are often methodologically poor (94) with trial durations being relatively 
short (18) with limited patient outcome data (89). There are also only a limited number of studies 
evaluating changes in the pharmacokinetics and pharmacodynamics of opioids associated with 
frailty and opioid use (310). A recent meta-analysis of opioids (303) concluded that there was 
insufficient evidence to determine if long-term opioids were effective at improving pain scores 
and physical functioning. Additionally, this review found that there was significant evidence of 
dose-dependent risks associated with the use of opioids, which will be discussed further in 
Section 2.2.3.2.  
 
Nevertheless, persistent pain guidelines do universally recommend the use of opioids for 
moderate to severe pain that is not adequately managed with non-opioid analgesics (311). Opioid 
analgesics are not recommended as first-line treatment or in isolation of other pharmacological 
and non-pharmacological treatment options (297, 312, 313). Generally, it is recommended that 
opioids are used as an add-on to non-opioid analgesics, particularly paracetamol (108, 217, 222).  
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There does not appear to be one opioid that should be used in preference to another (222, 303) 
with the exception of fentanyl and methadone which should not be commenced if the patient is 
opioid naïve (303, 314) due to the risk of toxicity.  Most guidelines recommend commencing on 
a low dose and titrating up to effect (92, 108, 222, 297, 315).  Sustained-release preparations are 
preferred for persistent pain conditions (222, 297, 312, 316); and parenteral opioids should be 
avoided in all persistent pain conditions (297, 316). Opioids should be tapered and ceased if there 
is no improvement in the patient’s symptoms after a trial period (normally lasting 4-8 weeks) 
with appropriate dose titration or if the patient choses to withdraw treatment or the pain has 
resolved (92, 222, 297, 312). The recommended maximum daily oral morphine equivalent 
(MEQ/d) dose varies from 100-120mg (Australia) (94, 312), 120mg (United States of America) 
(317), 120-180mg (United Kingdom) (297), to 200mg (Canada) (92).   
 
Theoretically, all opioids may be equally safe and effective for older or frail persons; however, 
due to interpatient variability opioid rotation or switching may result in better tolerability or 
efficacy for individual patients (222, 297). The use of weak opioids, including codeine and 
tramadol, generally results in similar adverse event profiles but less efficacy than their stronger 
counterparts and thus are often not recommended (108). Van Ojik and her colleagues (228) 
concluded there was little evidence of the effectiveness of opioids in the treatment of chronic pain 
in the frail elderly, with the following options having the most evidence to support their use in 
these individuals: buprenorphine, fentanyl, hydromorphone, morphine and oxycodone.  The most 
recent update of the Beers criteria, which makes recommendations about medications that 
should be avoided and medications that should be used preferentially in the elderly, has 
recommended tramadol, oxycodone or morphine, in combination with paracetamol as most 
suitable for elderly patients (289).    
 
2.2.3.2 Safety of opioids 
In line with the increasing use of opioids for persistent pain, there has been a trend towards 
increasing rates of deaths associated with opioid analgesic use (27-32), proportional to the dose 
being used (27, 318).  However, accidental overdose can occur even at doses within the 
recommended range (28, 232, 319) particularly in combination with alcohol or benzodiazepines 
(30).  In addition, another concern regarding opioids is the risk of addiction in patients taking 
long-term opioids.  The true rate of addiction is unclear, with one literature review (320) 
estimating between 0-50% of those taking opioids were addicted, however they noted the 
definitions and methods of determining addiction were variable. A Cochrane Review (321) 
however identified in well selected candidates for opioid treatment, where there was no history 
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of substance abuse the risk of addiction was minimal.  Currently the true rate of addiction is 
unknown and requires further prospective trials to identify the true risk.  
 
Side effects are very common with opioids, with approximately 80% of patients experiencing at 
least one adverse event (297) and patients more likely to cease taking opioids due to side effects 
compared to placebo (322). The most commonly report adverse events associated with opioids 
are nausea, respiratory depression, constipation, pruritus and drowsiness or sedation (220, 297). 
Some side effects associated with opioids are dose-dependent such as respiratory depression and 
sedation; however, others, particularly constipation are not (48). Similarly, some side effects are 
transient or improve with time, such as sedation, whereas others do not, such as constipation that 
persists throughout treatment.  
 
In addition to the common adverse events listed above, a number of endocrine abnormalities 
have been identified with the long-term use of opioids, including hypogonadism (323-325) and 
increased risk of fractures and falls (326-329). Opioids have also been implicated in affecting the 
immune system (330), including depleting lymphocytes in mice implanted with morphine pellets 
(331).  Further to this, certain opioids, primarily morphine, may also increase the likelihood of 
cancer metastases or recurrence; currently, further research is being conducted in this area to 
understand potential mechanisms behind this and which, if any opioids, are implicated (332). 
Clinical trial durations reviewing the safety and efficacy of opioids, as noted previously, are short.  
This prevents the incidence of these less common adverse events to be categorised.   
 
Nonetheless, opioids have a significant number of adverse events and should only be used when 
management with non-opioid analgesics has been optimised and the lowest effective dose should 
be used.  If opioids are found to not improve physical functioning of the patient they should be 
discontinued, due to the risk of adverse events. 
 
There appears to be limited difference between the side effect profiles of the available opioids, 
although some variations exists (222, 297). Although, switching to an alternative opioid can 
improve side effects for some patients (222, 297). Some opioids, namely tapentadol, tramadol 
and methadone, have a slightly different side effect profile compared to other opioids.  Given the 
serotonergic effects of tramadol and tapentadol, they have the potential to cause serotonin 
toxicity or serotonin syndrome, especially when combined with other serotonergic drugs such as 
antidepressants (333), in addition to the typical opioid-related side effects. This can be a 
limitation to their use, given the high concurrent rates of depression in patients with persistent 
pain (145). Methadone, which is generally reserved for refractory pain, has highly variable 
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pharmacokinetics (334) and has demonstrated an increased risk of death associated with its use 
(335), and other opioids should be used preferentially. 
 
2.2.3 Adjuvants 
Adjuvant medications are those that are not specifically designed as analgesics, and are used 
primarily for other indications; however, for some disease states they demonstrate analgesic 
effects (336). The different types of adjuvants used in the management of acute and persistent 
pain include antidepressants, AEDs, N-Methyl-D-Aspartate (NMDA) antagonists, alpha-2 
andrenergic agonists and local anaesthetics (336).  In addition, there are a number of adjuvants 
that are used to manage bone pain associated with metastatic disease, including corticosteroids, 
calcitonin and bisphosphonates (336). However, as the focus of this review is non-cancer related 
pain, these bone pain specific adjuvants will not be discussed further.  It is recommended, as with 
all medications, to use the medications with the best risk-benefit profile, commencing with one 
agent at a time and starting at low doses and titrating to effect (336). 
 
2.2.3.1 Adjuvant Effectiveness 
AEDs, particularly the gabapentinoids (pregabalin and gabapentin), are frequently employed in 
the management of neuropathic pain, and also perioperative pain management.  Gabapentin and 
pregabalin have been found to be effective for the management of neuropathic pain, can reduce 
opioid requirements following surgery and reduce opioid related adverse events (48, 337-341).  
A systematic review of the effect of pregabalin and gabapentin on the incidence of PPP showed a 
statistically significant reduction in the development of PPP in those taking a gabapentinoid 
(342), although this study did not include unpubished studies that potentially may bias the 
results, a reanalysis using unpublished results demonstrated no statistical difference (343). 
However, a more recent study did not find that pregabalin improved pain following traumatic 
nerve injury, including that caused by surgery (344).  Consequently, the long-term benefit of 
gabapentinoids following surgery is currently unclear.  Pregabalin has also been found to be 
effective in the management of pain associated with diabetic neuropathy (48). Whilst the 
gabapentinoids are the AEDs most often used in pain management, other AEDs such as 
carbamazepine may have a role in some patients, in particular those with trigeminal neuralgia 
(48).   
 
Antidepressants have been found to be beneficial in a number of persistent pain conditions, 
particularly neuropathic pain (48, 336, 338, 345). However, the evidence to support the use of 
these medications in acute pain management are generally based on extrapolation of trials in 
persistent pain (48). Tricyclic antidepressants (TCAs) have been found to be effective in the 
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management of neuropathic pain, fibromyalgia, and headaches (48). Duloxetine, an SNRI, is 
effective for management of pain associated with diabetic neuropathy and fibromyalgia (48, 108, 
338, 346).  Venlafaxine, another SNRI, has also been found to be effective in the management of 
persistent pain in patients with depression (347, 348), post-surgical pain  (349, 350) and diabetic 
neuropathy (350).  Studies have been conducted evaluating the effectiveness of certain selective 
serotonin reuptake inhibitors (SSRIs) in the management of neuropathic pain and they have been 
found to be effective (336); however, the evidence for the use of SSRIs is not as positive as SNRIs 
(351).  Currently there is insufficient evidence to recommend the use of antidepressants for the 
management of lower back pain, although they are frequently used for this condition (48, 352).  
Studies often reviewed the efficacy of specific antidepressants, it is however likely that the 
analgesic benefits would be a class effect. 
 
Generally, TCAs and gabapentinoids are used preferentially over SSRIs and SNRIs due to 
demonstrated efficacy (351). TCAs are not recommended in the elderly; rather SNRIs, SSRIs, 
gabapentinoids, capsaicin cream or lignocaine patches are recommended preferentially (289) 
due to the risk of adverse events, particularly anticholinergic events (16, 108).  Some of the side 
effects of adjuvants are similar to that of opioids such as sedation; however, due to the mode of 
action being vastly different, opioids and gabapentinoids have a different side effect profile.  
Pregabalin can cause visual disturbance, confusion, lethargy, memory impairment, weight gain, 
dry mouth, constipation, hallucinations, cardiac abnormalities and rarely bloody dyscrasias 
(220).  Gabapentin can cause memory impairment, peripheral oedema, weight gain, dry mouth, 
psychosis and rarely movement disorders (220).   Recently, there has also been concern raised 
regarding the abuse potential of gabapentin and pregabalin, and their use has been linked with a 
number of deaths (353). 
 
Other adjuvants used more commonly in perioperative pain management, but increasingly in 
persistent pain and more recently, refractory depression, include the NMDA antagonists, 
primarily ketamine (354, 355).   Ketamine causes a number of different effects throughout the 
body; however, the exact mode of action is still somewhat unclear (356).  Ketamine works by 
blocking NMDA and HCNI receptors and reduces the ability for nociception to occur (356).  
Ketamine can reduce the opioid requirements in postoperative pain, as well as opioid-related 
adverse events, (48, 357) although the results are inconsistent and the dose, route of 
administration and co-prescribed therapies make it challenging to estimate the true efficacy (357, 
358). Overall, the main benefit associated with ketamine appears to be in the prevention of 
hyperalgesia and allodynia, and reduced likelihood of tolerance to opioids (48, 359-361). It has a 
narrow therapeutic margin, which can limit its use as an analgesic, and increase the risk of 
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sedation or psychotomimetic effects (356). Ketamine has both immediate and delayed effects, 
and analgesic effects can continue beyond the duration of drug effect. (356)    
 
Some other adjuvant agents tend to be mainly used in acute pain management. Alpha-2 agonists, 
in particular clonidine, can improve analgesia following surgery; however, they are associated 
with significant adverse effects including hypotension and bradycardia, which limit its use (48, 
362, 363). Dexamethasone has also been shown to reduce the level of postoperative acute pain 
experienced as well as nausea and vomiting (48, 364).  This effect appears to be more consistent 
if dexamethasone is given pre-operatively rather than intraoperatively (365).   
 
Overall adjuvants can be useful for certain types of pain conditions particularly neuropathic, 
however the evidence is variable and the side effect profile requires careful dose adjustment and 
patient selection. 
 
2.2.5 Nerve blocks  
Local, regional (for example brachial-plexus blockade) or spinal and epidural anaesthesia nerve 
blocks are frequently employed in the management of acute and persistent pain.  These can be 
administered as bolus doses into the nerve or continuous infusions in an area proximal to the 
nerve or nerve plexus (366).    
 
2.2.5.1 Nerve blocks effectiveness 
All local anaesthetics have similar efficacy; however, their duration of action and duration until 
toxicity can occur vary between the treatment options (367).  These can be administered either 
locally or via epidural; however, epidural analgesia has been found to be more effective when 
given in combination with opioids (48).  Nerve blocks have been found to be opioid-sparing, 
improve postoperative pain management and reduce length of stay in hospital (48, 367). 
Although a recent Cochrane review suggested that trials supportive of the use of local 
anaesthetics infiltration in the peritoneal cavity following elective cholecystectomies were liable 
to bias, they however appeared to result in lower pain scores compared to the control group 
(368).  Generally these medications are used for acute pain; however, there is evidence to support 
the use of lignocaine in chronic neuropathic pain, particularly with the use of a patch (48, 367).  
Local anaesthetic and abdominal nerve blocks have been found to reduce opioid consumption 
following a caesarean section (369), breast surgery (although not clinically significant) (370) and 
evidence to support the efficacy of nerve blockages at reducing PPP is positive (371).  However, 
deficiencies in study methodology, including small sample size, variability in dose, route of 
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administration and study protocols that are liable to bias, including lack of concealment and 
failure to report all outcomes, are limitations of all these studies (369-371). 
 
Continuous peripheral nerve blocks have been found to reduce postoperative opioid 
consumption, and are associated with faster functional recovery and reduced length of stay (372).  
Continuous peripheral nerve blocks have been found to be effective in the management of acute 
postoperative pain, particularly thoracic and orthopaedic surgery and increasingly ambulatory 
surgery (372). A Cochrane review found that a femoral nerve block following a total knee 
arthroplasty was more effective than an opioid given by patient controlled analgesia (PCA) alone 
and equivalent to an epidural (373).  This same study found that using continuous peripheral 
nerve block was more effective than a single bolus injection (373).  Evidence to support the use 
of these medications following joint surgery though are variable with some demonstrating 
negligible benefit (374).  Thus, much of the evidence to support use of regional blockade and local 
anaesthetics is subject to bias and although they appear beneficial, more studies are needed to 
ascertain the true benefit of these interventions in both acute and persistent pain conditions.  
 
2.2.4.2 Safety of nerve blocks 
Generally the adverse effects associated with local anaesthetic blockades are minimal, and 
anaphylaxis is rare (367), however local anaesthetics systemic toxicity (LAST) can occur.  LAST 
is more common in the very young (less than four months) or old (aged over 70 years), those with 
heart conditions, metabolic disease or acidosis, liver disease or low blood protein levels (367).  
LAST can present with both cardiovascular effects and/or central nervous effects.  Cardiovascular 
effects include arrhythmias, both tachycardia and bradycardia, decreased blood pressure and 
heart failure (severe toxicity) (367).  CNS effects can included altered sensations including 
tingling of lips, peripheral numbness, tinnitus, metallic taste, vomiting, muscle twitching, sleep 
disturbance, confusion, sedation and potentially respiratory failure and death (severe toxicity) 
(367).  There is also a risk of nerve damage due to the nature of the procedure (367). 
 
The use of regional blockades is associated with a reduced risk of toxicity and overdose (367) 
compared to standard use of local anaesthetics.  The most common side effects reported with 
regional blockades are nerve injury, catheter infection (0-3.2%), LAST and bleeding (366).  The 
incidence of nerve injury is variable between retrospective (0.5-1%) and prospective studies (10-
15%) (366). A Cochrane review found that patients at high risk of cardiac problems who 
underwent a regional anaesthesia had a lower risk of mortality in the first 30 days than general 
anaesthesia (375).  However, there does not appear to be a benefit in other types of surgery, such 
as caesarean section, where safety for mother and child are comparable to general anaesthesia 
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(376).   Overall more prospective studies are required to ascertain which types of nerve blocks 
work most effectively for different surgical procedures. 
 
2.3 Areas requiring further research 
As mentioned throughout the previous section, the evidence to support the use of analgesic 
medications is often variable, with methodological deficiencies.  This area requires substantially 
more head to head multicentred, randomised, longitudinal controlled studies with patient 
outcomes related to physical function, pain intensity and adverse events to ascertain the true risk 
and benefit of these medications.  Unfortunately, these trials are difficult to conduct and 
extremely costly.  Sponsorship by pharmaceutical industry may increase the likelihood of bias, 
whether actual, potential or perceived.  Moreover, with availability of so many different pain-
causing conditions, management strategies and availability of over-the-counter analgesics, 
controlling these studies is fraught with difficulty.  In addition, due to the compounding factors 
associated with pain and the experience of pain, controlling for patient variability in 
psychological, biological and social/environmental factors would be near impossible.  Having said 
this, trials should be conducted to better determine efficacy and adverse effects. Until that point, 
trial and error and careful patient selection and individualisation of management strategies 
should be encouraged to improve patient function, improve tolerability and minimise risk of 
harm.  
 
The draft Australian Pain Strategy, an update from the 2010 version (36), has been recently 
published (35).  The National Pain Strategy has six goals: including pain as a national health 
priority; improving knowledge and skills in clinicians and consumers; quality improvement and 
evaluation; interdisciplinary pain clinic access and research (35).  The Pain Strategy’s sixth goal, 
research, includes many aspects such as undertaking evaluation of interventions for persistent 
pain management, assess attitudes towards pain and its management, and assessing the safety 
and efficacy of pain management in older patients (36).  A policy paper (38) in Australia also 
suggested further areas for research should include: identification of risk factors for the 
development of persistent pain conditions, improving the management of persistent pain, and 
reducing the harms around persistent pain management, specifically opioids. 
 
It is difficult to generalise internationally published literature to the Australia situation due to a 
number of varying practices and laws surrounding the use of opioids. There is a relative dearth 
of published data regarding the use of prescription opioids and analgesic use in Australia.  Only a 
limited number of studies have been published evaluating analgesic management of pain in 
Australia.  A number in New South Wales (6, 57, 58, 377, 378), one study in South Australia (7), 
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one in Queensland (379) and seven national reviews (21, 23, 25, 26, 380-382) of the use of opioids 
(without patient demographics, co-prescribed therapies, medical conditions), two reviews 
evaluating analgesics in ACFs (383, 384) and another in emergency departments (385).  Thus the 
lack of generalisability of some of these papers, as well as the time that has elapsed since some of 
these articles were published, coupled with the recommendation of the National Pain Strategy 
and the policy paper by the Royal Australian College of Physicians indicate the need for more 
research to evaluate how pain is being managed in Australia, who is taking analgesics, and what 
the risk factors for persistent pain are (38). 
 
Despite a significant number of studies identifying factors increasing the risk of persistent pain, 
a number of areas still remain poorly described in the literature.  It is for this reason that the 
Royal Australian College of Physicians’ policy paper suggests that this is an area that requires 
further research (38). At the 14th World Pain Congress, held in August 2012, PPP was highlighted 
as an area that requires additional research to identify causative factors and ways to optimise 
patient outcomes (386). Although a number of the studies have been undertaken in this field, they 
are small, of relatively poor quality or do not contain enough variables to ascertain predictors of 
chronicity and thus questions still remain over causative factors and ways to optimise therapy 
(81-83, 199, 211, 387).  Additionally, few studies have followed patients with acute post-surgical 
pain following discharge, to determine any links between management in this phase and the 
development of PPP (388, 389).   
 
As previously noted, the management of pain is challenging with poor trial evidence, difficult 
patient populations with multiple comorbidities and difficult to use clinical guidelines.  Thus, 
identifying ways that pain could be managed better may assist not only with the patient’s QOL 
and physical function, but also may assist in identifying ways to reduce the likelihood acute pain 
will progress to persistent pain.  To address these gaps in the literature, this PhD was developed 
with four major objectives: 
- Observe how pain is managed pharmacologically by patients, GPs, surgeons and 
anaesthetists; 
- Identify what factors are associated with the development of PPP; 
- Identify QUM issues related to the management of pain; and 
- Identify the barriers and enablers to pain management.  
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Chapter 3: Patient self-management of pain in the week following discharge after 
surgery: an Australian prospective observational study 
3.1 Abstract 
Background: Up to 80% of patients experience acute pain following surgery.  There is limited 
understanding about how patients take analgesics to manage this pain following discharge.  This 
study aimed to address this gap and identify barriers to optimal post-discharge pain 
management. 
 
Methods: A prospective observational study was conducted at the RHH, Australia between 
November 2014-March 2015. Eligible participants were 18 years or older, undergoing surgery 
requiring an incision; patients undergoing surgery related to cancer, childbirth or multi-trauma 
or those with dementia were excluded. Participants were identified through hospital discharge 
lists and mailed a survey within one week of discharge.  This survey asked about post-discharge 
pain, analgesic consumption and whether patients recalled being given advice regarding their 
pain management.  
 
Results: 500 surveys were mailed with 169 (33.8%) being returned. The median age of the 
participants was 57 years (range: 18-92 years); 53% were female. The majority (89.3%) of 
participants recalled receiving information about their pain management. Analgesics were 
reported to be used by 95.4% of participants in the week following discharge. Self-report 
moderate-severe pain was noted by 80 participants (47.3%); 63.7% of those, reported using 
fewer analgesics than directed, with 11.3% using more analgesics than directed.   
 
Conclusion: It was concerning to see a high proportion of patients reporting underusing their 
analgesics despite experiencing moderate-severe pain. Although the vast majority of participants 
reported receiving advice regarding pain management, this did not appear to translate into 
optimal pain management and a different approach to the provision of advice would appear to be 
necessary.  
 
3.2 Introduction 
Up to 80% of patients undergoing a surgical procedure requiring an incision will experience acute 
postoperative pain (390).  Uncontrolled acute postoperative pain has the potential to decrease 
QOL, reduce participation in rehabilitation activities, increase the risk of PPP and venous 
thromboembolism through inactivity, as well as increase the likelihood of readmission to hospital 
or extending the length of the initial hospital admission (82, 388, 391-393).   
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In hospital, especially large public hospitals, pain is carefully managed in the peri- and 
postoperative phase by a multidisciplinary team.  However, pain relief in the period following 
discharge from hospital is less structured and has less oversight by health care professionals.  
Numerous studies have found that patients often experience more pain after discharge than 
during their admission (48, 204, 393-397).  Post-discharge, patients must manage their own pain, 
making judgements about their level of pain and use of analgesics, which may be influenced by 
adverse effects, as well as patients’ expectations and underlying concerns related to use of 
medication for pain. To assist each patient’s self-management it is recommended that they are 
provided with detailed information regarding how to manage their pain after discharge (398).  
 
However, to be effective, adequate pain management requires that patients follow the advice they 
are given.  Numerous studies have found that patients do not take their analgesics as prescribed. 
This includes patients with persistent pain both under and overusing their analgesia (399-407) 
as well as patients with metastatic cancer (408-411) underusing their analgesia.   However, there 
have been fewer studies (395, 396, 412, 413) reviewing how patients self-manage their acute and 
sub-acute pain, and whether they are adherent to the advice provided regarding their 
medications.  
 
Additionally, there has been a trend towards a reduced length of hospital stay following major 
surgery and increasing use of day surgery for more minor procedures (414); both of which result 
in patients being required to self-manage their pain at home for a greater length of time. Thus, 
identifying how patients manage their pain following discharge is increasingly relevant. To assist 
in filling this gap in the literature, this study aimed to evaluate how patients take analgesics, if 
they are adherent to the pain management advice given and where they obtain analgesics from.  
From this, the barriers to optimal pain management in the post-discharge period could be 
identified and strategies to improve management recommended. 
 
3.3 Methods 
A prospective cross-sectional observational study was conducted at the RHH, Tasmania, 
Australia.  This study followed patients who had undergone a surgical procedure between 
December 2014-March 2015. Posters were displayed on relevant surgical wards of the RHH to 
inform patients of the study.  
 
Patient discharge lists and the digital medical records (DMR) were reviewed to identify patients 
who had undergone a surgical procedure at the RHH and were discharged home no more than 
seven days after surgery. Patients were included if they were 18 years or more and underwent 
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any type of surgery (both elective and emergency) that required an incision.  Participants 
underwent operations including sternotomies, orthopaedic or spinal related procedures, open or 
laparoscopic abdominal/genitourinary operations, wound debridement with reconstruction as 
well as operations associated with the sinus, eye or eye lids, mouth region and thyroid.   
 
Patients were excluded if they: had experienced a multiple trauma emergency; had a direct 
cancer-related procedure; had a non-invasive procedure (e.g. colonoscopy or cystoscopy); or 
were a resident in an ACF. Eligible patients were sent the paper-based survey in the mail within 
seven days of being discharged home. Patients with a past medical history of dementia or those 
who developed postoperative cognitive decline were also excluded through assessment of their 
DMR. Following the return of the written survey (within 14 days of discharge), the DMR was then 
accessed again to record further details about the patient’s hospital admission. This information 
included: length of stay, comorbidities, inpatient analgesic use, perioperative management and 
whether the hospital’s APS had been involved with their care during their admission. 
 
Written surveys (Appendix 1 and 2) included basic demographic details, level of education, self-
reported pain intensity during the seven days following discharge using an 11-point visual 
analogue scale, analgesic consumption following discharge (including drug, dose and directions 
of actual use), a description of the information (including verbal and written information) they 
had been given pre- and post-surgery regarding pain management after discharge and who they 
recalled giving them this advice; whether they adhered to the advice (self-reported) and whether 
they took their analgesics as prescribed, more than prescribed or less than prescribed.  Patients 
were also asked why they did or did not follow the advice given to them and where they obtained 
their analgesics from. The quality of the advice was not assessed as part of this study. Partially 
completed surveys were included where answers were provided.  
 
It was estimated that approximately 500 eligible patients would undergo surgery during the 
recruitment period at the RHH, with approximately 80% of these people likely to experience 
acute postoperative pain (390). From this, a sample size of 165 patients was calculated as being 
required for a statistically significant sample size to review the outcome of acute pain, using a 
confidence interval of 0.05. An incentive was used to enhance recruitment, which was the chance 
to win one of five $100 AUD gift cards.  
 
Statistical analysis was performed using SPSS Statistics 20 for Windows (SPSS Inc., Chicago, II, 
USA). Chi-square and Mann-Whitney U tests were used to evaluate patient and treatment 
differences between those who experienced moderate-severe pain in the week following surgery 
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and those who did not. Multiple variable binary logistic regression was undertaken to analyse the 
independent associations of variables between those who experienced moderate-severe pain 
following discharge and those who did not.  All variables with a p value of <0.1 in the univariate 
model were included in the logistic regression mode.  A p-value of <0.05 was considered to be 
statistically significant. This study was approved by the Health and Medical Human Research 
Ethics Committee (Tasmania).  
 
3.4 Results 
Five hundred surveys were posted to eligible patients during the recruitment period; of those, 
169 were returned (33.8%). The median age of the participants was 57 years (range: 18-92 years) 
and 53% of were female. Participants undergoing elective procedures accounted for 55% of the 
cohort.  Self-reported moderate-severe pain (≥4 on the 11-point visual analogue scale) in the 
week following discharge was experienced by 47.3% of participants.  Participants were asked 
what their average level of pain across the week since being discharged home was; the median 
score reported was 3 (range 0-10). Table 4 shows the differences in patient characteristics and 
pain management between those who reported experiencing moderate-severe pain and those 
reporting mild or no pain.   
 
The vast majority (89.3%) of patients were provided (or recalled being provided) some advice 
regarding their pain management following discharge.  Nurses (46.7%), doctors (35.5%), 
pharmacists (30.2%) and anaesthetists (13.6%) were reported most frequently as having 
provided advice. Thirty-two percent of respondents recalled being provided advice by more than 
one health care professional. Written information (either pre-admission or during discharge) was 
recalled as being provided to 72.1% of patients.  Most (78.7%) of the patients stated that they 
followed the advice that they were given. For those people who reported not following advice, 
they were most likely to report taking their analgesics differently to that prescribed.  
 
Analgesics were used by 95.3% of participants in the week following discharge, with 67.8% of 
patients using more than one class of analgesics. Underuse of analgesics, relative to the advice 
provided, was more commonly reported (28.4%) than overuse (5.3%). For those patients taking 
less analgesics than advised, the mostly commonly cited reasons were: not needed due to no/little 
pain (22.9), side effects (20.8), fear of overuse/running out (4.2%), not understanding directions 
(4.2%) and used to the pain/try and tolerate pain without analgesics (6.3%).   Moderate-severe 
pain was reported by 63.7% of those reporting underusing their analgesics. Ten patients reported 
taking more than 4g of paracetamol daily, with three patients taking 8g daily.  Eight of these 
patients reported experiencing moderate-severe pain (p=0.03).  Eight participants also 
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commented that they felt they were underprepared or had insufficient information to be able to 
self-manage their pain following discharge; of those, 75% rated their average pain intensity as 
moderate-severe in the week following discharge.  
 
Medications that were used in the week following discharge were most commonly provided by 
the hospital at the time of discharge (69.8%). Other sources of analgesics were reported to be 
purchased from a community pharmacy (28.2%); via a prescription from a GP (25.9%); 
analgesics already in the home (6.5%) or purchased from a supermarket (5.6%).   Opioids were 
reported as being taken by 59.7% of participants in the week following discharge, with 27.2% of 
participants reporting they used an NSAIDs and 78.6% reporting they used paracetamol. One 
patient also reported using illicit drugs in addition to their analgesics.      
 
Non-pharmacological strategies were reported to be used by 35.5% of participants.  Cold and/or 
heat packs (18.9%) and active strategies such as massage, physiotherapy, exercise and stretching 
(18.9%) were most frequently used.  A smaller proportion of participants (8.8%) reported using 
passive strategies such as rest, repositioning, elevation and praying, and five participants 
reported using other strategies including vitamin supplementation.  
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Table 4 Patient demographics of those who self-reported experiencing, on average, moderate-
severe pain in the week following discharge and those who did not.  
Variable Self-reported mild 
or no pain 
n=89 (%) 
Self-reported 
moderate-severe 
pain 
n= 80 (%) 
P 
value 
Baseline demographics 
Median age (IQR) 59.0 (48.5-68.0) 55.0 (43.3-66.5) 0.16 
Female (%) 44 (49.4) 45 (56.2) 0.38 
Level of education 
     ≤ Year 10 
     Year 11/12 
     Post-graduate education 
 
34 (38.6) 
26 (29.5) 
28 (31.8) 
 
27 (34.6) 
28 (35.9) 
23 (29.5) 
 
0.68 
Employment status 
     Employed 
     Retired 
     Unemployed/disability pension 
 
34 (38.2) 
33 (37.1) 
22 (24.7) 
 
32 (40.0) 
19 (23.8) 
29 (36.2) 
 
0.12 
Elective (%) 39 (43.8) 49 (61.3) 0.09 
Type of Surgery 
     Head (sinus, nasal, oral, ocular, thyroid) 
     Musculoskeletal (including spinal) 
     Open abdominal/genitourinary 
     Laparoscopic abdominal/genitourinary   
     Wash out/debridement of wound 
     Cardiothoracic 
 
16 (18.0) 
28 (31.5) 
8 (9.0) 
19 (21.3) 
15 (16.9) 
3 (3.4) 
 
4 (5.0) 
44 (55.0) 
8 (10.0) 
12 (15.0) 
10 (12.5) 
2 (2.5) 
 
0.02 
Reviewed by the APS 12 (13.5) 20 (25.0) 0.06 
What was their expected level of pain 
     None 
     Mild 
     Moderate/severe 
 
15 (17.4) 
37 (43.0) 
34 (39.5) 
 
5 (6.4) 
25 (32.1) 
48 (61.5) 
 
0.01 
Length of stay (nights) 
     0  
     1 or 2  
     3 or 4 
     ≥5 
 
8 (9.0) 
41 (46.1) 
20 (22.5) 
20 (22.25) 
 
8 (10.0) 
33 (41.2) 
27 (33.8) 
12 (15.0) 
0.33 
Medical History 
Median number of comorbidities (range) 2.0 (0.0-4.5) 2.0 (0.0-4.0) 0.78 
Pre-existing analgesic use 26 (29.2) 32 (40.0) 0.14 
Pre-existing persistent pain 23 (25.8) 45 (56.2) <0.01 
Previous history of anxiety 6 (6.7) 2 (2.5) 0.20 
Previous history of depression 12 (13.5) 10 (12.5) 0.85 
Recalled provision of advice 
Given written and/or verbal advice regarding 
pain management  
81 (91.0) 70 (87.5) 0.05 
Given advice on how many analgesic 
tablets/capsules to take 
63 (73.3) 
 
50 (62.5) 
 
0.14 
 
Given advice on what analgesics to take 64 (74.4) 58 (72.5) 0.78 
Given advice on when to contact the hospital 50 (58.1) 39 (48.8) 0.23 
Given advice on what activities they 
could/could not do following discharge 
51 (59.3) 41 (51.9) 0.34 
Provided any written advice 66 (74.2) 56 (70.0) 0.55 
Attended a pre-assessment meeting 56 (62.9) 45 (56.2) 0.38 
Followed advice post-discharge 70 (88.6) 63 (90.0) 0.78 
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Self-reported post-discharge pain management 
Patient self-reported use of analgesics: 
     Underused  
     As prescribed 
     Overused  
 
28 (31.5) 
61 (68.5) 
0 (0.0) 
 
20 (25.0) 
51 (63.7) 
9 (11.2) 
 
<0.01 
Was provided analgesics on discharge 51 (57.3) 67 (83.8) <0.01 
Used an opioid following discharge  39 (43.8) 62 (77.5) <0.01 
Used an NSAID following discharge 25 (28.1) 21 (26.2) 0.79 
Used paracetamol following discharge 65 (73.0) 68 (85.0) 0.06 
Used a gabapentinoid following discharge 1 (1.1) 6 (7.5) 0.04 
Used non-pharmacological strategies 27 (30.7) 33 (41.8) 0.14 
IQR: interquartile range; APS: Acute Pain Service; NSAID: non-steroidal anti-inflammatory medicines 
 
Table 5 Factors associated with self-reported moderate-severe pain following discharge in 
multivariate analysis 
Variable OR (95%CI) P value 
Elective (%) 1.64 (0.62-4.38) 0.18 
Type of Surgery 
     Head (sinus, nasal, oral, ocular, thyroid)  
     Musculoskeletal (including spinal)  
     Open abdominal/genitourinary  
     Laparoscopic abdominal/genitourinary 
     Wash out/debridement of wound  
     Cardiothoracic  
 
1 
5.66 (1.28-
25.01) 
6.36 (1.07-
37.93) 
2.29 (0.47-
11.13) 
4.66 (0.83-
26.21) 
4.71 (0.32-
69.36) 
 
0.20 
Pre-existing persistent pain 3.16 (1.19-8.39) 0.02 
Reviewed by the APS 0.49 (0.16-1.54) 0.22 
Recalled being supplied written and/or verbal 
advice regarding pain management  
0.20 (0.05-0.83) 0.03 
Provided analgesics on discharge 1.66 (0.42-6.64) 0.47 
Reported using an opioid following discharge  3.14 (0.90-
11.00) 
0.07 
Reported using paracetamol following discharge 1.63 (0.62-4.30) 0.33 
Reported using a gabapentinoid following 
discharge 
4.13 (0.37-
46.05) 
0.25 
What was their expected level of pain 
    None 
    Mild 
    Moderate/severe 
 
1 
1.91 (0.48-7.62) 
3.5 (0.79-12.74) 
 
0.20 
OR: odds ratio; CI: confidence interval; APS: Acute Pain Service 
3.5 Discussion 
The burden of pain in the week following surgery was high, with 47.3% of patients reporting they 
experienced moderate-severe pain.  Numerous studies have shown that high levels of acute pain 
following surgery is one factor that can increase the risk of persistent pain (82, 388, 391-393).  
However, the effect of high pain intensity in the period following discharge has not been well 
researched (388, 389).  In the few studies conducted in this area, which have reviewed patients 
following orthopaedic surgery, have shown an association between high pain intensity following 
43 
discharge and the development of PPP (206-208, 415). From this study it appears that post-
discharge pain is often (although not always) being undermanaged, by both clinicians and 
patients, and is an area that requires increased attention to improve patient outcomes.  
The reported use of analgesics following discharge was high, with 95.3% of participants using 
them in the first week. While this is not surprising, what is concerning is only 70% of the 
participants received analgesics on discharge.  This is despite the knowledge that at least 80% of 
patients who undergo surgery, requiring an incision, will suffer acute pain (390) and 
recommendations to tailor discharge medications accordingly (203).  Admittedly patients who 
reported experiencing moderate-severe pain were more likely to report receive analgesics on 
discharge (83.8% vs 57.3% p<0.01). However, with 6.5% of patients reporting they used 
analgesics that they already had at home, it appears that a significant proportion of patients were 
discharged with potentially limited access to analgesics.  Depending on the time of their hospital 
discharge, accessing supplies of analgesia outside of the hospital may have been difficult and this 
may have detrimentally affected their pain control.  These findings are supported by another 
study that found that a minority of patients were discharged from hospital with sufficient pain 
management planning (412). With so many patients going to a health care professional in the 
week following surgery (28.2% going to a community pharmacy and 25.9% to a GPs) to get 
additional analgesia, it suggests that provision of analgesia at discharge is sub-optimal. Post-
discharge pain management and planning for discharge requires more attention, to ensure that 
patients have sufficient knowledge and analgesia to self-manage their pain adequately.  
The pattern of analgesic use in our study was similar to that seen in other studies evaluating what 
analgesics patients used following discharge (395, 396, 412).  However, this study also identified 
that participants frequently reported underuse of their analgesics.  Underuse was more 
commonly reported (28.4%) by patients than overuse (5.3%), which has been found previously 
in patients with acute pain (404). The most common reasons patients self-reported under using 
their analgesics were side effects or low levels of pain.  This has been found in other studies also, 
with side effects, “putting up with the pain”, avoidance of any medication and fear of addiction 
frequently cited as reasons for under using analgesics (395, 396, 404, 413, 416).  Particularly in 
older patients, who tend to demonstrate more stoicism, it is important the information provided 
explains the role of using analgesics and the importance of not tolerating pain unnecessarily, due 
to the risk of both short and long-term adverse consequences from sub-optimal control of acute 
pain.    
Although the quality of the information provided to patients prior to discharge was not 
ascertained in this study, a number of patients did note that they felt ill equipped to manage their 
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pain following discharge.  Of the patients who noted this, 75% reported experiencing moderate-
severe pain.  This finding is supported by a recent Australian study (396) that found that 30% of 
patients discharged after a total knee arthroplasty felt they had received “somewhat adequate” 
or “inadequate” information on their discharge analgesics. This is an area that requires further 
research to identify what information patients would like to receive, in what level of detail and 
how this is best presented to them in order for them to feel well equipped to manage their pain 
following discharge. Additionally, who the advice regarding post-discharge pain management 
was provided by, was reported to be inconsistent.  To ensure all patients have good outcomes 
following their discharge it is important that it is determined within the hospital’s structure 
whose responsibility it is to provide this type of advice to patients. 
Patients who reported experiencing moderate-severe pain were more likely to undergo 
musculoskeletal surgery, including spinal and orthopaedic surgery.  This is not surprising as these 
types of surgery are highly invasive.  Having a pre-existing persistent pain problem (25.8% versus 
56.2% p=<0.01) was also associated with reporting moderate-severe pain following discharge.  
Those patients who recalled receiving pain management advice were slightly less likely to 
experience moderate-severe pain (87.5% vs 91% p=0.05).  Patients who reported experiencing 
moderate-severe pain were more likely to comment that they expected this level of pain 
compared to those who did not (p=0.01). It would appear that the APS is also identifying those 
patients more likely to experience acute pain; however, still only 25% of those who reported 
experiencing moderate-severe post-discharge pain were reviewed by the APS, and thus 
improvements could be made in this area.  
A number of factors were found to be independently associated with participants reporting 
moderate-severe pain following discharge.  Patients undergoing open abdominal or 
genitourinary surgery or musculoskeletal surgery were also more likely to report experiencing 
pain following surgery, which is not unexpected as these surgeries have significant potential for 
acute pain, than less invasive procedures such as debridement of wounds or laparoscopic 
procedures.  A history of persistent pain increased the likelihood of reporting moderate-severe 
pain following discharge, which is not unsurprising as persistent pain has been found to increase 
the likelihood of developing further pain conditions as well as being more sensitive to pain (81, 
82, 141). Conversely, recalling receiving advice regarding pain management reduced the 
likelihood of reporting moderate-severe pain. These findings indicate the importance of receiving 
information regarding pain management on a patient’s treatment outcome and, potentially, with 
more information, pain intensity could conceivably reduce further.   
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This study has a number of strengths including its prospective design which has less risk of recall 
bias regarding the level of pain experienced, how they managed their pain and where they 
obtained analgesics from.  There were, however, some limitations in this study, including the 
relatively small sample size and the reliance on patients’ recollection of the advice they were 
given during their admission, which is likely to be affected by analgesic consumption and the 
residual effects of anaesthesia.  In addition, discharge advice was not able to be cross-matched 
with discharge summary advice to verify discharge advice.  Nonetheless, if patients do not recall 
receiving information, then it is important that more written or alternative forms of information 
are provided to all patients so that they have the resources to use in the event that they experience 
pain following discharge.  Although this study had a response rate of approximately 30%, there 
still may have been the potential for self-selection bias with those patients more engaged in their 
health care or those who experienced more problems with their pain management more likely to 
respond.  However, the results of this study do mirror another Australia study (396) and thus is 
likely to be generalisable to other post-hospital settings.    
In conclusion, this study suggests that moderate-severe acute pain following hospital discharge 
after surgery is a significant issue.  Although most patients recalled receiving information about 
pain management, the way in which it was provided and/or the quality of the information may 
need to be reviewed to try and improve pain management in this sub-acute period.  This study 
also identifies a number of areas that require more research.  The first is to identify what patients 
would like to know in order to feel equipped to manage their pain and how this is best delivered, 
the second is whose responsibility it is to provide post-discharge advice to patients to ensure all 
patients receive counselling regarding post-discharge pain management, and finally whether 
patients are provided enough analgesics on discharge to allow for safe and effective pain 
management following discharge. 
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Chapter 4: Pain and physical function following sternotomy: a prospective 12-month 
observational study 
 
All of the research contained within this chapter has been published as Veal FC, Bereznicki LR, 
Thompson AJ, Peterson GM, Orlikowski CE, “Pain and functionality following sternotomy: a 
prospective 12-month observation study” Pain Medicine pp. 1-8. ISSN 1526-2375 (2016). DOI: 
10.1093/pm/pnv066 
 
4.1 Abstract 
Objective: to document self-reported pain intensity, physical function and analgesic use in the 12 
months following a sternotomy to identify factors associated with the development of persistent 
post-sternotomy pain. 
Design: Prospective observational study 
Settings: Royal Hobart Hospital, Australia 
Subjects: Patients undergoing a sternotomy between January-November 2013 
Methods: One hundred and ten patients were recruited and followed for 12 months, with 
telephone calls at ten days, six weeks, three months and 12 months.  An initial survey was 
completed at the point of recruitment including patient history, depression and anxiety scales, 
self-rated health and pain catastrophising scale.  
Results: The mean age of participants was 69.6 years, with the majority of participants being male 
(84.5%). The proportion of patients reporting pain in the early post-discharge period was high, 
with 30% of patients reported experiencing on average moderate-severe pain in the 10 days 
following discharge and 11% reported experiencing on average moderate-severe pain at six 
weeks. At 12 months, 15.5% of participants reported on average mild pain and 0.9% an average 
of moderate-severe pain in the preceding week at their sternotomy site.  Pain of neuropathic 
origin was reported by 41.2% of those with on average daily pain at 12 months.  
Conclusion: This study highlights the need for further research to investigate whether more 
intensive pain management in the post-discharge period following sternotomy as well as the 
early identification of patients with neuropathic pain symptoms can reduce the incidence of 
persistent postoperative pain at 12 months. 
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4.2 Introduction 
Chronic pain places a major burden both on those patients affected and the wider healthcare 
system. There are many potential causes of chronic pain, amongst which is PPP, defined as pain 
that develops after surgery and lasts for at least two months where other causes, including pre-
existing pain conditions, have been excluded (200). One British study found that surgery was 
implicated as a possible cause in approximately 20% of all patients with chronic pain requiring 
referral to pain clinics (417). It has been reported that the prevalence of PPP amongst those who 
have undergone surgery is between 30-50%, with 5-10% of patients suffering severe pain (81). 
Studies, both prospective and retrospective, have identified variable levels of pain following 
sternotomy, ranging from 18% (418) to 35% (419) in prospective studies and from 23% (420) 
to 56% (421) in retrospective studies with follow-up periods of at least 12 months. A subset of 
patients experienced moderate to severe pain, with rates varying from 6% (422)  to 36% (421) 
of patients in retrospective studies and 6% (423) to 29% (419) of patients in prospective studies. 
High levels of postoperative pain, as well as high analgesic consumption in the immediate 
postoperative period, have been identified as risk factors for PPP (81, 82, 201). Research has 
reported that patients often experience more pain following discharge from hospital after surgery 
than during the inpatient phase (394).  One study also found that patients who underwent a 
sternotomy had high levels of pain in the three weeks following their discharge (424). Some 
studies evaluating patients who have undergone orthopaedic surgery or trauma have found that 
high pain intensity following hospital discharge increased the likelihood of pain persisting at 6-
12 months (206 , 207, 208).  However it is unclear if there is an association between pain during 
the sub-acute phase (after discharge and up to three months following surgery) and pain 
persisting at 12 months following a sternotomy. Furthermore, very little research has evaluated 
the level of pain experienced after discharge following a sternotomy, the effect this pain has on 
physical function and the presence of neuropathic symptoms during this time. Thus, this study 
aimed to evaluate baseline patient and clinical factors and the level of pain that patients 
experience during the subacute phase and to follow these patients for 12 months to determine 
the prevalence of ongoing pain and whether higher pain intensity during the sub-acute phase 
increases the likelihood of pain persisting at 12 months.  
4.3 Methods 
The study population comprised patients undergoing a sternotomy at the RHH, a 550-bed 
hospital with the only cardiothoracic unit in the state of Tasmania, Australia.  Recruitment took 
place on weekdays between January and November 2013.  Patients were recruited either the 
afternoon prior to surgery or for a minority of patients up to five days after surgery, and at this 
time an initial survey was conducted in person. To be eligible, participants had to speak English 
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and be aged at least 18 years.  It was estimated that approximately 180 sternotomies would be 
undertaken at the RHH during the recruitment period; with an assumed incidence of PPP of 40%, 
and a confidence interval of 0.05 a sample size of 121 patients was needed for statistical 
significance to identify factors associated with PPP.   
Baseline demographic and clinical characteristics were recorded during the initial interview 
(Appendix 3) including age, gender, pre-existing pain and analgesic use, comorbidities and 
medications.  The Depression, Anxiety, Stress Scale 21 (DASS21) (425) and Pain Catastrophizing 
Scale (PCS) (426) were also administered.  A score of 30 or more on the PCS is considered to be 
clinically significant (170) and was used as the cut-off point in this study.  There are no clinically 
significant cut off points determined for DASS21 (425); however, scores indicating moderate to 
extreme symptoms were used as a cut off point for statistical purposes. Participants were also 
asked to rate their level of optimism (1 very pessimistic, 10 very optimistic), health (1 very 
unhealthy, 10 very health), pain tolerance (1 copes very well with pain, 10 unable to cope with 
pain), fear of pain (1 not scared of pain, 10 very scared of pain) and whether they had family or 
friends who would be able to support or assist the patient when discharged home during this 
initial interview.  Average postoperative pain intensity over the first 48 hours at rest and on 
movement as well as opioid consumption, converted to MEQ during the first 48 hours following 
surgery were also recorded from the patient’s medical notes.   
Participants were telephoned at ten days, six weeks, three months and 12 months following their 
hospital discharge (Appendix 4 and 5). If the initial attempt to contact the patient at day ten or at 
six weeks failed, the patient was telephoned daily for the following five days; at three months, 
patients were telephoned daily for 10 days.  If they could not be reached at any of these time 
points no data was collected and the patient was contacted as per the next point in the research 
protocol. If the participant could not be reached at 12 months, contact was attempted for one 
month; if they could still not be reached then no further action was taken and they were classified 
as being lost to follow-up and excluded from the study. During these calls, patients were asked to 
classify their level of pain at the sternotomy site (worst and average in the last week), physical 
function over the last week and analgesic use in the past 24 hours (irrespective of indication) 
were recorded. Pain scores were assessed via a numerical rating scale, which were later 
converted to three pain categories (none, mild, moderate-severe).  When patients were unsure 
what numerical value to assign to a pain score, they were asked to grade their pain as either none, 
mild, moderate or severe.  The 7-item Douleur Neuropathique 4 (DN4) was administered at three 
and 12 months to further document the characteristics of the pain; a score of three or more is 
considered to be consistent with pain of neuropathic origins (427).  All baseline and telephone 
interviews were conducted by the same researcher to reduce the likelihood of variation in 
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questioning or interpretation of patient responses.  Daily opioid doses were converted to MEQ 
(299) 
Statistical analysis was conducted using SPSS Statistics 20 for Windows (SPSS Inc., Chicago, Il, 
USA). Chi-Square and Mann-Whitney U tests were undertaken to assess for group differences at 
12 months. Differences in baseline demographics, clinical characteristics, intraoperative and 
postoperative factors, as well as pain scores at different time points, were tested between those 
patients who experienced pain at 12 months and those who did not.  The study was approved by 
the University of Tasmania’s Health and Medical Research ethics committee and all participants 
gave informed consent for participation. 
4.4 Results 
One hundred and thirty patients were approached, with 122 patients agreeing to participate. 
Twelve patients were subsequently excluded from the study due to the following reasons: 
cancelled surgery (4), death (2), withdrawal of consent due to illness (2), and loss to follow-up at 
12 months (4). Thus, 110 patients were included in the study. The mean age of the participants 
was 69.6 years, with the majority of participants being male (84.5%). Seventy-three patients 
(66.4%) underwent sternotomy as part of a coronary artery bypass graft (CABG), with or without 
a valve replacement; 35 patients (30.9%) underwent a valve replacement only or Bentall 
procedure (where the aortic root and valve are replaced) and two patients for other reasons.  The 
response rates for surveys were 90.9% at 10 days, 97.3% at six weeks, and 96.4% at three 
months. 
Table 6 shows the baseline demographics and clinical characteristics of patients with and without 
pain at 12 months. Younger age (p=0.03) and self-rated poor health (P=0.05) were associated 
with experiencing daily pain on average at 12 months. A previous musculoskeletal pain causing 
condition (p=0.02) and increased number of pain sites (p=0.03) were also associated with pain 
at 12 months. However the association was not seen with a specific type of musculoskeletal pain; 
with neither back pain (41.2% versus 23.7% p=0.13) nor joint pain (47.1% versus 30.1% p=0.17) 
being associated with pain at 12 months.   
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Table 6 Baseline demographics and clinical characteristics 
 Self-reported no 
pain (on average) at 
sternotomy site at 
12 months  
n= 93 
Self-reported pain (on 
average) at 
sternotomy site at 12 
months 
n= 17 
P 
value 
Baseline characteristics 
Median age in years (IQR)  73.0 (66.0-78.0) 68.0 (59.5-73.0) 0.03 
Male (%) 75 (80.6) 16 (94.1) 0.18 
Education level (%) 
     University/diploma 
     Completed year 12 
     <High school 
 
17 (18.3) 
33 (35.5) 
43 (46.2) 
 
2 (11.7) 
8 (47.1) 
7 (41.2) 
 
0.62 
Married/de-facto (%) 75 (80.6) 11 (64.7) 0.14 
Operation type (%) 
     CABG (± valve replacement) 
     Valve/Bentall Procedure 
     Other 
 
61 (65.6) 
30 (32.3)  
2 (2.2) 
 
12 (70.6) 
5 (29.4) 
0 (0.0) 
 
0.80 
Resternotomy required postoperatively 3 (3.2) 2 (11.8) 0.12 
Previous sternotomy 6 (6.5) 1 (5.9) 0.93 
Pre-operative PCS ≥ 30 (%) 3 (3.2) 0 (0.0) 0.45 
Pre-operative anxiety (DASS21 ≥ 10) (%) 19 (20.4) 7 (41.2) 0.06 
Pre-operative depression (DASS21 ≥ 14) (%) 20 (21.5) 6 (35.3) 0.22 
Pre-operative stress (DASS21 ≥ 19) (%) 29 (31.2) 9 (52.9) 0.08 
Median number of medications (IQR) 7.0 (5.0-9.0) 6.0 (3.0-7.0) 0.15 
Median number of medical conditions (IQR) 5.0 (3.5-6.0) 5.0 (3.0-6.0) 0.66 
Diabetes Mellitus  15 (16.1) 2 (11.8) 0.65 
Musculoskeletal pain (%) 43 (46.2) 13 (76.5) 0.02 
Non-musculoskeletal pain (%) 61 (65.6) 14 (82.4) 0.17 
Number of pain sites 1.0 (1.0-2.0) 2. (1.0-3.5) 0.03 
Pre-existing regular use of analgesics (%) 28 (30.1) 5 (29.4) 0.95 
Pre-existing use of opioid analgesics (%) 16 (17.2) 5 (29.4) 0.24 
Duration of previous pain (%) 
     No pain 
      ≤2 years 
      2-5 years 
      5-10 years 
      ≥10 years 
 
24 (25.8) 
2 (2.2) 
29 (31.2) 
8 (8.6) 
30 (32.3) 
 
2 (11.8) 
0 (0.0) 
5 (29.4) 
2 (11.8) 
8 (47.1) 
 
0.62 
Self-rated optimism (IQR) 8.0 (6.0-9.0) 8.0 (5.0-8.8) 0.21 
Self-rated health (IQR) 7.0 (5.0-8.0) 5.5 (3.5-7.8) 0.05 
Self-rated pain tolerance (IQR) 3.5 (2.0-5.0) 3.0 (1.0-4.3) 0.20 
Self-rated fear of pain (IQR) 1.75 (1.0-5.4) 1.0 (1.0-2.8) 0.16 
Smoking (%) 6 (6.5) 3 (17.6) 0.12 
Median average weekly alcohol consumption 
(IQR) 
1.0 (0.0-7.0) 0.25 (0.0-3.3) 0.46 
Support on discharge (%) 77 (82.8) 15 (88.2) 0.58 
Intra- and postoperative factors 
Median intraoperative opioid (mg) use (IQR) 200 (200-200) 200 (110-200) 0.29 
Use of PCA (%) 89 (95.7) 17 (100) 0.40 
On average moderate-severe pain on 
movement in the 48 hours after surgery (IQR) 
38 (40.8) 9  (52.9) 0.28 
On average moderate-severe pain on rest in 
the 48 hours after surgery (IQR) 
8 (8.6) 0 (0) 0.20 
Median postoperative opioid consumption 
(oral MEQ/day) (IQR) 
137.4 (98.8-232.4) 172.5 (126.2-242.2) 0.24 
Use of postoperative regular paracetamol (%) 84 (90.3) 15 (87.5) 0.79 
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Follow-up factors 
Reported moderate-severe average 10 day 
pain (%) 
23 (27.7) 6 (37.5) 0.43 
Reported moderate-severe average 6 week 
pain (%) 
4 (4.4) 1 (6.7) 0.70 
Reported moderate-severe average 3 month 
pain (%) 
4 (0.0) 0 (0.0) 0.37 
DN4 ≥3 at 3 months (%) 11 (12.5) 7 (43.8) 0.01 
DN4 ≥3 at 12 months (%) 3 (3.2) 7 (41.2) <0.01 
N: number; IQR: interquartile range; APS: Acute Pain Service; CABG: Coronary artery bypass graft; 
PCS: Pain Catastrophizing Scale; DASS21: Depression Anxiety Stress scale 21; PCA: patient 
controlled analgesia MEQ: morphine equivalence/day; mg: milligram; DN4: Douleur 
Neuropathique 4 
A DN4 score of three or more at three months (p=0.01) was associated with pain persisting at 12 
months. Sternum pain, with probable neuropathic origins was reported by 41.2% of patients who 
had pain persisting at 12 months, with only three people having a DN4 score of three or more at 
12 months not having pain on average at the sternotomy site (p<0.01). Reported moderate to 
severe pain at 10 days, six weeks or three months following discharge was not associated with 
pain at 12 months. 
There was a generally consistent approach to intraoperative management, with most patients 
receiving propofol infusions and 200mcg fentanyl, there was minimal use of nerve blocks (three 
patients) and intraoperative paracetamol.  Gabapentinoids were prescribed to one patient in the 
postoperative period, with a further four taking pregabalin in the follow-up period for unrelated 
medical conditions.    
Table 7 shows the level of pain that patients reported experiencing and their ability to undertake 
certain activities at ten days, six weeks, three months and 12 months. At 12 months, 34.5% of 
participants were still experiencing pain at the surgical site.  The proportion of patients reporting 
post-discharge pain at 10 days was high.  Eighty-five patients reported experiencing at least mild 
pain on average, yet only 82.1% (69) of these patients were taking any analgesics.  Amongst those 
patients experiencing on average moderate-severe pain, 89.7% were taking an analgesic at 10 
days.  A number of patients commented during the telephone survey that they preferred to 
reserve the use of analgesics (including non-opioid analgesics) for more severe pain or when they 
really needed them. At three months, 28 patients reported suffering, on average, at least mild pain 
and only 50.0% of these were taking analgesics.  
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Table 7 Self-reported pain scores and physical function across the follow up period 
Time period 10 days  
n= 100 (%) 
6 weeks 
n=107 (%) 
3 months 
n=106 (%) 
12 months 
n=110 (%) 
Pain – worst in past week 
     None  
     Mild 
     Moderate 
     Severe 
 
4 (4.0) 
27 (27.0) 
32 (32.0) 
37 (37.0) 
 
30 (28.0) 
48 (44.9) 
20 (18.7) 
9 (8.4) 
 
48 (45.3) 
45 (42.5) 
10 (9.4) 
3 (2.8) 
 
72 (65.5) 
29 (26.4) 
5 (4.5) 
5 (4.5) 
Pain – average over last week 
     None 
     Mild 
    Moderate 
    Severe 
 
15 (15.0) 
55 (55.0) 
29 (29.0) 
1(1.0) 
 
41 (38.3) 
55 (51.4) 
11 (10.3) 
0 (0) 
 
77 (72.6) 
25 (23.6) 
4 (3.8) 
0 (0) 
 
92 (83.6) 
17 (15.5) 
1 (0.9) 
0 (0) 
Effect of pain on sleep 
     None 
     Mild 
     Moderate 
     Severe 
 
57 (57.0) 
25 (25.0) 
9 (9.0) 
9 (9.0) 
 
79 (73.8) 
23 (21.5) 
2(1.9) 
3 (2.8) 
 
91 (85.8) 
12 (11.3) 
2 (1.9) 
1 (0.9) 
 
99 (90.0) 
7 (6.4) 
3 (2.7) 
1 (0.9) 
Effect on activities of daily living  
     None 
     Mild 
     Moderate 
     Severe 
 
68 (68.0) 
26 (26.0) 
5 (5.0) 
1 (1.0) 
 
88 (82.2) 
16 (15.0) 
2 (1.9) 
1 (0.9) 
 
102 (96.2) 
4 (3.8) 
0 (0) 
0 (0) 
 
110 (100) 
0 (0) 
0 (0) 
0 (0) 
Effect on walking 100m 
     None 
     Mild 
     Moderate 
     Severe 
 
89 (89.0) 
4 (4.0) 
5 (5.0) 
2 (2.0) 
 
102 (95.3) 
3 (2.8) 
1 (0.9) 
1 (0.9) 
 
103 (97.2) 
2 (1.9) 
0 (0) 
1 (0.9) 
 
110 (100) 
0 (0) 
0 (0) 
0 (0) 
Effect on participating in hobbies 
     None 
     Mild 
     Moderate 
     Severe 
 
94**(94.0) 
3 (3.0) 
2 (2.0) 
1 (1.0) 
 
96**(89.7) 
8 (7.5) 
2 (1.9) 
1 (0.9) 
 
99**(93.4) 
5 (4.7) 
2 (1.9) 
0 (0) 
 
103 (93.6) 
4 (3.6)  
3 (2.7) 
0 (0) 
Analgesic use in past 24 hours (not 
specific to post-surgical pain) 
     Paracetamol  
          Mean daily dose (g) 
     Opioids (mg MEQ) 
          Mean daily dose (range)  
 
 
75 (75.0) 
3.6g 
18 (18.2) 
12.5 (2.5-30) 
 
 
48 (44.3) 
2.8g 
2 (1.9) 
38.5 (7.5-
69.5) 
 
 
35 (31.4) 
2.5g 
5 (4.8) 
31.4 (1-108.5) 
 
 
36 (32.7) 
2.4g 
6 (5.5) 
 21.0 (2.6-60) 
** the restrictions on their movement were dictated by surgeons rather than pain being the main factor 
affecting participation in hobbies.  
Note: patients often rated that on average they had no pain over the previous seven days, however they 
may have had short last pain associated with movement or sneezing, which they rated in worst level of 
pain experienced in the previous seven days. 
G: Gram; mg MEQ: milligram morphine equivalence/day 
 
Self-reported average pain intensity at 12 months were low, with 16.4% of patients reporting 
pain. Pain at 12 months had no effect on the patient’s ability to perform activities of daily living 
or to walk 100m. PPP affected 6.3% of the participants’ ability to undertake hobbies, and in 10.0% 
their ability to sleep; however, in most cases these impacts were only reported as mild.  
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4.5 Discussion 
This is the first published Australian study evaluating post-sternotomy pain and the first study 
we are aware of that comprehensively documents the sub-acute phase following a sternotomy.  
We found the 12-month prevalence of PPP to be 34.5% however this took into account pain that 
was short lived and associated with a particular activity or movement.  Only 16.4% of patients 
reported experiencing pain, on average, every day at the sternotomy site. Taking into account the 
differences in the way questions were asked of participants and the classification of persistent 
pain, the results are reasonably consistent with prospective studies of similar duration in other 
countries (418, 419, 428).  
Undermanagement of pain in the acute phase immediately following surgery is a known risk 
factor for the development of pain at 12 months (419). This current study demonstrated better 
pain control than was recently reported in a Norwegian study (429); this difference was perhaps 
explained by the opioid consumption in the 48 hours following surgery being nearly four times 
higher in this study than the Norwegian study. Although nearly half of the patients reported 
moderate to severe pain on movement following surgery and 8.6% suffered moderate-severe 
pain at rest, average pain intensity in the 48 hours following surgery were not associated with 
pain persisting at 12 months and this may be explained by the high use of PCA possibly reducing 
central sensitisation occurring.  
Previous studies following patients who underwent orthopaedic surgery or experienced an 
orthopaedic trauma have indicated that high pain intensity during the sub-acute phase following 
hospital discharge increased the risk of pain persisting to 6-12 months (206-208).  No study has 
previously studied the sub-acute period in depth following a sternotomy to identify if high pain 
intensity persist, for how long for and what impact this has on long-term pain.  Despite a 
significant amount of pain reported following discharge by patients, moderate-severe pain 
following discharge was not associated with pain at 12 months for this cohort.  However further 
research evaluating whether more intensive pain management following discharge results in a 
reduction of the incidence and severity of pain persisting at 12 months is still needed.   
Although pain intensity during the sub-acute period were not associated with pain at 12 months, 
reported neuropathic pain symptoms at three months were associated with pain at 12 months. 
Furthermore, patients who reported experiencing on average pain at 12 months were more likely 
to have a DN4 score of greater than three. This is not surprising as PPP is often associated with 
neuropathic symptoms, although the incidence was higher in this study than others (430).  It is 
acknowledged however, that the 7-point DN4 scale is not as specific as the 10-point scale 
incorporating a physical examination. Nonetheless, the 7-point scale provides an easy to 
administer screening test, which could be easily incorporated as part of a follow-up procedure to 
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identify at risk patients.  Additionally, neither pregabalin nor gabapentin were used routinely in 
the immediate postoperative period.  This is despite some evidence they can improve acute pain 
(340, 341, 431) and potentially reduce the incidence of persistent pain following surgery (342); 
although this evidence is currently conflicting, and requires further studies to ascertain what role 
gabapentinoids have in the management of acute and persistent post-operative pain.  
Thus, there is a clear impetus to increase the amount of follow-up undertaken to identify those at 
high risk of developing neuropathic pain and improve the pain management of patients who 
undergo surgery and are then discharged home. Providing more intensive pain management 
following discharge from hospital has the potential to improve patients’ QOL and physical 
function.  Furthermore, in this cohort, improved pain control may facilitate engagement and 
capacity to participate in cardiac rehabilitation after surgery and potentially reduce mortality, 
morbidity and hospital readmissions related to cardiovascular disease (432-434). However, 
treating older patients’ pain, such as those in this study, has a number of barriers.   Once patients 
are discharged home they self-manage this pain.  Factors including fear of addiction to medication 
and reserving analgesics for severe pain only have been previous noted as reasons for lower 
analgesic use in older populations (435-437) and participants in our study also raised these 
concerns. Therefore, any approach to improving pain management during the subacute phase 
after discharge from hospital must include patient education to allay concerns and reduce 
barriers to appropriate use of analgesics.   
In our study, younger age, poorer self-rated health, previous persistent musculoskeletal pain, and 
a higher number of pain sites were all associated with pain persistence at 12 months, which is 
consistent with the factors previously identified as increasing the risk of PPP (81, 82, 141-144, 
438-440).  Previous studies have indicated that pre-operative anxiety was a risk factor for acute 
pain and possibly persistent pain as well, although the results are variable (200).  In this study a 
greater proportion of patients who had moderate-severe pre-operative anxiety did have 
moderate-severe pain at 12 months (20.1% versus 40.2%) however this was only trending 
towards statistical significance (p=0.06).  Potentially if the sample size had been met this would 
have been statistically significant between the groups.  Theoretically conducting a minority of 
initial baseline surveys following surgery may have resulted in slightly different levels of reported 
pre-operative anxiety affecting this result.  Alternatively potentially anxiety may be less of a risk 
factor in older patient cohorts such as this one. Nonetheless, early screening of patients at pre-
assessment clinics to identify those patients with poor self-rated health and pre-operative 
anxiety, and referring them to a psychologist prior to surgery could aid in reducing the risk of 
developing PPP in the future.   
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There are a number of strengths to this study related to the prospective methodology; in 
particular, the avoidance of recall bias. The main limitation was the small sample size, potentially 
underestimating the effect of some variables, namely pre-operative anxiety and stress, which 
were both trending towards statistical significance. However, this study demonstrates that pain 
following sternotomy is a significant problem, with over one-third of patients still experiencing 
pain at the operation site 12-months postoperatively. Positively, most patients reported that PPP 
only had a limited detrimental effect on their functional ability.  
The results of this study demonstrate the need for increased education of patients around pain 
management after discharge; the best way to overcome these barriers and optimise pain 
management warrants further investigation. There is also a need for future research to evaluate 
whether more intensive and increased reliance on multimodal pain management (including 
gabapentinoids) following discharge helps reduce both the prevalence and severity of persistent 
post-sternotomy pain at 12 months.  The optimal way to do this, whether through more face-to-
face consultations or regular follow-up phone calls with health care practitioners with additional 
pain-related training, should be evaluated further.  Finally, the early identification of those 
patients with symptoms consistent with neuropathic pain should also occur to ensure that higher 
risk patients are identified early and managed more closely.  As the most effective treatment for 
persistent pain is preventing it occurring in the first place, early identification and management 
of high-risk patients is imperative to improving patient outcomes. 
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Chapter 5: Persistence of pain and functional impairment following orthopaedic surgery: 
a prospective 12 month observational cohort study 
 
All of the research contained within this chapter has been published as Veal FC, Bereznicki LR, 
Thompson AJ, Peterson GM, Orlikowski CE, “Persistence of pain and functional impairment 
following orthopedic surgery: a prospective 12 month observational cohort study” Medicine 
(Baltimore): Analytical Reviews of General Medicine, Neurology, Psychiatry, Dermatology and 
Pediatrics, 94 (36) doi:10.1097/MD.0000000000001498 ISSN 0025-7974 (2015).  
 
5.1 Abstract 
Objective: The aim of this study was to document the level of pain and physical function in the 12 
months following orthopaedic surgery. 
Methods: An observational prospective cohort study was undertaken, following 87 patients 
(mean age 62.4 years (18-92); 47.1% male) who required orthopaedic surgery at the RHH, 
Tasmania, Australia. Following an initial survey, patients were telephoned at ten days, six weeks, 
three months and 12 months after discharge. 
Results: Post-discharge pain intensity were high with 97.4% of patients suffering pain at 10 days, 
81.2% at six weeks and 79.5% at three months.  Pain affected the ability to undertake activities 
of daily living for 32.7% and 20.0% of patients at 10 days and six weeks respectively. Twelve 
months after discharge, 65.5 % of patients reported pain persisting at the surgical site, with 
29.9% of all patients suffering moderate-severe incidental pain; and nearly one quarter of 
patients reported pain affected their sleep or activities of daily living.  Average pain intensity 
rated as moderate-severe at 10 days (p=0.01) and six weeks (p=0.02) and neuropathic pain 
symptoms at three months (30.2% vs 10.3% p=0.03) and 12 months (30.4% vs 4.9% p=0.01) 
were associated with persistent pain at 12 months. 
Discussion: Pain in the period following discharge from hospital is significant and undermanaged. 
Additionally, moderate-severe pain following discharge, and neuropathic pain symptoms at three 
months were associated with persistent pain at 12 months.  These findings have important 
implications for improving QOL as well as potentially preventing persistent pain. 
 
5.2 Introduction 
Up to 80% of patients undergoing surgery will experience acute postoperative pain (390).  Under 
management of postoperative pain is common (394) and can increase the risk of persistent pain 
(82, 388), poor healing, venous thromboembolism, myocardial infarction, readmission to hospital 
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and extended length of hospital stay (391-393).  One study found that following discharge from 
hospital for a surgical procedure, patients’ pain intensity often got worse (394).  Another study 
evaluating post-discharge pain after a total knee arthroplasty (204) found that one month after 
discharge 52% of patients reported moderate pain and 16% severe pain whilst walking.  Thus 
the issue of post-discharge pain is significant and can decrease QOL and ability to participate in 
rehabilitation activities.  
High opioid consumption following surgery and increased levels of acute postoperative pain are 
known risks factors for PPP (82).  Pain relief in the period following discharge from a surgical 
unit is potentially more complicated to manage than that during the inpatient phase.  Patients are 
in charge of their own medication, there is sometimes a gap (perceived or actual) in terms of who 
is responsible for treating the patient (GP or surgeon), and there may be a reduction in the 
potency or dosing frequency of opioid analgesics when patients transition from an inpatient to 
home environment. The potential for an association between high pain intensity following 
hospital discharge after surgery or trauma, and pain and physical function at 12 months has 
received minimal attention in the literature (388, 389)..  To address this gap in the literature, we 
aimed to evaluate the level of pain, analgesic consumption and functional status of patients over 
the 12 months following orthopaedic surgery, and identify if higher pain intensity during the sub-
acute period (following discharge from hospital to three months after surgery) increase the risk 
of persistent pain at 12 months. 
5.3 Methods 
A prospective, observational study was conducted following patients who underwent 
orthopaedic surgery for a joint replacement or fracture repair at the RHH, a 550-bed hospital in 
Tasmania, Australia between January and December 2013. At the time of recruitment, 
participants were required to be an inpatient and either have undergone surgery within the past 
five days, or have been scheduled to undergo surgery during their admission. Exclusion criteria 
were patients aged less than 18 years, an inability to speak English, a history of dementia or 
suspected cognitive decline; and those who experienced a multi-trauma event, allowing the focus 
to be on one surgical site.  
At the point of recruitment an initial face-to-face survey was conducted (Appendix 6). 
Participants were then contacted by telephone ten days, six weeks, three months and 12 months 
after discharge from the orthopaedic ward (Appendix 4 and 5). If the initial attempt at contact for 
the ten day, six week or three month surveys was unsuccessful, the participant was telephoned 
daily for between five and ten days.  If the participant could not be reached after this time no data 
was collected for that time point and the participant was contacted at the next scheduled data 
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collection point. At 12 months, all participants were telephoned and where the initial attempt was 
unsuccessful, repeated calls were made for one month, before the participant was considered lost 
to follow up.   
During the initial survey basic demographic and clinical characteristics of the patient were 
collected including age, social history and previous pain conditions.  In addition, the Hospital 
Anxiety and Depression Survey (HADS) was administered at baseline. A HADS score of eight or 
more for anxiety or depression is considered to be clinically significant (441).  The PCS was also 
administered at baseline, with a PCS score of 30 or more considered to be clinically significant 
(170, 426).  Participants were also asked to rate their level of optimism (1 very pessimistic, 10 
very optimistic), health (1 very unhealthy, 10 very health), pain tolerance (1 copes very well with 
pain, 10 unable to cope with pain), fear of pain (1 not scared of pain, 10 very scared of pain) and 
whether they had support when discharged home during this initial interview. 
The participant’s medical notes were reviewed to collect information about intraoperative and 
acute postoperative pain and its management, as well as medications and medical conditions on 
admission. The information collected during the follow-up interviews included the average and 
the worst levels of pain over the previous week as well as a number of aspects regarding physical 
function including sleep and ADLs. Analgesic use in the 24 hours prior to the interview was also 
recorded (irrespective of the indication for use) and opioid doses were converted to oral MEQ 
(299).  At three and 12 months the 7-item DN4 questionnaire was also administered; a score of 
three or more on the seven point scale was classified as being consistent with pain of neuropathic 
origins (427). 
 
Analysis was performed using SPSS Statistics 20 for Windows (SPSS Inc., Chicago, Il, USA).  Chi-
square and Mann-Whitney U tests were undertaken to evaluate for group differences.  
Associations between baseline demographics, clinical characteristics, intraoperative and 
postoperative factors as well as pain scores at different time points were tested against those who 
experienced pain at 12 months and those who did not.  A p-value of <0.05 was considered to be 
statistically significant. The University of Tasmania’s Health and Medical Research ethics 
committee granted approval for this project and all patients gave informed consent to participate 
in this study.   
5.4 Results 
One hundred and twenty patients were approached for inclusion in the study, with 101 patients 
agreeing to participate.  Fourteen patients were subsequently excluded for the following reasons: 
death (1); withdrawal from the study due to ill health/personal reasons (7); lost to follow-up (5); 
required further surgery (1).   
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Table 8 shows the demographics and clinical characteristics of the participants.  There were no 
statistically significant differences in relation to baseline characteristics between those who 
experienced on average, at least mild pain at 12 months and those who did not experience pain.  
The use of intraoperative ketamine was significantly different between the groups, with patients 
prescribed intraoperative ketamine being more likely to have pain persisting at 12 months 
(34.8% vs 14.6% p=0.03). Patients who were administered regular paracetamol postoperatively 
appeared less likely to experience pain at 12 months, although this was not statistically significant 
(p=0.07). Persistent pain at 12 months was associated with moderate-severe levels of pain (on 
average) at 10 days (p=0.01) and six weeks (p=0.02); and also with a DN4 score of three or more, 
at three months (p=0.03) and 12 months (p=0.01).  
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Table 8 Baseline demographics and clinical characteristics according to pain at surgical site at 
12 months following surgery (n=87) 
 
Variable No pain at surgical 
site 12 months 
following surgery 
n= 41 
Pain surgical site at 
12 months 
 
n=46 
P 
value 
Baseline characteristics 
Median age in years (IQR)  65 (50-76) 63 (57-71.5) 0.81 
Female (%) 21 (51.2) 25 0.77 
Education level (%) 
     University/diploma 
     Completed year 12 
     <High school 
 
14 (34.2) 
16 (39.0) 
11 (26.8) 
 
8 (17.4) 
24 (52.2) 
14 (30.4) 
 
0.19 
Married/de-facto (%) 19 (46.3) 26 (56.5) 0.34 
Operation type (%) 
     Elective joint replacement 
     Emergency hip arthroplasty 
     Dynamic hip screw/intramedullary nail 
     Open reduction and internal fixation 
 
19 (46.3) 
5 (12.2) 
4 (9.8) 
13 (31.7)  
 
19 (41.3) 
2 (4.3) 
9 (19.6) 
16 (34.8) 
 
0.36 
Emergency surgery (%) 22 (53.7) 27 (58.7) 0.64 
Pre-operative PCS ≥ 30 (%) 8 (19.5) 8 (17.4) 0.80 
Pre-operative anxiety (HADS ≥ 8) (%) 13 (31.7) 19 (41.3) 0.35 
Pre-operative depression (HADS ≥ 8) (%) 8 (19.5) 7 (15.2) 0.60 
Median number of medications (IQR) 4 (1.5-7) 4 (2-8.3) 0.54 
Median number of medical conditions (IQR) 4 (2.0-5.5) 4 (2-6.3) 0.56 
Previous pain causing condition (%) 31 (75.6) 37 (80.4) 0.59 
Pre-existing regular use of analgesics (%) 24 (58.5) 30 (65.2) 0.52 
Pre-existing use of opioid containing 
analgesics 
7 (17.1) 5 (10.9) 0.40 
Number of pain sites 1.0 (0.5-2.0) 2.0 (1.0-3.0) 0.09 
Duration of previous pain 
No pain 
      ≤2 years 
      2-5 years 
      5-10 years 
      ≥10 years 
 
10 (24.4) 
3 (7.3) 
6 (14.6) 
11 (26.8) 
11 (26.8) 
 
9 (19.6) 
3 (6.5) 
11 (23.9) 
6 (13.0) 
17 (37.0) 
 
0.41 
Self-rated optimism 7.0 (5.5-8.3) 8.0 (5.8-9.0) 0.52 
Self-rated health 7.0 (5.0-8.0) 7.0 (5.0-8.0) 0.58 
Self-rated pain tolerance 3.3 (2.0-5.0) 3.0 (2.0-4.2) 0.51 
Self-rated fear of pain 1.0 (1.0-4.3) 1.8 (1.0-5.6) 0.38 
Smoking 6 (14.6) 7 (15.2) 0.94 
Alcohol 0 (0-3.0) 2.0 (0.0-10.0) 0.06 
Support on discharge 37 (90.2) 39 (84.8) 0.44 
Intraoperative factors 
Median Intraoperative opioid (mg) use (IQR) 49.0 (20.0-75.9) 58.9 (26.9-77.5) 0.83 
Intraoperative 40mg parecoxib use (%) 13 (31.7) 16 (34.8) 0.76 
Intraoperative ketamine use (%) 6 (14.6) 16 (34.8) 0.03 
Epidural (%) 2 (4.9) 6 (13.0) 0.19 
Regional nerve block (%) 9 (22.0) 11 (23.9) 0.83 
Intraoperative local anaesthetic use (%) 11 (26.8) 10 (21.7) 0.58 
Intraoperative IV paracetamol 7 (17.5) 11 (23.9) 0.47 
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Postoperative (in hospital) factors 
Use of PCA (%) 21 (51.2) 26 (56.5) 0.62 
Median pain on movement in the 48 hours after 
surgery (11 point numerical scale)  (IQR) 
2.8 (0.5-4.7) 3.9 (1.9-5.2) 0.10 
Median pain at rest in the 48 hours after surgery 
(11 point numerical scale) (IQR) 
2.0 (0.5-4.1) 2.8 (1.0-4.0) 0.68 
Median postoperative opioid consumption (oral 
MEQ/day) (IQR) 
139.0 (70.0-204.0) 159.5 (74.4-
238.0) 
0.46 
Use of postoperative ketamine (%) 3 (7.3) 5 (10.9) 0.57 
Use of postoperative regular oral paracetamol 
(%) 
39 (95.1) 38 (82.6) 0.07 
Use of Postoperative oral regular NSAID (%) 10 (24.4) 11 (23.9) 0.96 
Reviewed by the APS (%) 22 (53.7) 30 (65.2) 0.27 
Postoperative gabapentinoid 1 (2.4) 1 (2.2) 0.93 
Follow-up factors 
Moderate to severe average 10 day pain 9 (24.3) 25 (59.5) 0.02 
Moderate to severe average 6 week pain 3 (8.1) 13 (29.5) 0.02 
Moderate to severe average 3 month pain 3 (7.3) 8 (18.2) 0.14 
DN4 ≥3 at 3 months 4 (10.3) 13 (30.2) 0.03 
DN4 ≥3 at 12 months 2 (4.9) 14 (30.4) 0.01 
N: number; IQR: interquartile range; APS: Acute Pain Service; PCS: Pain Catastrophizing Scale; 
HADS: Hospital Anxiety and Depression Scale; PCA: patient controlled analgesia MEQ: morphine 
equivalence/day; mg: milligram; NSAID: non-steroidal anti-inflammatory agent; DN4: Douleur 
Neuropathique 4 
 
Table 9 shows the level of pain, physical function and analgesic use across the 12-month follow-
up period.  At 10 days, 97.4% of participants reported pain, with 43.6% experiencing moderate-
severe pain on average.  Pain affected 69.3% of patients’ ability to sleep and 38.5% of patients’ 
ability to undertake ADLs. Analgesic use was high with 80.8% taking paracetamol and 56.4% 
taking opioids; 97.1% of participants with moderate-severe average pain used analgesics at ten 
days. 
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Table 9 Pain scores and physical capabilities across the follow-up period 
Time period 10 days  
n= 78 (%) 
6 weeks 
n=80 (%) 
3 months 
n=83 (%) 
12 months 
n=87 (%) 
Pain – worst in past week 
     None 
     Mild 
     Moderate 
     Severe 
 
2 (2.6) 
16 (20.5) 
29 (37.2) 
31 (39.7) 
 
15 (18.7) 
29 (36.3) 
25 (31.3) 
11 (13.7) 
 
17(20.5) 
36 (43.3) 
19 (22.9) 
11 (13.3) 
 
30 (34.5) 
31 (35.6) 
16 (18.4) 
10 (11.5) 
Pain – average over last week 
     None 
     Mild 
     Moderate 
     Severe 
 
4 (5.1) 
40 (51.3) 
31 (39.7) 
3 (3.9) 
 
22 (27.5) 
42 (52.5) 
15 (18.7) 
1 (1.3) 
 
29 (34.9) 
43 (51.8) 
10 (12.1) 
1 (1.2) 
 
41 (47.2) 
33 (37.9) 
11 (12.6) 
2 (2.3) 
Effect of pain on sleep 
     None 
     Mild 
     Moderate 
     Severe 
 
24 (30.8) 
29 (37.2) 
19 (24.3) 
6 (7.7) 
 
41 (51.2) 
22 (27.5) 
9 (11.3) 
8 (10.0) 
 
52 (62.7) 
22 (26.5) 
7 (8.4) 
2 (2.4) 
 
66 (75.9) 
15 (17.3) 
3 (3.4) 
3 (3.4) 
Effect on ADLs 
     None 
     Mild 
     Moderate 
     Severe 
 
49 (62.8) 
17 (21.8) 
8 (10.3) 
4 (5.1) 
 
64 (80.0) 
12 (15.0) 
3 (3.8) 
1 (1.3) 
 
63 (75.9) 
17 (20.5) 
1 (1.2) 
2 (2.4) 
 
66 (75.9) 
15 (17.2) 
4 (4.6) 
2 (2.3) 
Effect on walking 100m** 
     None 
     Mild 
     Moderate 
     Severe 
     N/A 
 
17 (21.8) 
8 (10.2) 
3 (3.9) 
17 (21.8) 
33 (42.3) 
 
30 (37.5) 
12 (15.0) 
6 (7.5) 
6 (7.5) 
26 (32.5) 
 
53 (63.9) 
13 (15.7) 
3 (3.6) 
5 (6.0) 
9 (10.8) 
 
72 (82.8) 
8 (9.2) 
0 (0) 
7 (8.0) 
0 (0) 
Effect on participating in 
hobbies* 
     None 
     Mild 
     Moderate 
     Severe 
     N/A 
 
18 (23.1) 
3 (3.8) 
2 (2.6) 
10 (12.8) 
45 (57.7) 
 
34 (42.5)  
4 (5.0) 
4 (5.0) 
4 (5.0) 
34 (42.5) 
 
48 (57.9) 
9 (10.8) 
2 (2.4) 
4 (4.8) 
20 (24.1) 
 
69 (79.3) 
8 (9.2) 
3 (3.4) 
7 (8.1) 
0 (0) 
Analgesic use in past 24 hours 
(not specific to post-surgical 
pain) 
     Paracetamol  
          Mean dose (g) (range) 
     Opioids (mg MEQ)  
  Mean dose (range) 
 
 
 
63 (80.8) 
3.0 (0.5-5.3) 
44 (56.4) 
27.3mg (2.5-
90) 
 
 
 
50 (62.5) 
2.3 (0.5-4.0) 
29 (36.3) 
23.2 (1.9-82.5) 
 
 
 
40 (48.2) 
2.6 (0.5-4.0) 
22 (26.5) 
28.2 (7.5-105) 
 
 
 
33 (37.9) 
2.4 (0.5-5.0) 
17 (19.5) 
36.6 (3.75-135) 
* N/A: not applicable - At 10 days, 6 weeks, and 3 months, pain was often not affecting the patient’s ability 
to walk or undertake hobbies rather the doctor’s directions or injury restrictions prevented the patient 
from undertaking these task.  Thus patients rated these as pain having no effect on the ability to 
undertake those activities.  
N: number; MEQ: morphine equivalence/day; mg: milligram 
 
 
At six weeks, 20.1% of participants experienced on average moderate-severe pain.  Pain affected 
48.8% of patients’ ability to sleep and 20.3% of patients’ ability to undertake ADLs.  Amongst 
those with moderate-severe pain, 94.1% reported taking analgesia.  
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By three months, pain intensity continued to improve, although 65.1% of participants were still 
experiencing some pain, with 13.3% experiencing moderate-severe average pain. At three 
months, 37.3% of patients found pain at the surgical site affected their sleep and 24.1% found 
pain affected their ability to undertake ADLs. Analgesics were taken by 90.1% of participants with 
moderate-severe average pain.  
At 12 months, 65.5% of participants reported at least mild pain during the week prior to the 
follow-up, with 14.9% of participants experiencing moderate-severe average pain. Nearly one 
quarter of participants reported that pain was adversely affecting their sleep, and/or their 
ability to perform ADLs. Analgesics were taken by 84.6% of participants with moderate to 
severe average pain, with 61.5% of this group taking an opioid. Four people with a DN4 of three 
or more at 12 months were taking opioids dosages ranging from 30mg to 135mg MEQ/d.  
5.5 Discussion 
This study followed 87 people for a twelve-month period after they underwent orthopaedic 
surgery. The level of pain as well as functional impairment following orthopaedic surgery was 
considerable. At 12 months, over 50% of patients reported experiencing some persistence of pain 
at the surgical site in the previous week. The use of analgesics, although generally high 
throughout the follow up period, was still sub-optimal in some cases, with a number of 
participants experiencing moderate-severe pain but not taking analgesia.  This study also found 
that moderate-severe average pain scores during the sub-acute period following hospital 
discharge was associated with pain 12 months following surgery. This finding is supported by 
other studies that found pain at discharge (206), high pain intensity in the first month after a hip 
fracture surgery (208) and pain at three months following a major trauma (207) all were 
associated with persistent pain beyond six to 12 months.  
There is clear evidence that the management of pain after discharge is an area that requires 
increased attention, not only with regard to the impact this has on persistence of pain 12 months 
following surgery, but also to improve the QOL and functional status of patients. A range of actions 
would be required to achieve this objective including greater patient education regarding 
management of postoperative pain and when to seek further assistance with pain management 
as well as additional follow up with the health care practitioners following discharge.       
There were no statistically significant differences between the groups in relation to baseline 
demographics, however this may be due to the small sample size.  The apparently 
counterintuitive finding that participants prescribed ketamine in the intraoperative period were 
more likely to have pain at 12 months is potentially due to anaesthetists identifying these patients 
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as being at a higher risk of acute or persistent pain.  Amongst those patients who did not receive 
regular postoperative paracetamol, 80.0% had persisting pain at 12 months, although this 
association was not statistically significant due to the small sample size.  Considering the good 
safety profile of paracetamol and evidence suggesting it reduces opioid consumption following 
surgery (442), it is concerning to see ten patients were not prescribed regular paracetamol 
postoperatively. 
A DN4 of three or more at three months was associated with pain at 12 months; and for those 
with pain at 12 months, a DN4 of three or more was common.  This was not surprising as a 
number of studies have identified persistent postoperative pain often has a neuropathic 
component (82, 430, 443).   Despite this, the use of gabapentinoids postoperatively was minimal, 
even though some studies have indicated that it can reduce acute postoperative pain and opioid 
consumption (340, 341, 431) and PPP (342). Further research into the role, optimal dose and 
duration of postoperative use of gabapentinoids is needed; however, increased use of 
gabapentinoids and early identification and management of those with neuropathic symptoms 
may potentially aid in reducing the incidence and severity of persistent pain following surgery.   
There are a number of strengths to this study, including the prospective nature and high 
participant retention rate throughout follow-up. This study could have been improved through 
the additional recording of discharge advice from the hospital based on medical notes to identify 
if patients followed this advice, as well as physiotherapy intervention following discharge to 
ascertain if this affected outcomes also.  Whilst the small sample size is a limitation that needs to 
be acknowledged; this study nonetheless shows that pain and disability in the post-discharge 
period following orthopaedic surgery is considerable and undermanaged.  In addition, we found 
that moderate-severe average pain scores at ten days and six weeks postoperatively, were 
associated with pain persisting at 12 months. These findings have important implications for 
improving QOL during this period as well as potentially preventing PPP. This study highlights the 
need for additional research to evaluate whether increased intervention regarding pain 
management following hospital discharge can improve pain outcomes and physical function 12 
months after orthopaedic surgery.   
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Chapter 6: Use of opioid analgesics in older Australians 
 
All of the research contained within this chapter has been published as Veal FC, Bereznicki LRE, 
Thompson AJ, Peterson GM, “Use of opioid analgesics in older Australians”, Pain Medicine, 2015: 
16 (8) pp. 1519-27. doi:10.1111/pme.12720  
 
6.1 Abstract 
Background: Persistent pain is a common complaint in elderly patients.  However, 
pharmacological management strategies, including the use of opioids, are complicated in elderly 
patients due to comorbidities, polypharmacy, and the risk of adverse events.  
 
Objective: To identify potential medication management issues associated with the use of opioids 
for persistent pain in elderly Australians.   
 
Design: Retrospective cross-sectional review of the utilisation of analgesics in 19,581 people who 
underwent a medication review in Australia between 2010-2012 was undertaken.   
 
Results: The average age of the population was 77±13 years. Opioid analgesics were documented 
as being taken by 31.8% patients, with 22.1% patients taking these regularly. Three major 
medication management issues were identified. Of patients documented as taking regular opioid 
analgesics, only 49.1% were recorded as also taking regular paracetamol at a dose of 3-4g/day. 
Concurrent use of anxiolytics/hypnotics amongst those taking regular opioid analgesics was 
common (45%). Finally, only 60% of those taking regular opioid analgesics were also taking a 
laxative.     
 
Conclusion: A pragmatic, quick reference guide for the pharmacological management of 
persistent pain in older people is needed. It should emphasise the initial use of optimised non-
opioid analgesia, highlight the risk of anxiolytics/hypnotics contributing to falls and fractures in 
people taking opioid analgesics, and the need for concurrent laxatives in people taking regular 
opioids.  
 
6.2 Introduction 
Up to 80% of ACF residents and 50% of older persons living in the community suffer from 
persistent pain (444). Persistent pain is a difficult condition to treat effectively in any population.  
However, pain management in older patients has a number of additional challenges including 
polypharmacy increasing the likelihood of drug-drug interactions, comorbidities increasing the 
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likelihood of drug-disease interactions.  As well as changes and variability in the 
pharmacokinetics and pharmacodynamics of analgesics (108), changes in perception of pain 
(101), and patient related barriers to pain management (445).     
 
Clinical guidelines often focus on which patients are good candidates for opioid analgesics and 
provide limited guidance as to what medications should be co-prescribed with opioid analgesics 
and at what dose. Opioid analgesics are not recommended as first-line treatment or in isolation 
of other pharmacological and non-pharmacological treatment options (108, 297, 312, 313). Yet, 
opioid analgesics are increasingly prescribed for the management of persistent pain, 
demonstrated by the dramatic increase in their use (21-24) and treatment duration (22, 27).  In 
line with this increasing use, there has been a trend towards increasing rates of deaths associated 
with opioid analgesic use (27-29), proportionally to the opioid dose being taken (27, 318). For 
non-cancer pain, Australian guidelines recommended a maximum opioid dose equivalent to 100-
120mg of oral MEQ per day (94, 312). However, the risk of overdose and adverse events, such as 
falls and fractures, exists at doses significantly lower than this recommended maximum (319, 
329, 446). 
 
In Australia, the PBS (447), which is the national formulary for government subsidised medicines, 
generally lists opioids as restricted for the management of “severe disabling pain not responding 
to non-narcotic analgesics”.  The restriction is silent on the issue of co-prescription of non-opioid 
analgesics. Despite this restriction, a recent Australian study evaluating the PBS prescriptions 
dispensed for veterans in Australia found that 34% of community patients and 20% of ACF 
residents commenced on oxycodone had not received non-opioid analgesics in the previous four 
months (382).   
 
This study aimed to identify potential medication management issues in relation to the use of 
opioid analgesics in the treatment of persistent pain amongst older Australians undergoing a 
medication review, and suggest ways to improve the management of persistent pain.   
 
6.3 Methods 
A retrospective cross-sectional study of people undergoing medication reviews in Australia was 
undertaken. In Australia, two forms of pharmacist-conducted comprehensive medication reviews 
are undertaken, HMR for community dwelling patients with multiple medications and/or 
comorbidities and RMMR for any permanent ACF residents.  
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Pharmacists can choose to enter data from these reviews into different software programs to aid 
in assessing patient therapy and report writing.  Medscope™ is one such software system.  All 
patient records in the Medscope™ database as of June 2012 were included in this review.   The 
extract, contained 19,996 de-identified medication reviews conducted between January 2010 and 
June 2012; 382 reviews were excluded as they included no medical history.   
 
Patient’s date of birth and review, gender, allergies and medical history, type of review 
undertaken (HMR or RMMR) and medications prescribed (or purchased over-the-counter), 
including dose and directions, were included in the database.   
 
Opioids that were prescribed for non-pain indications were excluded from the study, namely 
methadone liquid, dihydrocodeine and pholcodine cough mixtures and codeine linctus if the 
directions indicated it was prescribed for non-pain symptoms (e.g. cough). All regularly-dosed 
(RD) opioids were converted to the daily oral MEQ based on an Australian conversion table (299).  
Non-opioid analgesics, paracetamol, NSAIDs (including aspirin ≥300mg/day) and topical anti-
inflammatories were recorded. Paracetamol was defined as optimised if a daily dose of 3-4g was 
prescribed and taken regularly (219).  Concurrent use of anxiolytics and hypnotics 
(benzodiazepines and non-benzodiazepines) and adjuvant therapies, including gabapentinoids 
(pregabalin and gabapentin) and TCAs, were also evaluated. 
 
A number of medical conditions have been associated with differences in opioid prescribing or 
risk factors in previous studies and these were reviewed. They included a history of falls (327), 
fractures (327), osteoporosis (448), congestive heart failure (CHF) (449), respiratory disease 
(450), history of substance or alcohol abuse (154, 229) and a history of depression and/or anxiety 
(154).  Charlson Comorbidity Index (CCI) (451) was calculated for all patients.  Pain was classified 
as either musculoskeletal pain or pain not otherwise specified (NOS) which included pain 
conditions or descriptions such as neuropathic/nerve pain, chronic pain, pain (unspecified). 
 
Analysis was performed using SPSS Statistics 20 for Windows (SPSS Inc., Chicago, Il, USA).  Chi-
square analysis and Mann-Whitney U tests were undertaken to evaluate differences between 
patient groups.  Ethics was granted from the Social Science Human Research Ethics Committee, 
University of Tasmania. 
 
6.4 Results 
Table 10 includes patient demographics.  Analgesics (non-opioid and opioid), excluding topical 
anti-inflammatories, were documented as being taken by 15,823 (80.8%) patients reviewed; 
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6,235 (31.8%) reviews documented opioid use, with 4,334 (22.1%) patients taking RD opioids. 
Oral NSAID use was relatively low; meloxicam and celecoxib were the most commonly prescribed 
NSAIDs followed by ibuprofen, diclofenac and naproxen. Table 11 shows the use of analgesics for 
patients recorded as taking RD opioids; this table includes these patients’ regular and as required 
medications.  Of those patients taking RD opioids and anxiolytics/hypnotics, temazepam was 
most frequently used followed by diazepam, oxazepam and alprazolam; only 44.1% of those 
taking an anxiolytic or hypnotic had a documented history of anxiety and/or depression or 
insomnia.   
 
There was no statistically significant association between the MEQ/d for RD opioid analgesics 
and a history of falls (p=0.88), fractures (p=0.73), osteoporosis (p=0.98), congestive heart failure 
(p=0.94) or respiratory disease (p=0.14). However, for people in ACFs, a history of osteoporosis 
increased the daily RD opioid dose (85.8mg versus 75.1mg p=0.037).  People with a history of 
depression and/or anxiety had a statistically significant higher mean daily RD opioid analgesic 
dose compared with those without such a history (91.1mg versus 71.3 mg; p=0.003).  Similarly 
people with a history of substance or alcohol abuse had a statistically significant higher mean 
daily RD opioid dose compared to those without a history of abuse (83.8mg versus 79.4mg, 
p=0.002).  For people with a history of musculoskeletal pain the RD opioid dosage was 59.5mg 
compared to 55.9mg for those who did not have musculoskeletal pain (p<0.001).  Pain NOS had 
significantly higher RD daily doses of opioids, than those who did not have pain NOS (76.9mg 
versus 51.6mg p<0.001). 
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Table 10 Demographics, medical conditions and analgesics used of the study population 
 
Variable 
Community 
n=12,272 (%) 
ACF 
n=7309 (%) 
Overall 
n=19581 (%) 
Age in years (±SD)** 72.5±12.9 84.4±9.1 77.0±13.0 
Male**  5136 (41.9) 2291 (31.3) 7427 (37.9) 
Disease states 
History of cancer (excluding non-
melanoma skin cancer) 
1130 (9.2) 700 (9.6) 1830 (9.3) 
History of musculoskeletal pain** 5627 (46.0) 2659 (36.4) 8286 (42.3) 
History of pain not otherwise specified** 2019 (16.5) 829 (11.3) 2848 (14.5) 
History of diabetes**  4420 (36.1) 1546 (21.2) 5966 (30.5) 
History of CHF** 1030 (8.4) 899 (12.3) 1929 (9.9) 
History of respiratory disease** 3436 (28.1) 1232 (16.9) 4668 (23.8) 
History of depression and/or anxiety** 3193 (26.0) 2616 (35.8) 5809 (29.7) 
History of substance or alcohol abuse 244 (2.0) 196 (2.7) 440 (2.2) 
Average CCI** 1.7±1.7 1.9±1.5 1.8±1.7 
Medications 
Taking analgesics (excluding topical anti-
inflammatories)** 
9189 (75.0) 6634 (90.8) 15823 (80.8) 
Taking paracetamol** 8449 (69.0) 6446 (88.2) 14895 (76.1) 
Taking optimised paracetamol** 2921 (23.9) 2905 (39.7) 5826 (29.8) 
Taking an NSAID** 2353 (19.2) 435 (6.0) 2877 (14.7) 
Using topical NSAIDs** 284 (2.3) 446 (6.1) 730 (3.7) 
Taking an opioid analgesic** 3393 (27.7) 2842 (38.9) 6235 (31.8) 
Taking an RD opioid analgesic** 2277 (18.6) 2057 (28.1) 4334 (22.1) 
Taking an anxiolytic/hypnotic** 3388 (27.7) 3033 (41.5) 6421 (32.8) 
Statistical analysis: comparing the analgesic usage between people in the community and 
people in ACF **p<0.001; *p<0.05 
SD: standard deviation; CHF: congestive heart failure; CCI: Charlson Comorbidity Index; NSAID: 
non-steroidal anti-inflammatory drugs; RD: regularly dosed. 
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Table 11 Analgesic use for patients prescribed regularly dosed opioid analgesics 
 Community 
n=2277 (%) 
ACF 
n=2057 
(%)
  
Overall 
n=4334 (%) 
Non-opioid analgesic use 
Paracetamol** 2011 (88.3) 1901 (92.4) 3912 (90.2) 
Optimised paracetamol** 971 (42.6) 1155 (56.1) 2127 (49.1) 
NSAIDs** 613 (26.9) 158  (7.7) 771 (17.8) 
Using a topical NSAIDs** 66 (2.9) 194 (9.4) 260 (6.0) 
Opioid analgesic use 
Median MEQ/d (mg) RD 
opioid dose (range mg)^ 
36.0 (0.65-1180) 30.0 (2-853) 30mg (0.65-1180) 
Mean MEQ/d RD dose* 58.6±80.9mg 56.9±78.0mg 57.8 ± 79.5mg  
Buprenorphine patch** 499 (21.9) 895 (43.5) 1394 (32.2) 
Oxycodone IR**  459 (20.2) 661 (32.2) 1121 (25.9) 
Codeine containing** 809 (35.5) 270 (13.1) 1079 (24.9) 
Oxycodone CR 508 (22.3) 474 (23.0) 982 (22.7) 
Tramadol** 647 (28.4) 156 (7.6) 803 (18.5) 
Fentanyl patch**  216 (9.5) 526 (25.6) 743 (17.1) 
Morphine CR*  161 (7.1) 113 (5.5) 274 (6.3) 
Morphine IR** 32 (1.4) 141 (6.9) 173 (4.0) 
Other opioids^ 182 (8.0) 214 (10.4) 396 (9.1) 
Other medications 
Laxatives/softener** 815 (35.8)  1698 (82.5) 2513 (60.0) 
Anxiolytics or hypnotics** 945 (41.5) 996 (48.4) 1941 (44.8) 
Taking an antidepressant* 1102 (48.4) 1066 (51.8) 2168 (50.0) 
Taking an SNRI** 274 (12.0) 162 (7.9) 436 (10.1) 
Taking a TCA** 378 (16.6) 177 (8.6) 555 (12.8) 
Taking a gabapentinoid** 64 (2.8) 22 (1.1) 86 (2.0) 
Note: Patients can appear in more than one row.  The average number of opioid analgesics 
taken by each person documented as taking an RD opioid was 1.6 as this table include as 
required and RD opioid analgesics. 
^ no statistical analysis was conducted on this variable 
Statistical analysis: comparing the analgesic usage between people in the community and 
people in ACF **p<0.001; *p<0.05 
NSAID: non-steroidal anti-inflammatory Drug; MEQ/d: morphine equivalence per day; RD: 
regularly dosed; IR: immediate release; CR: controlled release; SNRI: serotonin and 
noradrenalin reuptake inhibitor; TCA: tricyclic antidepressant 
 
6.5 Discussion 
Analgesic use was high in both the community and ACF population.  Approximately 80% of the 
population were documented as taking at least one analgesic, although the indication for use 
could be for chronic, intermittent or incidental pain, with paracetamol and opioids most 
commonly used. The finding that 22% of the reviews recorded RD opioid analgesics clearly 
demonstrates the extent of opioid usage in older Australians and is consistent with the 
increasing number of opioid prescriptions being supplied in Australia (21, 23). 
 
From Table 10 and 11 it can be seen there are substantial difference in the pattern of analgesics 
and adjuvant use between those in the community and those in ACFs.  The use of NSAIDs was 
71 
low, particularly ACF residents which is in line with guidelines which tend to recommend 
caution when using NSAIDs in older people restricting their use to the lowest effective dose for 
the shortest period of time (108, 219, 313).  TCA use was low in ACF residents, which is as 
expected based on guidelines recommending cautious use of TCAs due to the risk of side effects 
(108). For patients taking RD opioids, immediate release strong opioids (morphine and 
oxycodone) and patches (buprenorphine and fentanyl) were more frequently used in ACFs than 
the community, whereas in the community weak opioids (tramadol and codeine) were more 
commonly prescribed than in the ACFs.  The use of CR oxycodone was similar in both groups, 
with a slightly higher proportion of community patients taking CR morphine than those in ACFs. 
 
It is not unsurprising that the use of opioids in people with a history of depression and/or 
anxiety and those with a history of substance or alcohol abuse were higher and has previously 
been noted (154, 229).  Falls, fractures or osteoporosis (excluding those in ACFs) were not 
associated with variations in RD opioid dosage, which was slightly surprising, as these have 
been associated with higher level of persistent pain (448, 452), however this does not seem to 
have corresponded to a higher level of opioid consumption in this cohort.   
 
Overall paracetamol use was high with 90% of people prescribed regular opioids also taking 
paracetamol, however only 49.1% of these people were also taking optimised paracetamol, 
despite evidence suggesting that it improves pain control (453).  It has been established that 
multimodal analgesic regimens in acute postoperative pain reduce opioid requirements (442), 
and it is likely that this approach would reduce opioid analgesic requirements in persistent pain 
also.  Thus, it was encouraging to see that the levels of paracetamol use were higher in this study 
compared to previous Australian studies (379, 384, 452, 454); however, there is still significant 
room for improvement in this area. 
  
There was extensive use of anxiolytics/hypnotics concurrently with RD opioids. Nearly 50% of 
ACF residents and 41.5% of community patients prescribed regular opioids were also prescribed 
anxiolytics/hypnotics.  This is concerning given that anxiolytics and hypnotics are recommended 
for short term use and this combination, particularly in older people, further increases the risk of 
falls and fractures (327).   
 
Despite guidelines recommending the prophylactic use of laxatives for people taking long-term 
opioids (108, 219, 313), only 60% of the population were using laxatives indicating potentially 
sub-optimal management of opioid-induced constipation, especially in community based 
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patients.  Usage of laxatives was more common in ACF residents with only 35.8% of community-
based patients taking laxatives with concurrent regular opioids.   
 
Based on this research there appears to be a significant need for a pragmatic, quick reference 
guide for pain management in the elderly. Although the WHO are in the process of writing 
guidelines for the management of chronic non-malignant pain in adults (455), it is unclear the 
amount of detail that will be provided specifically talking about the management of pain in the 
elderly. As older people are at increased risk of adverse events from opioid analgesics, including 
confusion, respiratory depression, constipation, falls and fractures, which are compounded by 
high rates of comorbidities and polypharmacy, there is a need to ensure their pain is managed 
safely and effectively.  
 
In addition, multiple guidelines exist with information about “good” candidate patients for 
opioids; however, they are often laborious to read and provide limited practical information on 
what other medications should be co-prescribed or at what dose. Thus, there is a need for a quick 
reference pharmacological guideline for the management of pain in the elderly, including the 
recommended steps, co-prescribed therapies (such as non-opioid analgesics and laxatives) and 
recommended doses, as well as additional relevant information, such as opioid analgesic trial 
durations. These guidelines should emphasis the optimisation of non-opioid analgesia before the 
addition or escalation of opioid analgesics and the regular use of laxatives in people taking regular 
opioids. Furthermore, there should be an associated increase in prescriber education in these 
areas, as well as the avoidance of concomitant anxiolytics and hypnotics in people taking opioids.   
 
There are a number of strengths with this study, including the use of Australia-wide data, 
containing a comprehensive patient medical and medication history (including both over-the-
counter and prescription medications). However, there is the potential that data may have been 
incorrectly entered by the pharmacists undertaking the review, which cannot be verified.  There 
is also the potential that patients may take their medication differently to how it was documented 
in the medication review, which could both under- and over-estimate analgesic use. 
Unfortunately, the recommendations made by the pharmacists and which ones were 
implemented by the doctors was not recorded in the dataset; however, this would have helped 
inform the discussion around the QUM in this patient population.  Finally, due to the way that 
data was recorded, neither the duration of opioid analgesic use nor the specific indication for the 
analgesic could be ascertained.           
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In conclusion, it is concerning to find suboptimal use of paracetamol in combination with RD 
opioid analgesics in older Australians with persistent pain.  Furthermore, the widespread use of 
anxiolytics/hypnotics concurrently with opioid analgesics should prompt guidance in this area, 
given the associated increase in risk of falls and fractures.  
 
A pragmatic, quick reference guide for the pharmacological management of persistent pain in 
older people is needed. It should emphasise the initial use of optimised non-opioid analgesia, 
highlight the risk of anxiolytics/hypnotics contributing to falls and fractures in people taking 
opioid analgesics, and the need for concurrent laxatives in people taking regular opioids.  This 
strategy has the potential to improve care through better pain control whilst at the same time 
minimising the risks associated with opioid analgesics in older people, where the burden of 
persistent pain is significant.   
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Chapter 7: Pharmacological management of pain in Australian aged care facilities 
 
All of the research contained within this chapter has been published as Veal FC, Bereznicki, LR, 
Thompson AJ, Peterson GM, “Pharmacological management of pain in Australian aged care 
facilities”, Age and Ageing, 2014: 43 (6) pp. 851-856. doi:10.1093/ageing/afu072  
 
7.1 Abstract 
Background: Up to 80% of residents in ACFs experience pain, and previous studies have found 
that older patients with pain are often undertreated. Few studies have been conducted in 
Australia evaluating the use of analgesic therapy in ACF residents.  
 
Objective: To explore the use of analgesics amongst ACF residents, including independent 
predictors of analgesic use, evaluate analgesic use against pain management guidelines and 
identify potential medication management issues. 
 
Methods: A retrospective analysis of 7,309 medicines reviews conducted on Australian ACF 
residents was undertaken. Medication use was compared with published guidelines relating to 
the management of pain in elderly patients or ACF residents. Multiple variable logistic regression 
was used to identify independent predictors of analgesic use.         
 
Results: Nearly 91% of residents were prescribed analgesics. Of those, 2,057 residents were 
taking regular opioids (28.1%).  Only 50% of those taking regular opioids received regular 
paracetamol at doses of 3-4g/day.  The concurrent use of sedatives was high, with 33.3% of those 
taking regular opioids also taking an anxiolytic/hypnotic. 
 
Conclusion: There is a need to optimise the prescribing and administration of regular 
paracetamol as first line and continuing therapy for pain management in ACF residents, to 
potentially improve pain management and reduce opioid requirements.  Furthermore, with the 
risk of falls and fractures increased by concurrent use of opioids and sedatives, the widespread 
use of these drugs in a population already at high risk was concerning, indicating a need for better 
education of health professionals in this area.  
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7.2 Introduction 
Pain in the elderly is a common issue, with up to 80% of residents in ACFs experiencing persistent 
pain (444).  Despite persistent pain being recognised as a major cause of disability in elderly 
patients, significant under-treatment in this population has been reported (449, 452, 456, 457).   
 
Age-related changes affect how the elderly experience pain, including a reduced production of 
endogenous analgesic substances and changes in pain perception (100, 101).  Furthermore, there 
is greater heterogeneity in the way older patients respond to medications, including analgesics 
(16).  This is partly attributable to pharmacokinetic and pharmacodynamic changes (108), but 
also to comorbidities that potentially affect the response to analgesics (109).  
 
A number of guidelines relating to the management of pain in elderly patients or ACF residents 
exist. Generally, these recommend regular (by-the-clock) dosing of analgesics for patients with 
persistent pain (219), with paracetamol recommended as the first line option (108) (1g 6-hourly) 
(219) and continued as a baseline analgesic when more potent agents (e.g. opioids) are added 
(16, 219).  The use of weak opioids in the management of both cancer pain and chronic pain has 
been debated, with some suggesting that low dose strong opioids are a more suitable alternative 
after non-opioid analgesics have failed to adequately manage pain alone (458).  Guidelines also 
recommend that, due to the risk of side effects, NSAIDs should be avoided if possible, or used at 
the lowest effective dose for the shortest period of time (108, 219).  Potentially, these restrictive 
recommendations make guidelines difficult to follow in practice, leaving prescribers with 
relatively few options to treat pain amongst elderly patients.  
 
Another complication when treating pain in the elderly is the prevalence of comorbidities and 
high rates of polypharmacy, increasing the risk of adverse drug events.  Certain types of pain 
(459), as well as some analgesics, have been implicated in increasing the risk of falls (327, 459).  
With the consequences of falls and fractures being so significant in the elderly, it is challenging 
for clinicians to minimise this risk whilst still adequately controlling pain.   
 
In Australia few studies have been undertaken to evaluate the use of analgesics in ACF residents 
(382-384). With limited options to manage pain in this group and multiple conflicting treatment 
priorities, this study aimed to investigate pain management practices in ACFs, identify patient 
factors that increase the likelihood of analgesic use, and examine any medication management 
issues. 
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7.3 Methods 
ACFs in Australia provide a range of support from high dependency (nursing home) to low 
dependency (residential homes). Residents from both high and low dependency care have been 
included in this review.  The Australian Government funds biennial RMMRs by accredited 
pharmacists for any Australian residents who live permanently in an ACF, to attempt to reduce 
the occurrence of drug-related problems.  Several different software programs exist to aid 
pharmacists with handling data obtained during their review, assessing medications and writing 
reports; one of which is Medscope™. It is estimated that 20-25% of all reviews conducted in 
Australia involve use of this software system. The Medscope™ database includes basic 
demographic details, prescription and over-the-counter medications (including prescribed dose 
and directions) and brief medical history, which are entered by the pharmacist conducting the 
review. De-identified data from all RMMRs recorded in the database between January 2010 and 
June 2012 were extracted from Medscope™ and were included in the study.    There were 33 
reviews that had no documented medical history and these were removed from the analysis, 
leaving 7,309 reviews. 
 
Analgesics evaluated in this study, included paracetamol, NSAIDs (including aspirin at doses 
≥300mg/day) and opioids.  Opioids were classified as being taken as a RD or not (if taken on an 
as required basis).  Oral MEQ per day was calculated (299).  Opioids used predominantly as 
antitussives (dihydrocodeine or pholcodine), or codeine linctus with a direction indicating that 
its use was for cough or diarrhoea, were not included as analgesics. The following opioids were 
classified as weak: tramadol, codeine and dextropropoxyphene; with morphine, oxycodone, 
fentanyl, buprenorphine, methadone and hydromorphone classified as strong opioids. 
Paracetamol was defined as being optimised if the daily dose was 3-4g and given by-the-clock. 
Anxiolytics/hypnotics were defined as benzodiazepines and non-benzodiazepines hypnotics 
(zopiclone and zolpidem); other sedating agents (antidepressants, antipsychotics and sedating 
antihistamines) were also recorded.  
 
In ACFs, residents have their medication managed by nursing staff in multidrug blisters, packed 
by pharmacies.  For this reason prescribed doses for RD medications are likely to reflect 
medications administered to the patient. However, for “as required” medications, the dose and 
frequency administered to the patient is not specified in the database.  
 
The CCI (451) score was calculated for each patient. Pain was classified into musculoskeletal pain, 
which included the following conditions: back pain, joint pain, spondylosis and osteoarthritis; and 
pain NOS, which included the following medical descriptions noted in the medical history: “pain”, 
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“chronic pain”, neuropathic pain, nerve pain, post-herpetic neuralgia, fibromyalgia, and headache, 
migraine. Other chronic medical conditions previously noted to be associated with different 
patterns of pain or increased usage or risk of problems associated with analgesics (particularly 
opioids) were also determined, including a history of substance abuse (154), depression and/or 
anxiety (154), falls (327), dementia (460), Parkinson’s disease (461), diabetes (461), chronic 
obstructive pulmonary disease (COPD) (450), stroke (462), CHF (449), osteoporosis (448) and 
fractures (452).   
 
Statistical analysis was performed using SPSS Statistics 20 for windows (SPSS Inc., Chicago, Il, 
USA). Chi-square, Mann-Whitney U and Wilcoxon Signed Rank tests were undertaken to evaluate 
differences between patient characteristics and analgesic use. Multiple variable binary logistic 
regression was subsequently used to analyse the independent associations between non-
injectable analgesic use and patient demographics, co-prescribed therapies and comorbidities. 
All variables with P values <0.1 were assessed for multicollinearity prior to inclusion in the 
multiple variable binary logistic regression model. 
 
7.4 Results 
The majority of residents were women (68.7%), with an average age of 84.4 years (±9.1) and an 
average CCI score of 1.9 (±1.5). Analgesics were prescribed to 6,634 of the residents; 2057 
(28.1%) residents were prescribed RD opioids (86.5% of opioids were strong opioids; 9.5% weak 
opioids and 4.0% both strong and weak opioids). Of those residents taking RD opioids, 1155 
(50.1%) residents were taking optimised paracetamol. There was no significant difference 
between the CCI score of those prescribed analgesics and those not (p=0.50).  However, there was 
a small, but statistically significant difference, in the CCI score between those taking RD opioids 
and those not (1.97 v 1.87; p=0.01).    
 
Table 12 shows the pattern of all analgesics used in the study population. Non-opioid analgesics 
only were prescribed to 3793 (51.9%) residents, with 2676 (36.6%) residents prescribed both 
non-opioid and opioid analgesics. Table 13 shows the proportion of each opioid prescribed; the 
majority of opioids prescribed to residents were strong opioids (80.6%), with weak opioids 
accounting for 19.4% of opioids prescribed.  The mean dose of RD opioids was 57.8mg MEQ/d 
(±79.5mg) and the median dose of RD opioids was 30mg MEQ/d. There was no statistical 
difference between the RD opioid dose of those with a history of falls and those without (p=0.50).  
The use of TCAs was low, with 402 (5.5%) residents prescribed a TCA and 177 residents 
prescribed RD opioids concurrently prescribed a TCA.  Gabapentinoids were infrequently 
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prescribed, with only 36 residents prescribed one; 23 residents were prescribed concurrent RD 
opioids and a gabapentinoid. 
 
Anxiolytics/hypnotics were prescribed to 41.5% of the residents, with 43.2% and 32.8% of those 
taking analgesics and RD opioids, respectively, also prescribed these sedative drugs. There was 
no statistical difference between the MEQ/d for those on RD opioids who were taking an 
anxiolytic/hypnotic and those not (p=0.19). Of those patients prescribed anxiolytics/hypnotics, 
55% did not have a documented history of insomnia or anxiety/depression.  
 
Table 14 shows the likelihood of residents being prescribed analgesics, non-injectable opioids, 
RD opioids and optimised paracetamol. Opioids were more likely to be prescribed to females, and 
those with a history of musculoskeletal pain, pain NOS, history of fractures, osteoporosis or taking 
anxiolytics/hypnotics or other sedating agents. Patients taking opioids or RD opioids were more 
likely to have a history of cancer; RD opioids and optimised paracetamol were more likely to be 
taken by patients with a history of CHF. Patients with dementia were less likely to receive 
optimised paracetamol, opioids or RD opioids. 
 
Table 12 Use of all analgesics 
Type of analgesia Resident taking analgesics n (%) 
Regularly Dose opioids 2057 (28.1)  
Opioid + optimised paracetamol  1155 (15.8) 102 (1.4) also administered NSAIDS 
Opioid + paracetamol  746 (10.2) 51 (0.7) also administered NSAIDS 
Opioid only 153 (2.1)  
Opioid + NSAID  7 (0.1)  
As required opioids  785 (10.7)  
Opioid + optimised paracetamol  395 (5.4) 22 (0.3) also administered NSAIDS 
Opioid + Paracetamol  373 (5.1) 29 (0.4) also administered NSAIDS 
Opioid only  14 (0.2)  
Non-opioid analgesia only 3793 (51.9)  
Paracetamol only 2427 (33.2) 102 (1.4) also administered NSAIDS 
Optimised paracetamol only  1352 (18.5) 102 (1.4) also administered NSAIDS 
NSAID only 14 (0.2)  
No analgesics 674 (9.2)  
NSAID: non-steroidal anti-inflammatory drugs 
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Table 13 Use of opioids   
Opioid Number of 
those taking 
opioids 
Percentage of 
those taking 
opioids* 
Proportion of 
the study sample  
 
Buprenorphine patch 898 31.6  12.3 
Codeine ± combination 560 19.7 7. 7 
Controlled-release morphine 96 3.4 1.3 
Controlled-release oxycodone 483 17.0 6.6  
Fentanyl patch 520 18.3 7.1 
Immediate-release morphine 310 10.9 4.2  
Immediate-release oxycodone 1028 36.2 14.1  
Morphine injection 238 8.4 3.3  
Other 105 3.7 1.4 
Tramadol 252 8.9  3.5 
* Equals more than 100% as the average number of opioids used per resident (using opioids) 
was 1.9. 
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Table 14 Associations with analgesic usage 
 
 Any analgesia 
(odds ratio 95% 
CI) 
Any non-
injectable 
opioids 
(odds ratio 95% 
CI) 
RD opioids 
(odds ratio 95% 
CI) 
Optimised 
Paracetamol 
(odds ratio 95% 
CI) 
Age  
     <60 
     60-<70 
     70-<80 
     80-<90 
     ≥90 
 
1 
0.39 (0.19-0.80)* 
0.67 (0.34-1.31) 
0.65 (0.34-1.27) 
0.94 (0.48-1.85) 
 
1 
1.01 (0.65-1.56) 
1.23 (0.83-1.84) 
1.05 (0.71-1.55) 
1.11 (0.75-1.64) 
 
1 
0.88 (0.55-1.43) 
1.00 (0.65-1.55) 
0.93 (0.61-1.41) 
0.95 (0.62-1.45) 
 
1 
0.91 (0.57-1.47) 
1.02 (0.67-1.57) 
0.92 (0.60-1.40) 
0.92 (0.60-1.40) 
Female 1.20 (1.01-1.42)* 1.21 (1.08-1.35)* 1.38 (1.21-1.56)** 1.35 (1.19-1.52)** 
Depression 1.00 (0.84-1.22) 1.04 (0.93-1.16) 1.00 (0.89-1.21) 1.11 (1.00-1.24) 
History of Falls - - - 0.99 (0.78-1.04) 
CCI 
     0-1 
     2-3 
     4-5 
     ≥6 
-  
1 
1.12 (1.00-1.26) 
1.01 (0.83-1.22) 
1.15 (0.82-1.62) 
 
1 
1.11 (0.98-1.26) 
1.00 (0.82-1.23) 
1.10 (0.77-1.58) 
- 
Dementia - 0.75 (0.66-0.84)** 0.68 (0.60-0.76)** 0.71 (0.64-0.79)** 
Asthma 1.29 (0.88-1.88) 1.06 (0.86-1.31) 1.10 (0.88-1.12) 1.14 (0.92-1.40) 
Parkinson 
disease 
- 0.87 (0.71-1.07) 0.80 (0.64-1.01) - 
CHF - 1.11 (0.94-1.29) 1.23 (1.04-1.46)* 1.25 (1.07-1.47)* 
Stroke 0.65 (0.41-1.04) - - - 
COPD - 1.06 (0.90-1.29) 1.08 (0.90-1.30) - 
Anxiolytics/ 
hypnotics 
2.28 (1.90-2.75)** 1.70 (1.53-1.88)** 1.41 (1.27-1.58)** 1.48 (1.33-1.64)** 
Other sedating 
agents 
1.21 (1.02-1.44)* 1.34 (1.23-1.56)** 1.49 (1.33-1.68)** - 
Musculoskeletal 1.90 (1.57-2.30)** 1.63 (1.47-1.80)** 1.63 (1.46-1.82)** 1.62 (1.45-1.80)** 
Pain NOS 1.93 (1.38-2.69)** 2.26 (1.94-2.64)** 2.44 (2.09-2.85)** 2.45 (2.10-2.85)** 
Osteoporosis 1.24 (0.98-1.58) 1.29 (1.14-1.46)** 1.22 (13.07-1.40)** 1.21 (1.06-1.38)* 
Fractures 1.92 (1.39-2.66)** 1.60 (1.38-1.86)** 1.54 (1.32-1.80)** 1.56 (1.34-1.82)** 
Falls Risk 
     0 
     1 
     2 
     ≥3 
 -  
1 
0.84 (0.71-1.00)* 
0.70 (0.58-0.85)** 
0.67 (0.53-0.83)** 
- - 
History of 
cancer  
- 1.32 (1.10-1.60)* 1.38 (1.13-1.68)* - 
* P<0.05; ** P ≤ 0.01 
 
7.5 Discussion 
Previous studies have noted low use of analgesics in elderly patients (449, 452, 456, 457). This 
study found that the vast majority (90.7%) of residents were prescribed an analgesic (62.8% 
taking analgesics regularly), which is considerably higher than the level of analgesic use found in 
a previous Australian study (384).  This increase could be partially attributed to the Australian 
Pain Society’s Guidelines on the management of pain in ACF (219) being released in 2005, 
increasing awareness of the management of pain in the elderly.   Potentially the patients in our 
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study may have also been seen by pharmacists previously for a review in an attempt to improve 
pain management. Consistent with other studies (449, 452), we found that paracetamol was the 
most commonly prescribed analgesic. However, the use of optimised paracetamol was low, only 
being prescribed to 40% of residents overall and 50% of those patients on RD opioids, which are 
similar rates to those found in other studies (452). The use of NSAIDs was low, which is in line 
with clinical guidelines (108). 
 
Three major medication issues were identified in the study: (i) low use of optimised paracetamol, 
particularly in patients who were taking RD opioids; (ii) high use of anxiolytics/hypnotics in 
combination with opioids, which substantially increases the risk of falls and fractures; and (iii) 
potentially sub-optimal management of pain in patients with dementia. Although the safety of 
paracetamol at therapeutic doses has recently been questioned by some (463), it is generally 
regarded as the safest option available for elderly patients and is recommended by guidelines 
(16, 108)  as a first line option for pain management. The use of regular paracetamol at an 
appropriate dose was low, particularly in patients taking RD opioids. This is consistent with a 
recent Australian study (382) evaluating oxycodone use in a similar population, which found that 
only 41% of residents of ACFs had had a trial of a non-opioid analgesic prior to commencing 
oxycodone. These findings suggest that the use of paracetamol in chronic pain needs to be given 
prominence in clinical guidelines, particularly as a means to minimise use of opioids, their 
associated side effects and improve pain management. There may be a place for regulatory 
bodies, which approve and monitor long-term opioid therapy, to require maximum tolerated 
doses of paracetamol be used before the addition, or dose escalation, of opioids. 
 
The second issue was the use of anxiolytics/hypnotics in combination with opioids, both of which 
increase the risk of falls and fractures (327, 329, 464). The combination is not recommended, 
particularly in the elderly, due to falls risk (465). It appears that warnings about the danger of 
combining sedating agents, such as anxiolytics/hypnotics with opioids, are not being heeded. 
There is a need to increase the education of health professionals about such combinations in an 
attempt to minimise their use, whilst still addressing the requirement for adequate pain relief.   
 
The third issue identified was the low use of analgesics in patients with a history of dementia, 
which has been identified previously (460).  Potentially, this may indicate judicious use of 
medications, in that these patients have high potential to develop adverse events with opioids 
(466).  However, it is unlikely that these patients experience less pain than their counterparts 
without dementia (460), and the low level of optimised paracetamol and opioid use in this group,  
indicates that patients with dementia are likely to have sub-optimal pain management. Increased 
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emphasis of regularly dosed analgesics, particularly paracetamol, in patients with dementia 
should be encouraged if pain is suspected.  This is particularly important in patients with a history 
of dementia, as often these patients are unable to request or adequately communicate pain and 
thus regular dosing of analgesics is essential to assist in managing the patient’s pain. 
 
The pattern of opioid use in published studies is highly variable. Nearly 40% of the residents 
reviewed in our study were documented as receiving opioids, which is consistent with some other 
studies (383, 452), but not all (461). Of those taking opioids, 72.4% were taking opioids regularly, 
which is higher than previously reported (384). There was also greater use of strong opioids than 
previously noted (449), accounting for 80.6% of opioids prescribed.  However, the use of weak 
opioids was still relatively high, potentially indicating prescriber’s concerns over the use of strong 
opioids in this patient group or perceived efficacy.  As the trial evidence to support the use of 
weak opioids is difficult to extrapolate to clinical practice (458) this use may be justified and 
suitable in these patients.         
 
Not surprisingly, musculoskeletal pain, pain NOS, fractures and osteoporosis were the most likely 
independent factors associated with analgesic use. Residents with a history of CHF were more 
likely to use RD opioids and optimised paracetamol, in contrast to another study (449) that found 
ACF residents were less likely to receive opioids if they had a history of CHF.  Potentially this 
increased use of opioids reflects the avoidance of NSAIDs in patients with heart failure as well as 
increased acceptance of the use of opioids for persistent pain in elderly patients. 
 
There are some limitations associated with this dataset. Unfortunately, the recommendations 
made by the pharmacists and which ones were implemented by the doctors, as well as non-
pharmacological management strategies employed were not recorded in the dataset; however, 
this would have helped inform the discussion around the QUM in this patient population.  The 
clinical indications for analgesic use, cause of pain or satisfaction with pain management were 
not able to be determined from the data. In addition, medications were listed with their 
prescribed directions rather than administered dose, which is particularly relevant to 
medications given on an ‘as required’ basis, and therefore we may have underestimated the 
extent of use of these medications. However, as the vast majority of ACFs use pharmacist-
prepared medication packs administered by nursing staff, the prescribed dosages for RD 
medications are likely to represent the actual usage. There is the potential that pharmacists may 
be more likely to use decision support software where patients are more clinically complicated.  
However, chronic pain is difficult to manage and these patients tend to have multiple 
comorbidities, for this reason it is expected that the results from this study are consistent with 
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analgesic use in Australian ACFs. Despite these limitations, this data still has some significant 
strengths, including the large patient population throughout Australia, no recall bias, and the 
inclusion of both prescription and over-the-counter medication. In addition, this sample 
appeared to be broadly representative of Australian ACF residents, which is not unsurprising 
noting that the vast majority of residents in ACFs undergo a medicines review   
 
In conclusion, three medication management issues were identified: low rates of optimised 
paracetamol use, particularly in patients taking regular opioids; high concurrent use of 
anxiolytics/hypnotics with opioids; and potentially inadequate pain management in patients with 
dementia. The risk of falls and fractures with opioids is a strong reason to encourage the 
prescribing and administration of regular paracetamol at a dose of 3-4g/day, before the addition 
or uptitration of opioids, particularly when the patient is also taking sedating agents. It is clear 
there is a need for increased education of ACF staff and medical practitioners in an attempt to 
minimise potentially risky combinations of sedating agents. There is also a need to emphasise 
that optimised paracetamol should be used as a baseline and ongoing analgesic in the 
management of pain. In addition, regulatory bodies could have a role to play in requiring 
paracetamol to be prescribed at an optimised dose as a baseline analgesic before approval for 
long-term opioids is granted.    
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Chapter 8: The barriers to pain management in Tasmanian general practice 
 
8.1 Abstract 
Background: Pain is difficult to manage and is often both under and over treated.   Numerous 
factors complicate treatment, including poor trial evidence of analgesics in long-term use, safety 
and addiction concerns regarding opioids and patient factors.  This study aimed to identify how 
GPs in Tasmania manage pain and what the perceived barriers to pain management within 
Tasmania are.  
 
Methods: An electronic survey was distributed to Tasmanian GPs between November and 
December 2015.  Publically available email addresses of GP practices were used when available, 
and all general practices that could be identified through an online search were contacted to 
request an email address.  Information about the survey was also distributed in November 2015, 
via the Primary Health Network newsletter, which is electronically distributed to all Tasmanian 
General Practices.   
 
Results: 41 surveys (5.6%) were completed. The median number of years practicing as a GP was 
17.5 (range: 2-49).  The median number of patients experiencing pain, seen each week was 
estimated to be 20 (range 3-56). The major barriers to pain management were identified as poor 
access to pain clinics and allied health services, analgesic adverse effects, and unrealistic patient 
expectations.  Participants also suggested that pain management could be improved through 
additional education for health professionals and patients.  
 
Conclusion: There are a number of health system barriers to optimal pain management.  
Strategies that require significant policy change and Government cost are required, however, 
they will take time to implement.  More immediate methods of improving pain management could 
include additional patient and prescriber education.  
 
8.2 Introduction 
Acute pain, which has an identifiable cause, is more straightforward to treat than persistent pain, 
where the cause of the pain is not always so clear.  The evidence to support the use of analgesics 
in acute pain is good (48) and treatment options are dependent on patient comorbidities and co-
prescribed therapies. In contrast, persistent pain is a challenging condition to treat, with poor 
evidence to support the use of analgesics long-term (89, 228, 303), common misconceptions 
amongst patients regarding pain and its management (467, 468), the want for a ‘quick fix’ (469, 
470), and the lack of public funding for allied health services (471) and pain clinics (472).  
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Guidelines recommend that persistent pain should be managed by a multidisciplinary team in 
order to improve patient outcomes and function (473).  However, the vast majority of 
consultations regarding persistent pain management occur in general practice (1, 2) and it has 
been reported that over one third of all GP appointments involve patients with persistent pain 
conditions (474). The prevalence of conditions associated with persistent pain are increasing 
(475), due in part to an ageing population, longer term survival following cancer diagnosis and 
an increased number of surgical procedures, after which some patients develop PPP. The 
complexity of the issues facing patients with persistent pain pose particular challenges to GPs, 
when a standard Medicare Benefits Schedule (MBS) funded GP appointment typically lasts only 
12 to 14 minutes (476). 
 
Some information is known about prescribing of analgesic in Australian general practice. The 
studies that have been conducted have used data from the Bettering The Evaluation And Care of 
Health (BEACH) program, which was a now defunct longitudinal cross-sectional program 
surveying approximately 1250 Australian GPs annually, documenting 100 consecutive 
consultations each (477).  These studies have identified analgesic prescribing rates, indications 
for prescribing, use of non-pharmacological strategies, and how frequently patients are provided 
advice and sent for pathology or other tests (10, 478-480). However, BEACH data is unable to 
provide information about the barriers and enablers to pain management, or specifics 
surrounding guidelines and what information is provided to patients.   
 
Numerous barriers to optimal persistent pain management in general practice have been 
identified internationally.  One study from the United Kingdom found that GPs identified the main 
barriers to optimal pain management as: adverse effects, patient compliance, and efficacy of 
medications (481). A qualitative British study (482) identified a number of barriers including: 
feeling underprepared to manage persistent pain patients; poor evidence around opioids making 
management plans difficult to formulate; an absence of shared treatment goals; patient 
reluctance to use non-pharmacological strategies; pain being relegated in favour of acute 
problems; and a reluctance to deprescribe opioids. Another qualitative British study (77) found 
that GPs often felt ill-equipped to assessing the level of pain, felt they had low levels of training 
on the area and demonstrated a more conservative approach to prescribing compared to 
prescribing in cancer pain.  One American study reported that the major barriers to pain 
management were uncertainties about best treatment options, the biopsychosocial nature of 
persistent pain, risk of abuse, and the limited time available to manage persistent pain (483). 
Additional factors were identified by another American study, which found that inadequate 
training, low satisfaction with the management of pain, and patient-related aspects including 
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patient psychology, self-management and compliance were barriers to management (474). 
However, with healthcare funding models, service availability and accessibility and legislation 
varying from country to country, it may not be appropriate to apply the international literature 
to the Australian context. Consequently, this study aimed to identify how persistent pain is 
managed by GPs in Tasmania, the perceived barriers to optimal pain management, and potential 
ways in which these could be overcome.    
 
8.3 Methods  
An electronic survey was distributed to the Tasmanian general practice community through a 
variety of channels. The local Primary Health Network published information about the survey in 
their electronic newsletter, which is distributed monthly to all GP practices in Tasmania.  In 
addition, contact details for general practices in Tasmania were obtained through an extensive 
Internet search.  For those practices where an email address was not publicly available, the 
practice was contacted by phone to obtain an email address so that the survey could be 
distributed to the GPs at the practice.  If the practice preferred, the information sheet and link to 
the survey was provided by fax or hard copy in the mail. All attempts to contact all GP practices 
in Tasmania was made. At the time of the study, there were 698 practicing GPs in Tasmania (484). 
Ethics approval was granted by the Tasmanian Health and Medical Research Ethics Committee. 
An incentive was used to enhance recruitment, which was the chance to win one of five $100 AUD 
gift cards. 
 
The survey (Appendix 7) was conducted through Lime Survey (485).  Participants were asked 
how many years they had worked in general practice; on average how many patients they saw 
each week with acute pain, persistent pain (both non-malignant and malignant), palliative care 
and neuropathic pain. Participants were also asked questions regarding guideline(s) used to 
inform management of pain, perceived barriers to pain management in general practice and how 
these could be overcome. Tick box responses were required for most questions with the option 
to annotate responses with free text.  The tick box options were based on previously recorded 
factors influencing pain management, compliance or barriers. The question regarding ways to 
overcome barriers to pain management was entirely free text. Free text answers were 
subsequently categorised into themes. 
8.4 Results 
Fifty-eight participants commenced the survey, with 41 completing the survey.  The median 
number of years practicing as a GP was 17.5 years (range: 2-49 years).  The median number of 
patients experiencing pain, seen each week was estimated to be 20 (range 3-56). Table 15 
provides further information about the types of pain managed by GPs on a weekly basis. 
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Therapeutic Guidelines (Analgesic) (240) was most commonly used by GPs to guide their pain 
management (68.3%); followed by the WHO pain ladder (217) (36.6%); and the Royal Australian 
College of General Practitioner’s guideline for the non-surgical management of hip and knee 
osteoarthritis (313) (31.7%).   A small minority of GPs used other guidelines. One GP used “clinical 
judgment” and one GP said that they did not use guidelines rather they said “… I make it up as I 
go”. Table 16 provides information about the strategies used by GPs to manage pain, particularly 
when using opioids. 
Table 15 Number of patients seen by GPs each week with different types of pain (n=41) 
Type of pain Median number of patients/week (range)  
Acute pain 5 (1-25) 
Persistent non-malignant pain 5 (1-30) 
Persistent malignant pain 1 (0-5) 
Palliative care 1 (0-30) 
Neuropathic pain 4 (0.5-15) 
 
 
Table 16 Strategies used by GPs in the management of pain  (n=41) 
 
Strategy 
n (%) 
Discussion around pain management expectations 30 (73.2) 
Opioid trials of ~8 weeks 20 (48.8) 
Urine drug screening to monitor compliance and inappropriate drug taking 5 (12.2) 
Referral for CBT 11 (26.8) 
Referral for physiotherapy 31 (75.6) 
Regular reviews of the 5As (analgesia, activity, adverse events, aberrant 
behaviour and affect) 
10 (24.3) 
CBT: cognitive behaviour therapy 
 
Table 17 provides information about the perceived patient compliance to analgesics by GPs.  The 
most common reasons that GPs thought patients were non-compliant were: poor analgesics 
efficacy (76.5%), fear of addiction (61.8%), reserving analgesics for severe pain (58.8%), tablet 
burden (55.9%), fear analgesics will not work if they use them too often (50.0%), pain 
catastrophising (50.0%), fear of pain (41.2%), misuse or diversion (32.4%), and lack of patient 
knowledge (8.8%). 
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Table 17 Percentage of GP’s who perceive patients are adherent or non-adherent to analgesics 
(n=34) 
Acute pain 
 Less than  
Prescribed 
As prescribed More than 
 prescribed 
Paracetamol 22 (64.7) 8 (23.5) 4 (11.8) 
NSAIDs 13 (38.2) 14 (41.2) 7 (20.6) 
RD opioids * 4 (12.5) 24 (75.0) 4 (6.3) 
PRN opioids  7 (20.5) 15 (44.1) 12 (35.3) 
Chronic/persistent pain 
 Less than  
Prescribed 
As prescribed More than 
 prescribed 
Paracetamol 23 (67.6) 10 (29.4) 1 (2.9) 
NSAIDS* 12 (37.5) 15 (46.9) 5 (15.6) 
RD opioids ** 0 (0) 27 (81.8) 6 (18.2) 
PRN opioids*** 4 (12.9) 9 (29.0) 18 (54.5) 
Adjuvants ** 4 (12.1) 27 (81.8) 2 (6.5) 
Note: * two participants did not respond to this aspect; **one participant did not respond to this 
aspect; *** three participants did not respond to this aspect. 
NSAIDs: non-steroidal anti-inflammatories; RD: regularly dosed; PRN: as required 
 
 
Major barriers to optimal pain management could be classified into four themes: patient factors, 
medication factors, pain condition related factors and healthcare system factors. Healthcare 
system factors were the most frequently cited as barriers to optimal pain management. Specific 
examples included waiting times for and access to pain clinics, limited government funding of 
allied health professions (psychologists and physiotherapists), surgical waiting times and lack of 
support for GPs. Patient factors cited as barriers included unrealistic patient expectations, patient 
psychology (for example, psychological comorbidities and coping strategies) and a reluctance to 
use non-pharmacological or self-management strategies.  Medication factors included the risk of 
misuse or diversion, adverse effects, lack of efficacy, lack of evidence, and guidelines that are 
difficult to use. Pain-related factors included difficulties in terms of diagnosing causes of 
persistent pain and the complexity of pain management.  
Multiple suggestions were made regarding ways to overcome these barriers.  The most common 
of these were: better access to pain clinics or support of GPs by pain clinics, improved access to 
allied health care professionals (including physiotherapy, psychology and multidisciplinary 
teams), and increased education of patients, GPs and allied health care professionals. Improved 
management of acute and post-surgical discharge pain, better and simpler guidelines, and 
increased time available to manage patients with pain were also noted as desirable by some GPs. 
8.5 Discussion 
This is the first study we are aware of that has surveyed Australian GPs regarding the barriers to 
optimal pain management in general practice. A number of factors identified by Australian GPs 
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were similar to those in international studies, including medication and patient-related aspects. 
However, the most commonly cited barriers in this study were related to health system factors. 
GPs identified that major barriers to optimal pain management were a lack of access and long 
waiting times for pain clinics, and a lack of government funding for allied health professionals to 
assist in multidisciplinary management of patients with persistent pain.  
These are not factors that have been previously identified in international studies and this may 
reflect differences in the health systems and funding models in place other countries.  However, 
other Australian studies have reported that the health system poses barriers to optimal 
management of patients with cancer or palliative care related pain.  These included difficulty in 
accessing non-pharmacological management options and a lack of coordination between 
different services (486-488). These factors do appear to be consistent across a number of health 
care providers (including specialists, community nurses and GPs) and in different pain 
management settings (including cancer pain and palliative care).   
Long waiting times for multidisciplinary pain clinics in Australia have also been identified 
previously (472). This is an area that requires additional policy change and financial support, 
although the most cost-effective way to improve access requires further investigation.  A number 
of initiatives to improve pain clinic access and pain management in this area have been 
implemented in Australia (35, 489). Pain clinics are primarily funded by individual states and 
territories and, increased resources would be required at this level to improve the management 
of pain.  If this is financially unviable, then potentially empowering GPs by increasing the support 
and assistance provided by pain clinics may be a more cost-effective approach. This could be 
undertaken through improving GP access to the expertise of pain specialists, who may be able to 
advise on management strategies for difficult cases via phone or email. Additionally, it would take 
significant policy changes and increased Commonwealth funding to increase the MBS subsidy of 
physiotherapy and psychology to assist in the multidisciplinary management of pain.    
Another key area identified as having the potential to improve patient management was 
increased education of GPs and allied health care professionals.  This could be undertaken 
through increased continuing professional development (CPD) in pain management and 
increased availability of pain management related post-graduate courses. A number of courses 
are already available (35, 490, 491) but require medical professionals to undertake these 
activities in their own time.  Further incentives may be required to increase the number of GPs 
with additional training in pain management.   If these types of initiatives were expanded to 
include other health care professionals this could further assist with efforts to improve pain 
management.  However, there is also a need for an increased focus on pain management in 
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undergraduate courses for allied health care professions, not solely medicine.  This has previously 
been identified as an area where GPs believe they have insufficient grounding and assessments 
of undergraduate medicine curriculum have identified deficiencies (474, 492, 493). Although 
there has been a recent increased emphasis on training early career doctors (494) this needs to 
be introduced earlier into doctors’ training.  A concerted effort from all Australian universities 
would be required to better integrate pain management into the curriculum of medical 
undergraduate and graduate courses as well as allied health profession degrees.  This is likely to 
have significant long-term benefits, although it would presumably take many years before the 
impact of this would be seen in clinical practice.  
Barriers related to the poor evidence base, adverse effects and difficult to use guidelines (which 
in part is due to the poor evidence base) are difficult to overcome completely.  Patient-related 
barriers to optimal pain management may be overcome, to some extent, through improved 
patient education around pain management, expectations, and the role of analgesics and self-
management strategies.  Although a number of initiatives exist which focus on improving patient 
knowledge and public awareness of pain and its management, particularly by Chronic Pain 
Australia (35), there may be room for further development of these.  Focus groups and interviews 
with patients may allow for further insight into what type of information patients want and how 
they would prefer it to be delivered in the Australian context.  
Another potential approach, although not explicitly mentioned by the GPs, is to expand the role 
of pharmacists to allow for more patient education. This has been previously suggested in 
Australia (495) as well as internationally (496, 497).  This could be through accredited 
pharmacists who visit patients in their home to carry out HMRs or pharmacists who work in GP 
clinics, a program which is likely to be expanded over the coming years (498). Pharmacist led 
interventions, including educational programs (499), medication reviews (500), and pharmacist-
nurse led pain clinics (501) have been found to reduce adverse events and pain intensity, as well 
as improve physical functioning and patient satisfaction. Increased collaboration between GPs 
and pharmacists may provide opportunities to improve patient outcomes and also reduce the 
burden of pain management on GPs.  
BEACH data found that approximately 20% of patient episodes, with new onset pain conditions 
were provided with advice about their pain management, although what the content of the advice 
was, is not specified (478, 479). Whereas, 73.2% of the GPs in thus study reported talking to 
patients about expectations, which is a positive finding (although it was not recorded how 
frequently GPs conducted these discussions with patients). Without such discussions, patients 
may assume that freedom from pain is achievable and that once an analgesic is started for 
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persistent pain it will be automatically be continued. Nonetheless, it is concerning to see that only 
half (48.8%) of the GPs participating in the survey use opioids trials.  For persistent pain, opioids 
often to do not decrease the level of pain substantially or improve physical function (502) and 
opioid trials are recommended to ascertain benefit and adverse events (18, 503, 504). This is an 
area that requires increased emphasis and is closely aligned with patient expectations.  Without 
discussion surrounding a trial of an opioid, any subsequent desire to deprescribe may become 
more challenging. Approximately one quarter (24.3%) of doctors regularly reviewed the 5As 
(analgesia, activity, adverse events, aberrant behaviour and affect) with patients. To a substantial 
degree, these results are likely reflective of the significant time constraints on GPs. While 
increased involvement from nurse practitioners or pharmacists working in general practice may 
assist in managing some of these aspects, increasing the ability for GPs to spend more time with 
complex pain patients would be the optimal option. However, this may not be feasible given the 
fee-for-service model and commercial pressure on GPs to see more patients. Discussions around 
treatment trials and expectations could, however, be supplemented by additional patient 
information and education.  
The guidelines or recommendations most frequently reported being used by GPs were the 
Therapeutics Guidelines, the WHO pain ladder and the Royal Australian College of General 
Practitioner’s guideline for the non-surgical management of hip and knee osteoarthritis.  
Nonetheless, it is important to note that previous BEACH data indicated that GPs do not 
necessarily treat patients in accordance with guidelines (478). Although most (95%) GPs 
reported using guidelines in their management of pain, it is concerning that no GPs referred to 
the use of document ‘Pain in Residential Aged Care Facilities’ (219) produced by the Australian 
Pain Society, despite this being considered to be a definitive pain management resource by the 
Australian Department of Health (35).  As 80% of ACF residents experience persistent pain, it is 
highly likely that responding GPs would be involved in the care of patients with pain in ACFs and 
yet this resource was not used. The practicalities of guidelines generally was noted as a barrier 
to pain management and this was supported by another study of Australian GPs that found they 
would prefer succinct (2-3 pages) guidelines (505). Previous studies found that the Therapeutic 
Guidelines was also the resource most frequently used by Australian palliative care physicians, 
nurses and oncologists working with cancer patients with pain. However, these studies found 
lower guideline utilisation than our study of GPs [22% (oncologists); 45% (palliative care 
physicians); 71% (community nurses)] (486-488).  
The median number of pain patients seen each week by the participants was 20, which based on 
an average of 90 consultations a week (477) accounts for 22% of patients seen by GPs.  This is 
consistent with BEACH data, which found approximately 19-25% of GP encounters were 
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regarding persistent pain, 1.2% cancer-related pain and 5.2% persistent nerve pain (506, 507). 
Non-adherence to analgesics in patients who suffer from persistent pain is common with 
prevalence ranging from 8-62% (407) which is reflected in the perceptions of GPs.  Previous 
studies have identified that analgesic underuse is more common than overuse in persistent pain 
(402, 407) and acute pain (406).  In previous studies underuse in persistent pain has ranged from 
2-53% with overuse ranging from 9-51%, with an average prevalence of 33% underuse and 
overuse (407).  This was similar to what the GPs noted, although participants thought there was 
substantial overuse of as required opioids that is not in line with previous studies.  As the 
previous adherence studies were not conducted in Australia it would be worth undertaking 
further investigations of patient adherence rates to the different types of analgesics in those with 
acute and persistent pain. Tasmanian regulations (508) require strict intervals between each 
dispensing of opioids, it is very concerning if this is the true rate of overuse of these opioids.  Non-
adherence is difficult to overcome, however often underuse is associated with misconceptions 
about analgesics, and overuse associated with increased pain intensity (407).  Increased patient 
education and empowerment to better self-manage their pain may improve adherence rates.       
It is acknowledged that these results may not be wholly generalisable to the Tasmanian or 
Australian GP community as there is potential for self-selection bias to occur. Nonetheless the 
results are consistent with previous studies in this area and are likely to be generally applicable 
to the Tasmanian and Australian population.  Additionally, these results provide a solid basis for 
further targeted research into the future.    
Identification of barriers is the first step required to overcome them (509). Pain management is 
complex for various reasons, including patient factors, medication factors, the complexity of the 
diagnosis and management of pain, and health system factors.  Some of these barriers may be 
amenable to modification, however, others require substantial financial investment, policy 
changes and coordinated efforts across undergraduate and post graduate medical courses to 
improve the way pain is managed in general practice.  In the shorter-medium term, education of 
allied health care professionals, GPs and patients is likely to be the most effective way at 
improving patient outcomes and reducing pressure on GPs. Improving the use of other members 
of the healthcare team, such as practice nurses and pharmacists may further assist in the 
management of persistent pain, and help support GPs to enhance patient outcomes.  Particularly 
until a time where more services and funding are available to allow patients increased access to 
multidisciplinary teams managing pain.   
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Chapter 9: Identification of factors influencing Australian anaesthetists’ perioperative 
management and perceived barriers to optimal postoperative pain management  
9.1 Abstract 
Background: Perioperative pain management can influence the incidence and severity of acute 
and persistent postoperative pain.  This study aimed to identify what factors anaesthetists 
perceived as increasing the risk of postoperative pain; what factors influenced clinical practice; 
and potential ways to reduce the incidence of PPP.  
 
Method: Private anaesthetic practices and public hospitals with a surgical unit were identified 
through an Internet search and contacted to ask that an electronic survey be distributed to all 
anaesthetists and anaesthetic registrars between November 2015 and January 2016. 
 
Results: 175 surveys were completed. Three-quarters of respondents were consultants. Factors 
associated with PPP included: somatic persistent pain (87.3%); depression (80.1%); anxiety 
(79.5%); pain catastrophising (73.5%); visceral persistent pain (72.3%); and duration (70.5%) 
or severity (65.7%) of pre-operative pain. Clinical judgment (86.3%) and patient (85.7%) and 
operation factors (82.9%) were the most common factors influencing perioperative pain 
management. Potential ways to reduce the incidence of PPP included increased follow-up after 
discharge (49.1%), post-surgical neuropathic pain assessment (62.9%), pre-surgical screening 
of psychological factors (48.0%) and identification and production of a PPP risk assessment tool 
(62.3%).  
 
Conclusion: Large-scale studies are needed to identify risk factors for PPP and develop a 
predictive model so that at-risk patients can be more readily identified. Additionally, randomised 
controlled studies are needed to evaluate the effect of pain specialist undertaking post-discharge 
follow-up on the incidence of PPP, as well as assessing the effect of psychological counselling 
aimed at reducing anxiety, pain catastrophising and increasing coping strategies on the incidence 
of PPP.  
9.2 Introduction 
In Australia there are approximately 2.4 million operations conducted each year (510), and at 
least 80% of patients experience acute pain following surgery with 20% experiencing severe pain 
(390, 511).  Significant post-discharge pain has also been reported following surgery, with 30-
54% of patients experiencing moderate-extreme levels of pain in the two weeks following 
discharge (415, 512, 513). Acute post-surgical pain can have short and long-term consequences, 
including increased risk of transition to PPP, which can occur in 5-85% of post-surgical patients 
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(82, 388), postoperative delirium, particularly in the elderly (514), increased risk of re-
hospitalisation or extended duration of admission (392, 393, 515) and reduced capacity to 
participate in rehabilitation (393).  Thus, it is essential to optimise the management of acute and 
post-discharge pain to reduce the incidence of these adverse events occurring.    
A number of factors have previously been implicated in increasing the risk of acute post-surgical 
pain and PPP.  Factors identified as increasing the risk of acute postoperative pain include type 
of surgery, surgeon experience, patient sex, age, genetics, pre-operative anxiety, pre-operative 
pain and pre-operative pain related disability (391, 439, 516-518).  A number of these factors are 
the same or similar to that of PPP.  The most common factors associated with PPP are high levels 
of acute pain, younger age, female, nerve damage during surgery, genetics, psychological factors 
such as anxiety, depression, and pain catastrophising, and pre-operative pain and duration (82, 
141, 388).  However, the evidence to support which factors influence the likelihood of post-
surgical pain is poor, with a lack of standardised definition, studies often inadequately powered, 
variables not consistently recorded or reliance on patient recall (82, 388) making them difficult 
to apply to clinical practice. For these reasons, anaesthetists are likely to manage patients based 
on their previous experience in addition to clinical evidence.  
A number of factors have been found to affect perioperative management of patients; most of 
these are comorbidities affecting the way in which patients are managed, including age and 
cognitive status (519); smoking status (520) comorbidities including diabetes (521, 522) 
cardiovascular disease (523, 524) or medications such as anticoagulants (525).  However, the 
way pain is managed and what guides decisions regarding perioperative pain management is less 
clear.  Guidelines regarding the management of perioperative pain provide general information 
about treatment options; however, they do not provide specific details about management or 
which of the large number of medications should be used preferentially or together (48, 526). 
Thus, there is the potential for substantial variability in the way perioperative pain is managed.   
This study aimed to identify the factors that anaesthetists’ associated with increased likelihood 
of pain following surgery, and how their management differed in these patients. Additionally, this 
study aimed to identify barriers and enablers to perioperative and post-discharge pain 
management to be able to identify ways to improve pain control and potentially reduce the 
incidence or severity of PPP.  
9.3 Methods 
An electronic survey was distributed to Australian anaesthetists and anaesthetic registrars.  An 
extensive search of the Internet resulted in the contact details for private Australian anaesthetic 
practices and public hospitals undertaking surgery throughout Australia.  For those organisations 
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where a publicly available email address was not available, the hospitals or private practices were 
contacted by phone to obtain an email address where the survey could be distributed through to 
all anaesthetists and anaesthetic registrars working at that facility.   
The survey (Appendix 8) was conducted through Lime Survey (485).  Participants were asked if 
they were registrars or consultants, if they worked in public or private practice (or both), for how 
many years they had worked in anaesthetics, and what type of procedures they most frequently 
attended.  Based on previously identified pre-operative factors contributing to post-surgical pain 
(82), participants were asked which of these patient factors they considered increased the 
likelihood of acute and persistent postoperative pain, how their treatment would change if they 
identified patients as being at high risk of acute or persistent postoperative pain and what this 
was based on (for example, clinical guidelines, patient or operation factors or clinical judgment). 
Participants were also asked what measures would assist in reducing the incidence of PPP and 
barriers to acute and post-discharge pain. All variables were tick box, with the option of free text 
additional answers.  Free text answers were classified into themes.  The survey was open from 
November 2015 until January 2016. An incentive was used to enhance recruitment, which was 
the chance to win one of five $100 AUD gift cards. Ethics was approved by the Tasmanian Health 
and Medical Research Ethics Committee. 
9.4 Results 
Two-hundred and thirty participants commenced the survey, with 175 completing the survey.  
Only completed surveys were included in the analysis.  The median number of years practicing in 
anaesthetics was 13 years (range 1-40 years). Of those who responded 132 were consultants and 
43 (24.5%) were registrars.  Registrars worked primarily in public hospital (95.3%), with the 
remainder working in both public and private sectors.  Consultants most frequently worked in 
both public and private facilities (48.5%), followed by public hospitals only (43.0%) and a 
minority (8.3%) worked in private hospitals only.  The median number of operations attended 
weekly was 20 (range: 4-40).  Only 16 (12.8%) anaesthetists worked in one surgical specialty, 
with most working across more than one type of surgery.   Anaesthetists attended procedures in 
general surgery (71.4%); day surgery (64.6%); and orthopaedics (63.4%) most frequently. Other 
specialties included obstetrics and gynaecology (48.0%); colorectal (44.0%); plastics and 
reconstruction (39.4%); head and neck (24.0%); paediatrics (25.7%); vascular (20.6%); 
interventional radiological procedures (17.7%); neurosurgery (16.0%); cardiothoracics (10.9%); 
other (9.1%); and 6.3% listed no specific surgical specialty.  
Table 18 shows the factors that anaesthetists considered most likely to contribute to acute post-
surgical pain or PPP.  Other free text factors cited by anaesthetists as increasing the likelihood of 
acute pain were smoking status (3), obesity (2), younger age (2), infection (2), cancer (2) and its 
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treatment (3), lack of social support (2), compensation claim (2) and negative expectations of 
health carers (2).  Three factors commonly cited by anaesthetists in both acute and persistent 
pain were perioperative factors (5, 4 respectively), pre-operative opioids (8, 5 respectively) and 
illicit substance abuse (5, 3 respectively).  Five anaesthetists also noted severe acute 
postoperative pain was a predictor of PPP.   
Table 18 Pre-surgical factors that anaesthetists considered were associated with the 
development of postoperative pain  (n=166) 
 
Variable Acute postoperative pain 
n (%) 
PPP risk factors  
n (%) 
Depression 109 (65.7) 133 (80.1) 
Anxiety 153 (92.2) 132 (79.5) 
Pain catastrophising 138 (83.1) 122 (73.5) 
Somatic persistent pain 141 (84.9) 145 (87.3) 
Visceral persistent pain 106 (63.9) 120 (72.3) 
Low socio-economic status 42 (25.3) 44 (26.5) 
Low education level 40 (24.1) 45 (27.1) 
Pre-operative pain severity 135 (81.3) 109 (65.7) 
Duration of pre-operative pain 116 (69.9) 117 (70.5) 
Re-operation on site 76 (45.8) 88 (53.0) 
 
The most common influence on how the participants managed patients during the perioperative 
period was clinical judgment (86.3%), closely followed by patient factors (85.7%) and operation 
factors (82.9%).  Hospital or department protocols (62.9%) or Australian (44.0%) or 
International (22.9%) guidelines were less frequently used to guide practice.  Table 19 shows the 
different treatment modalities and how these would be used if patients were identified as being 
at high risk of experiencing acute post-surgical pain or PPP.  
Table 19 How management changes if patients are identified as being at high risk of acute or 
persistent postoperative pain (n=161) 
 
 Acute postoperative pain  
n (%) 
Persistent postoperative pain 
n (%) 
Regional Anaesthesia 129 (80.1) 116 (72.0) 
Epidural 73 (45.3) 85 (52.8) 
Perioperative local anaesthetic 106 (60.6) 93 (57.8) 
Perioperative ketamine 118 (65.8) 127 (78.9) 
Parecoxib 110 (68.3) 83 (51.6) 
A short course of gabapentinoids 81 (50.3) 117 (72.7) 
Patient controlled analgesia 123 (76.4) 88 (54.7) 
Postoperative ketamine infusion 102 (63.3) 121 (75.2) 
Postoperative local anaesthetic 49 (30.4) 63 (39.0) 
 
Other free text suggestions that were made in relation to the management of pain if the patient 
was at high risk for acute pain were: multimodal analgesia (3), use of clonidine (3), patient 
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education (2), early intervention by the APS (1), loading dose of paracetamol (1), nursing 
education (1), neuraxial morphine (1), total intravenous anaesthesia (1), high dependency or 
intensive care admission (1).  Other free text suggestions that were made in relation to the 
management of pain if the patient was at high risk for PPP were: multimodal analgesia (3), early 
involvement of a multidisciplinary pain team and/or APS (4), patient education (3), use of a TCA 
(1), clonidine (1) and total intravenous anaesthesia (1).  
A number of potential initiatives were suggested to the anaesthetists and they were asked, which 
if any may assist with reducing the incidence of PPP. The most commonly selected options were: 
identification of and production of an assessment tool for predictors of PPP (62.3%) and post-
surgical neuropathic pain assessment (62.9%). Nearly half of respondents (49.1%) thought 
increased follow-up after discharge and pre-surgical screening of pain catastrophising, anxiety 
and depression (48.0%) would assist in reducing the incidence of PPP. Other free text suggestions 
made by the anaesthetists included: Around the clock APS access (1), aggressive and/or improved 
acute pain management (2), appropriate post-discharge analgesics (1), early referral to chronic 
pain specialists (1), education about post-operation expectations and management strategies (6), 
pre-operative pregabalin (1), increased used of perioperative ketamine (1), routine NSAID (1), 
staff education regarding PPP (1), increased familiarity with regional anaesthetic techniques by 
ward staff and anaesthetists (1), postoperative physical therapy in patients with persistent pain 
(1) and ice-bucket immersion test in pre-operative clinic for moderate-major procedures (1).  
Table 20 contains a list of the barriers to acute postoperative pain management and Table 21 
contains a list of the barriers to post-discharge pain management.  In acute pain management, 
analgesic adverse events and under-use were commonly cited as barriers to pain management. 
Free text responses from anaesthetists frequently cited staffing capacity (7.4%), knowledge of 
nurses (5.7%) and conflict between other specialties, or professions about pain management 
(7%) as other common barriers.  One anaesthetist commented that a barrier to pain management 
was a “Belief that pain is not important (I know many surgeons who feel it is beneficial as "keeps 
BP [blood pressure] up")”.  A lack of communication between the hospital and general practice, 
over and under use of analgesics and a lack of post-discharge resources were most commonly 
cited barriers to post-discharge pain.  
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Table 20 Barriers to optimal acute postoperative pain management (n=156) 
Factor n (%) 
Postoperative analgesic over use 14 (9.0) 
Postoperative analgesic under use 71 (45.5) 
Adverse drug reactions 90 (57.7) 
Education/knowledge 
     Nurse 
     Patient 
     Generally 
     Anaesthetists  
 
10 (6.4) 
8 (5.1) 
2 (1.3) 
1 (0.6) 
Patient factors 
     Expectations 
     Comorbidities 
     English comprehension 
 
4 (2.6) 
3 (1.9) 
1 (0.6) 
Management factors 
     Identification of pain/recognition it was a problem 
     Inappropriate prescribing/planning of discharge medications 
     Interference/conflicting goals between different specialities/professions 
     Staffing and resource capacity limiting treatment modalities and management 
     No dedicated APS 
     Delays in getting anaesthetic/pain management team to handle complicated 
patients 
     Early discharge preventing follow-up by pain team 
 
7 (4.5) 
6 (3.9) 
7 (4.5) 
13 (8.3) 
1 (0.6) 
2 (1.3) 
1 (0.6) 
Medication related 
     Opioid phobia/underprescribing due to fear of overdose/diversion/addiction 
     Overuse of opioids 
     Medication safety 
     Outdated/non-existent protocols 
     Reluctance to use regional blockades or epidurals due to concerns from surgeons,   
     patients, anaesthetist due to the risk of adverse events, evidence to support their 
use and time taken to use them. 
 
3 (1.9) 
1 (0.6) 
2 (1.3) 
1 (0.6) 
2 (1.3) 
Other 
     Barriers to pain assessment pre-operatively 
     Reluctance to use minimally invasive surgical techniques 
 
1 (0.6) 
1 (0.6) 
APS: Acute Pain Service 
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Table 21 Barriers to optimal post-discharge pain management (n=156) 
Factor n (%) 
Post-discharge analgesic overuse 28 (17.9) 
Post-discharge analgesic underuse 59 (35.5) 
Post-discharge undertaking activities beyond recommended 45 (27.1) 
Poor/slow communication between hospital and general practice. 107 (68.6) 
Patient factors 
     Patient education/knowledge/health literacy 
     Patient psychology and comorbidities 
     Patient expectations 
 
10 (6.4) 
3 (1.9) 
1 (0.6) 
During admission 
     Inadequate discharge planning 
     Availability of medical personal at discharge with pain management knowledge 
     Not taking the patient into consideration with discharge prescribing 
 
2 (1.3) 
2 (1.3) 
1 (0.6) 
Medication related 
     Opioidphobia 
     Safety 
     Mismanagement of pain by surgeon or GP 
 
8 (5.1) 
3 (1.9) 
1 (0.6) 
Post-discharge resources 
     Inadequate discharge analgesia 
     Inadequate discharge information/poor communication with patients 
     Lack of patient resources 
     Patients understanding of how to take medications/wean 
     Lack of allied health services post-discharge 
     Lack of ongoing advice/prescription 
     Lack of follow-up with pain specialist  
 
3 (1.9) 
3 (1.9) 
1 (0.6) 
5 (3.2) 
1 (0.6) 
1 (0.6) 
3 (1.9) 
GP: general practitioner 
9.5 Discussion 
This is the first study that we are aware of that has reviewed the opinions of anaesthetists about 
the barriers to acute and post-discharge pain and what factors influence perioperative pain 
management. The anaesthetists suggested the most likely factors associated with acute 
postoperative pain were anxiety (92.2%), somatic persistent pain (84.9%), pain catastrophising 
(83.1%), pre-operative pain severity (81.3%) and its duration (69.9%). The pre-operative factors 
that anaesthetists thought were associated with PPP were somatic persistent pain (87.3%), 
depression (80.1%), anxiety (79.5%), pain catastrophising (73.5%), and visceral persistent pain 
(72.3%).  Although these are consistent with previous studies (82, 202), based on these results it 
is clear that there is not a consensus among anaesthetists. Because perioperative pain 
management varied depending on perceived risk it is important to strengthen the evidence 
behind what factors put patients at increased risk of acute and persistent pain.  
To date, the primary ways that studies have attempted to reduce the incidence of PPP are by 
trialling different peri- and postoperative pain management strategies to reduce the incidence of 
severe acute pain and prevent central sensitisation (203, 342, 527-532), using nerve sparing or 
minimally invasive surgical techniques (533), the development of predictive models for PPP (534, 
535), although these are yet to be tested and require validation. Few other strategies have been 
trialled.  Psychological factors have been found to influence many aspects of pain including the 
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likelihood of experiencing acute and persistent post-surgical pain (82, 536). However there has 
been no study that could be found that evaluated the impact of augmenting psychological factors, 
through, for example, CBT on the incidence of PPP.  Nearly half (48.0%) of the participants in this 
study agreed that pre-surgical screening of pain catastrophising, anxiety and depression could 
potentially reduce the incidence of PPP.   One study has incorporated psychological assessment 
and counselling to those at risk of or experience PPP, although this study has not evaluated the 
effect of this intervention on the incidence of PPP (537).  This area requires substantial further 
research to identify if early identification and CBT influences the incidence and/or severity of 
PPP.   
Numerous barriers to acute pain management were noted. These included analgesic under-use 
and adverse events, knowledge and education of patients and nurses about analgesics and 
staffing resources, reducing the capacity for certain modalities to be used. A number of 
anaesthetists also made free text comments regarding late or minimal involvement of 
anaesthetics or pain management specialists in care, low levels of nursing knowledge about pain, 
conflict between different priorities and different specialties, as well as limited knowledge of 
discharge doctors on the management of pain. These factors indicate that there is an increased 
need for APS (where available) or a dedicated anaesthetic or pain management staff member to 
review all post-surgical patients rather than just patients where pain is difficult to manage. 
Potentially, the involvement of the APS or a pain management team for every patient following 
surgery may improve both in-hospital acute pain as well as post-discharge pain through 
increased patient knowledge, clear patient expectations and the opportunity for the provision of 
suitable and sufficient discharge analgesics.  It would also provide an opportunity for early 
identification of neuropathic pain symptoms associated with PPP, which anaesthetists commonly 
agreed (62.9%) would be beneficial in potentially reducing the incidence of PPP (538, 539).  
Barriers to post-discharge pain include poor or slow communication between hospital and 
general practice and the lack of post-discharge resources, including analgesics and information 
as well as follow up potential.  Few post-discharge resources coupled with low patient knowledge 
and health literacy indicates that this is an area that could be further targeted to improve post-
discharge pain management.  This could be undertaken through a number of methods including: 
increased patient written resources, a dedicated member of staff to see all patients at discharge 
to discuss their pain management, a dedicated pain-related contact number to call following 
discharge with queries and ensuring all patients, irrespective of their inpatient pain control are 
reviewed by a member of an APS or pain team.  To further support patients manage their post-
discharge pain, it is essential that hospitals make a clear decision about whose responsibility it is 
to provide pain management counselling on discharge. Putting a policy in place to ensure that all 
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patients are counselled about their post-discharge pain management by a suitably knowledgeable 
staff member, will likely improve post-discharge pain management and may reduce hospital costs 
through readmission due to pain as well as potentially reduce the transition from acute to 
persistent post-surgical pain.  
In conclusion, these results demonstrate the need for more definitive studies to truly ascertain 
the risk of different patient factors on the development of acute and persistent pain, so that 
management can be tailored to those most likely to experience them. Furthermore, the 
development and validation of a pre-assessment tool to aid in the identification of those at high 
risk of PPP should be undertaken and utilised in pre-assessment screening in an attempt to 
reduce the incidence of PPP.  The development of post-discharge resources to empower and 
sufficiently education patients to self-manage their pain is paramount for patient pain 
management, QOL and post-surgical rehabilitation.  Randomised controlled trials assessing the 
effectiveness of increased pre- and post-discharge follow-up by pain specialists or the APS as well 
strategies aimed at reducing anxiety, pain catastrophising and improving coping mechanisms 
pre-operatively are needed in the hope that these strategies may reduce the incidence of severity 
of PPP in the future.    
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Chapter 10: The barriers to optimal pain management in Tasmanian aged care facilities: 
a qualitative study 
10.1 Abstract 
Background: Up to 80% of residents in ACFs experience pain; unfortunately, their pain is often 
sub-optimally managed.  This study aimed to characterise pain management in ACFs, and identify 
the barriers to optimal pain management.  
Methods: Semi-structured interviews were conducted with 23 staff (enrolled and registered 
nurses, and facility managers) at five southern Tasmanian ACFs from September to November 
2015. Interviews included questions about how pain was measured or assessed, what happened 
if pain was identified, barriers to pain management and potential ways to overcome these 
barriers. 
Results: There were no formal requirements regarding pain assessment at the ACFs reviewed; 
however, pain was frequently informally assessed. Nursing staff noted the importance of 
adequate pain management for the residents’ quality of life and employed both non-
pharmacological and pharmacological techniques to reduce pain, when identified.  The barriers 
to optimal pain management included: difficulty identifying and assessing pain, residents’ 
resistance to reporting pain and/or taking medications and communication barriers between the 
nursing staff and GPs.  
Conclusion: Nursing staff interviewed were dedicated to managing residents’ pain effectively, 
however a number of areas could improve resident outcomes. These include a more consistent 
approach to documenting pain in residents’ progress notes and improving nurse-GP 
communications to ensure that new or escalating pain is identified and expedient changes can be 
made to the resident’s management.   Additionally, resident, family, nurse and carer education, 
conducted within the facilities on a regular basis, would assist in improving the pain management 
of residents. 
10.2 Introduction 
Up to 80% of residents of ACFs experience pain (444). Pain management in the elderly is 
complicated by minimal trial evidence supporting medication efficacy and safety (228, 540). ACF 
residents have a high number of comorbidities and co-prescribed therapies (108, 228), which 
increase the risk of adverse events and drug or disease interactions. Additionally, in this 
population dementia, dysphagia and hearing impairment are common comorbidities, which 
further complicate the ability for patients to adequately communicate their pain (219, 541, 542).   
103 
Assessment of pain in patients without cognitive impairment has often relied on self-reporting. 
However, older patients have been previously identified as being reluctant to take analgesics for 
numerous reasons including not wanting to be a nuisance or wanting to be a good patient, fear of 
addiction, fear that pain is a sign of something sinister and a patient belief that pain is a normal 
part of ageing (404, 437, 541, 543-545). These factors reduce the likelihood of patients reporting 
pain (546). For those patients with cognitive impairment, the assessment tools for identifying 
pain are poor, with limited evidence to support their reliability and effectiveness at identifying 
pain (547). Additionally, behavioural problems in dementia, caused by unrelieved pain, are 
sometimes being mismanaged with the use of antipsychotics rather than pain relief medication 
(540, 548). All of these factors make the management of pain in this population group challenging.   
Pain is often undermanaged in elderly patients in in ACFs (12, 13). A number of international 
studies have evaluated the knowledge and attitudes of those working with ACF residents 
regarding pain (549-551). Numerous factors have been identified as detrimentally affecting pain 
management in ACF including workloads, difficulty identifying pain, knowledge deficits, nursing 
and physician attitudes and misconceptions, patient barriers, patient stoicism, patient 
communication and GP-ACF communication (219, 541, 542, 549-553). However, minimal 
research has been undertaken in Australia identifying barriers to optimal pain management in 
Australian ACFs. This research aimed to characterise pain management in ACFs in southern 
Tasmania, and identify the barriers to optimal pain management. 
10.3 Methods 
All southern Tasmanian (Australia) ACFs, with both dementia specific and non-dementia specific 
beds, were contacted via mail regarding participation in the study, with follow-up phone calls to 
the facility managers. Of the 16 ACFs contacted, five agreed to participate within the research 
timeframe. These ACFs had a median of 99 beds (85-171), mainly consisting of high dependency 
(nursing homes) beds.  Participating ACFs were asked to provide the details of five or six staff 
members (enrolled or registered nurses) who would be willing to undertake 15-20 minute semi-
structured interviews to discuss pain management at the facility.  The facility manager at each 
ACF was also interviewed.  As carers (lifestyle workers) are unable to provide analgesics to 
residents, they were not interviewed for this study. Semi-structured interviews (Table 22) were 
conducted with 23 staff at the participating ACFs from September to November 2015. 
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Table 22 Semi-structured questions for interviews 
Number of years working in aged care facilities 
Working primarily with (ie. Dementia patients, non-dementia patients, both) 
How important is adequate pain management for residents to you? 
For residents receiving analgesics, how often each shift would you ask the resident what their 
pain was like or ask them to rate their pain? 
What do you do with this information? 
For residents prescribed as required analgesics, what are the most common reasons that would 
result in you providing them analgesics? 
For residents who are unable to communicate, how do you identify if they are in pain? 
What do you think is the major barrier(s) to pain management in residents of aged care facilities 
who do not have dementia? 
What do you think is the major barrier(s) to pain management in residents of aged care facilities 
who do have dementia? 
How do you think the barriers to pain management in ACFs could be overcome? 
Have you done any formal or informal training regarding pain management in aged cared facility 
residents? 
How would you describe the level of knowledge you have about pain management in elderly 
patients? 
Do you think it would be useful to have further training in pain management of elderly patients? 
 
Following data collection and subsequent verbatim transcribing, the data were segmented into 
themes through the process of coding. Deductive coding was initially undertaken using pre-
determined categories, based on previously published barriers and enablers to pain 
management, developed prior to the data collection. Following initial coding, the data was then 
categorised using inductive coding to ensure all themes and sub-themes were identified.  Both 
inductive and deductive coding was completed by one researcher.  
The interviews were analysed using QSR NVivo Version 10 (NVivo qualitative data analysis 
Software; QSR International Pty Ltd. Version 10, 2014).  The results were tallied to identify the 
most commonly cited themes and sub-themes. Each interviewee received a $20 AUD gift card to 
compensate them for their time.  Ethics was approved by the Tasmanian Social Science Human 
Research Ethics Committee. 
10.4 Results 
Twenty-three interviews were undertaken with enrolled nurses (EN) (n=7), registered nurses 
(RN) (n=11) and facility managers (n=5). The median number of years that individuals had been 
working in aged care was 20 (range 2-43). All participants suggested that pain and its 
management was paramount to residents’ quality of life. For example, one interviewee said:  
“If you’re in pain, you have poor quality of life. It ruins everything for you”. (Interviewee 
11)  
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Participants frequently noted that mismanagement of pain was time-intensive, with one 
commenting: 
“Well if you’ve got a resident that has their pain completely unmanaged and they’re crying 
out in pain – that’s going to take up an incredible amount of resources and staff time. So 
if we’ve got someone that is unmanaged – I’ve seen it happen before – it takes an 
incredible amount of time to bring that pain under control. So you’re using a lot of 
resources to try and then bring them back to a level where they’re comfortable.”  
(Interviewee 16) 
Staff also commented that good pain management reduced behavioural issues, made the work 
environment more pleasant and improved staff motivation and job satisfaction:  
“I actually feel as though I’m doing my job properly if I know that somebody hasn’t got 
pain”. (Interviewee 2)   
Most ENs and RNs believed that they had adequate or good knowledge about pain and its 
management; however, most suggested more training would be useful.  Four out of five facility 
managers also agreed that more pain management training would be beneficial to staff. Topics 
that participants wanted more training on included: identification and assessment of pain, 
medication management, non-pharmacological management, and information on pain-causing 
conditions.  Two participants specifically mentioned the University of Tasmania’s Massive Open 
Online Course (MOOC) on dementia care (554) as a good educational tool.      
There were no specific guidelines or policies regarding the frequency of asking about pain or 
recording pain intensity at any of the ACFs; despite this, pain was still informally assessed 
frequently by staff during shifts. Generally, ACF staff assessed pain primarily using the Abbey pain 
scale or the to a lesser extent the face scale chart for those with cognitive decline or dementia. 
Pain was more commonly assessed through question asking and observation for those without 
cognitive impairment. Some participants also mentioned by that it was important to rephrase 
questions and use different language when asking about the resident’s experience of pain. One 
participant said:  
“That’s the other thing too - not to use the word pain because a lot of people don’t 
understand or perceive the word pain is the right word for them.  So if I say to someone 
‘have you got pain’ when I know that non-verbally they look uncomfortable, and then I’ll 
scale it down to something else like ‘are you uncomfortable?’ You’ve got to find the right 
word that suits them”.   (Interviewee 6) 
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The importance of knowing the residents well so that any change in behaviour could be more 
readily identified and managed was frequently noted.  For example, one interviewee noted:  
“I think that the one barrier could be if you don’t know them that well. A lot relies upon 
what you see, because they can’t tell you. So new staff can be a bit of a barrier.” 
(Interviewee 3) 
In addition, it was frequently noted that carers often identify and report pain to the RNs, 
one interviewee said: 
And of course the carers get involved in that a lot too, because they’re with the 
resident. So I expect them to be able to recognise pain and they’re often the ones that 
will come to the nurses first or come and say ‘look – I think they’ve got pain’, or ‘this is 
happening with them and this is different to what they normally are’. And so nurses 
have to learn to respect the carers and trust their judgments sometimes too.” 
(Interviewee 22) 
A numerical rating scale was also frequently used; however, 12 participants commented on the 
lack of effectiveness of pain scales.  One respondent said:  
“… I know that’s the tool to be used, and it’s the tool that we use during those periods 
of assessment, but in a general day to day I think it’s more a case of using familiar type 
language to get that response”.  (Interviewee 23) 
If pain was identified by nursing staff, generally they would administer ‘as required’ analgesics 
(if charted) and monitor for effect, liaise with the GP to change analgesic prescriptions, utilise 
non-pharmacological management strategies and record the presence of pain in the 
computerised record system. In relation to what they do if someone is in pain, one interviewee 
said: 
“Yeah, so massage, heat packs, repositioning, resting – it depends upon where they are, 
what they’re doing at the time of that pain and what their needs are at that time. And 
we’ll work that out and provide a lot of other remedies rather than just the analgesic 
because that’s not just the sole purpose of it”.  (Interviewee 17) 
Table 22 summarises the main barriers to optimal pain management in ACFs.  In residents with 
dementia, these barriers were identification of pain, residents’ resistance to taking medications 
and dementia-related behaviour disguising the diagnosis of pain. The major barriers identified in 
the management of pain in residents without dementia were the influence of families over the 
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management of pain, resident stoicism and residents’ reluctance to report pain.  One interviewee 
said:  
“Some people deal with their pain a bit differently. But you can usually tell, but you do 
have to prompt some residents to say – yes my shoulder is hurting. They can sit there 
and not want to complain”. (Interviewee 8) 
Other barriers included fear of giving too much pain relief, for example: 
 “I think that sometimes there’s still a little bit of mythology about opioids and ‘oh you 
know I didn’t want them to die on my shift so I didn’t give them the morphine’”. 
(Interviewee 18) 
A lack of staffing resources was also noted, with one interviewee commenting:  
“For an RN, they love doing pain management they would love to do it their entire shift 
no problem, but there are a whole lot of other things that are taking priority – somebody 
falls on the floor, all the emergencies that they’re dealing with means it’s always going 
to be put back. It’s always at the end of the list”. (Interviewee 10) 
There was also concern regarding nurse-GP communication.  For example, one interviewee said: 
“To be honest, we don’t always have GPs that understand or are willing to look at pain 
management and utilise perhaps the available resources that we have for that”. 
(Interviewee 23) 
Another commented: 
 “And they (young nurses) do really good clinical handover and if the GPs actually 
stepped back and looked at what was being communicated to them by these grad nurses 
its actually high quality stuff”. (Interviewee 11) 
Additionally, one interviewee also noted that sometimes it was necessary to request second 
opinions regarding pain management; they said:  
“There were a couple of conversations last week around a particular GP … that was 
very stingy in terms of pain relief that he was providing for a resident that was end 
stage care. And in the end we had to go above his head and ask palliative care to come 
in and become involved and get what we wanted. We don’t like to do that, but we’re 
here for the resident. Residents’ care, comfort and safety is paramount for us, and we 
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don’t believe in egos or any of that crap, so if we need to step on people’s toes to make 
the resident comfortable then we will. And we did”. (Interviewee 16) 
Table 24 summarises the suggested methods to overcome barriers to optimal pain management 
in ACFs, including improved nurse-GP communication:  
“Maybe if the organisation as a whole developing better relationships with our 
doctors”. (Interviewee 2) 
Another suggestion to improve pain management was improved assessment and documentation: 
“One of the needs that I think we could improve upon is the assessment side of it. Not 
just the visual assessment, the monitoring the reporting and the documenting of the 
residents’ pain in a professional way”. (Interviewee 23)   
Further staff education was also cited by some, as well as resident education: 
“They [residents] will listen once you explain and give them medication and say ‘you 
are not going to get addicted to having 8 Panamax [paracetamol 500mg] a day’. The 
majority will listen and say ‘oh I didn’t realise that”. (Interviewee 14) 
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Table 23 Barriers to the management of pain in aged care facilities (n=23) 
 
Theme n (%) 
Resident related barriers – non-dementia 
Resident related barriers to optimal pain management 
     Stoicism 
     Honesty of reporting pain 
     Families’ influence over medication 
     Resistance to taking medications 
     Not wanting to be a bother 
     Communication barriers (deafness) 
     Stigma regarding pain 
     Lack of trust in staff 
Medication related barriers to optimal pain management 
     Fear of side effects 
     Dislike of taking tablets 
     Fear of addiction 
     Concern about medication cost 
18 (78.3) 
13 (56.5) 
11 (47.8) 
11 (47.8) 
10 (43.5) 
4 (17.4) 
1 (4.4) 
1 (4.4) 
1 (4.4) 
 
5 (21.7) 
3 (13.0) 
2 (8.7) 
1 (4.4) 
Resident related barriers – dementia patients 
Dementia resident related barriers to optimal pain management  
     Identification of pain  
     Resistance to taking medication 
     Dementia related behaviour can disguise pain 
     Patients are unable to accurately report pain 
     Effect of families on the management 
     Difficulties assessing effectiveness of pain management strategies 
     Difficulty in administering medications 
22 (95.7) 
19 (82.6) 
9 (39.1) 
8 (34.8) 
6 (26.1) 
3 (13.0) 
2 (8.7) 
2 (8.7) 
Doctor related barriers 
Doctor related barriers to optimal pain management 
     Reluctance to medicate 
     Disregard nursing staff opinion 
     Lack of doctor engagement 
     Lack of knowledge 
     Unwilling to try new medication 
     Slow to respond 
12 (52.2) 
5 (21.7) 
5 (21.7) 
3 (13.0)  
1 (4.4) 
1 (4.4) 
1 (4.4) 
Facility related barriers 
Facility related barriers – non dementia 
     Efficacy/usefulness of pain scales 
     Staff reluctance to use strong pain relief 
     Resourcing and prioritisation of time 
     Lack of understanding of pain and triggering conditions 
Facility related barriers – dementia patients 
     New staff not being able to identify pain in patients 
     Time involved in the identification and management of pain in those who cannot 
articulate pain 
Facility related barriers – generally 
     Nurse fear of providing too much analgesia 
     Staff uncomfortable contacting prescribers to change medication orders 
     Challenges identify pain in residents 
     Red tape around the provision of pharmacological and non-pharmacological 
     management strategies 
     Poor/unstructured communication with doctors 
     Lack of continuity of care with part-time staff 
     Delegation of pain management to specialists staff 
     Lack of integration of pain assessment outcomes into general knowledge 
     Pre-conceived ideas around residents assessment of pain 
12 (52.2) 
8 (34.8) 
2 (8.7) 
2 (8.7) 
1 (4.4) 
 
4 (17.4) 
4 (17.4) 
 
 
4 (17.4) 
4 (17.4) 
4 (17.4) 
2 (8.7) 
 
2 (8.7) 
1 (4.4) 
1 (4.4) 
1 (4.4) 
1 (4.4) 
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Table 24 Ways that barriers to optimal pain could be overcome in aged care facilities (n=23) 
 
Theme N (%) 
Staffing factors 
Pain management training for staff 
Being observant – watching for non-verbal signs of pain 
Greater staffing resources 
Empowering staff to advocate on the patient’s behalf 
Person centred care 
Rostering of staff to ensure continuity of care 
Involving new staff members in pain assessment for alternative 
opinions/perspectives 
 
5 (21.7) 
4 (17.4) 
3 (13.0) 
1 (4.4) 
1 (4.4) 
2 (8.7) 
1 (4.3) 
Doctors-ACF interactions 
Guiding doctors’ to make decisions regarding pain management  
When GPs are reluctant to change pain therapy the ACF obtain a second onion e.g. 
from palliative care services 
When communicating with doctors ensuring nursing staff have sufficient and 
ordered information to present to the GP 
Use senior staff to communicate with doctors 
Improving relationships between staff and doctors 
 
3 (13.0) 
3 (13.0) 
 
2 (8.7) 
 
2 (8.7) 
1 (4.3) 
Patient and family factors 
Utilising collaborative treatment approaches with family consultations 
Improved communication with families about pain management 
Refer patient/family to GP if ACF cannot convince GP to change analgesic order 
Education of residents 
Education of families 
Using different language when describing/questioning residents about pain 
Providing reassurance and encouragement to overcome resistance to treatment 
Supporting families to changes GPs if the family is concerned about their loved 
one’s management 
 
6 (26.1) 
5 (21.7) 
4 (17.4) 
4 (17.4) 
3 (13.0) 
3 (13.0) 
2 (8.7) 
1 (4.3) 
Patients’ reluctance to use analgesia 
Hiding analgesia in food 
Gaining the residents trust 
Referring patients/families to GP if patient is non-compliant 
Using alternative dosage forms 
Trial and error to find a successful management strategy 
Persisting when patients refuse analgesia 
Offering non-pharmacological treatment strategies when analgesic are resisted 
 
5 (21.7) 
4 (17.4) 
4 (17.4) 
4 (17.4) 
4 (17.4) 
3 (13.0) 
2 (8.7) 
GP: general practitioner; ACF: aged care facility 
10.5 Discussion 
This is the first qualitative study we are aware of identifying barriers to optimal pain management 
in Australian ACFs. The staff interviewed were all very cognisant that pain and its management 
was important to residents. Pain was frequently assessed through both formal and informal 
methods, although none of the ACFs required pain to be assessed a certain number of times per 
shift. When pain was identified by staff, the management strategies employed were dependent 
on the resident and their circumstances.  A number of barriers to optimal pain management were 
identified; these included resident factors such as a reluctance to report pain or take analgesics, 
factors related to the identification and assessment of pain, particularly in those with dementia, 
and communication barriers with GPs.   
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It was concerning that only 70% of participants said that the presence of pain was recorded in 
the facility’s computer system, which is what staff generally refer to when reviewing patient 
progress and health. A previous study evaluating pain management in ACFs found documentation 
of pain assessments in a one-month period was 85%; however, it was only 32% during a week 
and this documentation often lacked details regarding location, severity, characteristics or QOL 
(555). This is an area that could be improved upon, and would also allow for improved 
documentation to be provided to the GPs when making decisions regarding a resident’s pain 
management. 
Most participants (over 60%) indicated that they would contact prescribers to change analgesic 
orders if escalation of pain management was required.  However, communication with doctors 
was noted as a barrier to pain management, in terms of both the confidence of the nurses to speak 
to the doctors as well as the doctors’ reluctance to change therapies, or having sufficient 
documentation to justify a change to medication orders to the doctor. Nurse-prescriber 
communication has previously been identified as a barrier to patient safety and outcomes (553). 
Potentially, some of these barriers could be overcome by putting in place more definitive 
procedures and increased documentation in the resident care software.  Additionally, changing 
the way in which interactions with GPs occur may reduce some of the barriers.  One approach 
could be for all interactions to occur with the senior nursing staff only to improve communication, 
reduce fear of communicating with GPs, improve the lines of communication between the ACF 
and the GP, and improve the speed with which analgesic orders and changes are made.  While 
every effort should be made to optimise communication with the GP, other avenues to improving 
pain relief for residents, particularly those in a palliative situation should also be considered, 
including timely referral to a palliative care service if needed.   
Increased knowledge and education around pain management in ACFs can improve the 
knowledge and beliefs of nurses (550, 551, 556, 557). Often these programs involved education 
sessions over multiple weeks or months with nursing staff only (551, 556, 557) or integrated with 
both nursing staff and residents (558), with a comparison of nursing knowledge and beliefs 
before and after. However, it is unclear whether the improved knowledge and attitudes persisted 
and whether increased knowledge did in fact result in behaviour change in the medium-long 
term. Thus, the best way for these types of education interventions to be implemented and the 
true effect of them in the short and longer term on the management of pain in ACF needs to be 
further assessed.   
Participants in this study felt unable to consistently and accurately identify pain in residents with 
dementia and exhibited concerns regarding providing too much analgesia.  Education, which was 
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wanted by the vast majority of ENs and RNs, could provide some assistance in the identification 
and improved management of pain. However, as noted previously, the tools available for 
assessment of pain in residents with dementia have poor evidence to support their use (547). The 
advent of a new phone application, Electronic Pain Assessment Tool (559), designed to assist with 
the identification of pain in people with dementia has the potential to provide significant benefits 
to the speed of identification and management of pain in these residents. As staffing resources 
and time were noted as barriers to pain management, this could reduce some time pressures 
through faster identification of pain. Watching for signs of resident discomfort or changes in 
behaviour should also be encouraged by all staff, which could be facilitated by further staff 
education.   
If educational activities were to be undertaken, a previous Australian study (560) found that 
these would need to be easily accessible, affordable and would require the employer’s support.  
Consequently, online resources, or in-facility education sessions would appear to be the most 
suitable options. Education should also be undertaken with carers, as they spend substantial 
amounts of time with the residents undertaking a number of activities of daily living.  Improving 
carers’ knowledge of signs of pain might improve reporting and management of pain.   
Based on the responses from staff, residents provide a significant barrier to their own pain 
management which is consistent with previous literature(404, 437, 541, 543-545).  It is 
important that some of these barriers are overcome. One approach could be joint or individual 
resident and family education sessions around pain and its management, which a number of staff 
did comment was an effective way to overcome barriers around pain management.  The inclusion 
of family members is also important as some studies, although not necessarily undertaken in 
ACFs, have indicated that the expectations of family members can influence the assessment of 
pain (219) and having a supportive family has been found to reduce analgesic consumption and 
pain intensity, and improve physical function (561). Additionally, education programs 
incorporating family caregivers of cancer patients living in the community found that they 
improved patient and carer knowledge and attitudes, as well as patient QOL (558). However, 
there is a dearth of literature surrounding the education of family members and the effect that 
this has on pain management of residents in ACFs. Further studies are needed in this area. 
In conclusion, a number of barriers to optimal pain management were identified, including 
resident, prescriber and facility related factors.  A significant number of the barriers could be at 
least partially overcome through increased education of residents, families, RNs, ENs and carers. 
Routine documentation of suspected or actual pain in the resident’s medical notes is likely to 
improve continuity of care and monitoring of new or escalating pain, particularly noting the part-
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time workforce in ACFs was cited as a barrier to pain management. Barriers associated with the 
management of pain between GPs and ACFs are more difficult to overcome. However, increased 
documentation of pain in medical notes and the use of only senior staff to contact prescribers 
about the requirements to change or escalate analgesics may provide better communication 
between GPs and the ACFs and allow for more expedient changes to pain management.  
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Chapter 11: Concluding discussion 
11.1 Thesis background and research objectives 
Nearly all people experience acute pain in their lifetime and while persistent pain, defined as pain 
lasting greater than three months, is less common, it is nonetheless experienced by 20% of the 
general population, 50% of elderly patients living in the community and 80% of those in ACFs (5-
17).  Prevalence rates appear consistent from studies undertaken in different continents, 
indicating that persistent pain is a significant global problem.  It is also very costly (53, 56), with 
patients who suffer from persistent pain conditions more likely to present to a GP (58) and have 
increased absenteeism from work (161). 
The evidence base for acute management generally supports the use of analgesics (48), although 
are variable; however,  there is poor evidence to support the use of analgesics in persistent pain 
management (89, 231). Elderly and frail patients are disproportionally affected by persistent 
pain, but unfortunately, they are often underrepresented in, or excluded from clinical trials (228, 
231). This further complicates decision making, as the lack of information is a barrier to reliable 
assessment of the balance between adverse effects and effectiveness. Elderly patients experience 
altered pharmacokinetics and pharmacodynamics, take multiple medications and often have 
multiple comorbidities, all of which expose them to an increased risk of adverse events and 
altered responses to the medications (101, 227, 228).   Older patients are also less likely to report 
pain and take analgesics (404, 437, 541, 543-545) and those with neurodegenerative diseases 
such as dementia or following a stroke may be unable to adequately communicate their pain, and 
therefore assessment by nursing stuff is required to identify pain.  Consequently, there have been 
many studies demonstrating that pain is undermanaged in the elderly (449, 452, 456, 457). 
Pain and its management has been highlighted as an area of health requiring more research.  One 
of the goals of the National Pain Strategy [Australia] (35, 36) is to increase the amount of research 
being conducted in areas such as assessing attitudes towards pain and its management, and 
reviewing the safety and efficacy of pain management in Australia.  Further to this, The Opioid 
Policy developed by The Royal Australasian College of Physicians (38) suggested further areas 
for research should include: identification of risk factors for the development of persistent pain 
conditions; improving the management of persistent pain; and reducing the harms around 
persistent pain management, specifically opioids. 
Because there are so many different aetiologies that cause pain, this thesis reviewed pain 
management in the elderly, more broadly, as well as focusing on one specific type of pain, post-
surgical pain (from acute to PPP). Reviewing the transition from acute postoperative pain to PPP 
was also recommended at the 14th World Pain Congress (386) and in the National Opioid Policy 
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(92) to aid in identifying predictors of PPP.  There are 2.4 million operations conducted each year 
in Australia, and at least 80% of those patients will experience acute pain. Around 20% of all 
patients will transition from acute postoperative pain to PPP; however, the range varies between 
5% and 85% depending on the surgical procedure (82, 202). PPP contributes significantly to the 
overall population who have persistent pain; for example, surgery was identified as a potential 
cause of pain in 20% of patients attending British pain clinics (417). Due to an increasing number 
of health problems in older people, they frequently require operations. The most common age 
group requiring surgery are those aged 55-64 (562). As this population continues to age, it is 
important that the factors associated with PPP in older Australians are assessed and ways to 
improve outcomes determined. 
In conclusion, this thesis aimed to add to the literature regarding pain management in Australia 
and identify predictors of persistent pain through a number of complementary studies. The 
specific research objectives were to: 
 Observe how pain is managed pharmacologically by patients, nurses, surgeons, GPs and 
anaesthetists; 
 Identify what factors are associated with the development of PPP; 
 Identify QUM issues related to the management of pain; and 
 Identify the barriers and enablers to pain management. 
11.2 Research objective outcomes 
 
11.2.1 Objective 1: Observe how pain is pharmacologically managed by patients, GPs, nurses, 
surgeons and anaesthetists 
A number of Chapters (Three to Six) reviewed how patients took their analgesics to manage their 
pain. The management of pain by patients was often (although not universally) characterised by 
underutilisation, with a reluctance to take analgesics, a stoicism to try and endure with the pain 
and a fear of over using analgesics, being cited as common justifications for underuse. However, 
some patients were also noted to overuse their analgesics, including 6% of patients in Chapter 
Three using more than the recommended dose of paracetamol, putting them at risk of liver 
failure.  These findings add to the existing literature about how patients, particularly elderly 
patients, take their medications. Previous studies have demonstrated similar results, particularly 
in relation to patient factors (404, 437, 541, 543-545); however, the studies included as part of 
this thesis add to the body of country-specific literature about how older Australian patients 
manage their pain with analgesics. These results also demonstrate that despite previous studies 
indicating patient reluctance to report and manage pain, substantial headway has not been made 
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into improving patient expectation, knowledge and capacity to self-manage pain, particularly in 
older Australians. 
Chapters Six, Seven, Eight and Ten reviewed aspects of how GPs manage pain. The prescribing of 
analgesic by GPs was, at times, not in accordance with guidelines, particularly in relation to the 
use of opioids and the use of optimised paracetamol. A number of harm minimisation strategies 
were also infrequently used. These included less than one quarter of GPs regularly reviewing the 
5As (analgesia, activity, adverse events, aberrant behaviour and affect) in patients with 
persistent pain despite analgesics, particularly opioids, often causing substantial adverse effects 
and having variable effectiveness.  
Inappropriate and unsafe medication combinations were frequently prescribed to those patients 
reviewed in Chapters Six and Seven.  Noting the risks of these combinations in this elderly 
population these results are concerning.  The concurrent prescribing of benzodiazepines and 
opioids has been frequently noted in the developed world (563).  This practice continues despite 
safety concerns and guidance recommending benzodiazepines should not be used for more than 
two to four weeks (220).  Similarly, the use of opioids at doses exceeding the recommended 
maximum was also relatively common. However, to some extent, several factors conspire to 
force GPs into using opioids and increasing their doses in an attempt to help their patient.  These 
factors include poor access to pain clinics and limited funding of allied health services, both of 
which have potential to improve physical function. However, there was still low concordance 
with guidelines in relation to non-opioid analgesics and inappropriate co-prescribing, increasing 
the risk of adverse events including confusion, falls and fractures in the elderly, as well as limited 
use of harm minimisation strategies, which are largely under the direct control of GPs. There is 
a need for an increased emphasis on pain and its management during undergraduate and GP 
specialist training as well as ongoing CPD. Such education should aim to try and improve 
concordance with guidelines and reduce the incidence of inappropriate prescribing, particularly 
in relation to opioids.    
The way in which perioperative and postoperative pain was managed by anaesthetists was 
reviewed in Chapters Four, Five and Nine. There was significant variation in the way 
anaesthetist’s managed pain, particularly for those patients undergoing orthopaedic surgery, as 
described in Chapter Five.  Based on anaesthetists’ responses in Chapter Nine, the management 
appears to be strongly reliant on clinical judgment, patient factors and operation factors, rather 
than guidelines and protocols.  It was noted that the management strategies employed by the 
anaesthetists varied depending on the perceived risk of acute and persistent postoperative pain. 
There was also a lack of consistency regarding which factors were perceived to increase the risk 
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of PPP, which is likely reflective of variability in studies published to date (82, 202).  However the 
management strategies employed by the anaesthetists for those patients perceived to be at risk 
of PPP were different to those who were at increased risk for acute postoperative pain. Because 
perceived risk and clinical judgment affected the perioperative management of pain, the need for 
accurate and complete information in relation to the predictors of PPP is needed. Further large-
scale studies, using similar research protocols and definitions, should be undertaken in this area 
to help anaesthetists target at risk patients more accurately.     
The way in which surgeons managed pain was reviewed through the discharge medications 
prescribed to patients in Chapters Three, and to a lesser extent Chapters Four and Five.  There 
was substantial variation in the way in which discharge prescribing of analgesics was managed, 
with only just over 50% of surgical patients receiving discharge analgesia in Chapter Three, 
despite 95.3% of participants requiring analgesics in the week following discharge.  Chapter 
Three in particular demonstrated that there is a need to improve the consistency of discharge 
prescribing to ensure that all patients have sufficient, but not excessive access to analgesics 
following discharge to adequately manage their pain. This is an area that requires further 
investigation to identify what, if any, protocols exist to dictate whether patients receive discharge 
analgesics and what type they receive in order to optimise the management of post-discharge 
pain.   
In Australia, there has been very little research into the management of pain in ACFs and we 
sought to fill this gap in the literature. Our study (Chapter Ten) generally found that ACF staff 
reviewed pain informally through observation (69.6%) and for patients with cognitive 
impairment the Abbey Scale (47.8%) or a face scale (13%) were used most frequently.  If patients 
were identified as having pain, nursing staff would provide an “as required” analgesic (if charted) 
(56.5%), liaise with a GP to change the analgesic order (60.9%), utilise non-pharmacological 
management strategies (56.5%), and record the presence of pain in the patient’s medical notes 
on their computer system (69.6%).  Overall, a number of barriers to pain management in ACFs 
were identified, including patient stoicism and reluctance to take analgesics, challenges with 
identifying pain in patients with cognitive impairment, and conflicting opinions between the ACF 
staff and GPs relating to how pain should be managed in some patients. The results of this study 
were consistent with previous barriers to optimal pain management reported in international 
studies (219, 541, 542, 549-552, 564-568), particularly in relation to patient stoicism and 
reluctance to take analgesics. This study significantly contributes to the current body of literature, 
as no other published studies could be identified that reviewed nursing-related barriers to pain 
management in Australian ACFs.  
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11.2.2 Objective 2: Identify what factors are associated with the development of PPP 
Surgery in older patients is becoming increasingly commonplace, including those very elderly 
patients (over the age of 80).  It is important that the factors associated with the development of 
PPP in this older population is specifically assessed as numerous factors including differences in 
pain experience and perception, patient factors including stoicism and the way in which 
pharmacological agents work in this population are different to that of a younger adult cohort.  
Numerous factors have been previously identified as increasing the risk of PPP; these include 
psychological factors such as anxiety, pain catastrophising, pre-existing persistent pain 
conditions, and uncontrolled acute pain (82, 202, 203) however with the changing demographics 
of who is undergoing operations these factors need to be continually assessed to ensure that they 
are consistent across age groups.  Chapters Four and Five incorporated all major previously 
identified patient factors and intraoperative factors (where consistently available).  The studies 
conducted as part of this research also focused on the post-discharge period, up to three months 
postoperatively.  This is a period that has not previously been the subject of much research; 
however, the few studies in this area have indicated that uncontrolled pain following hospital 
discharge is associated with pain persisting (206-208).   
The factors that increased the risk of pain at 12 months following a sternotomy included younger 
age, pre-operative anxiety, pre-existing musculoskeletal pain, number of pre-existing pain sites, 
self-rated poor health, a DN4 ≥3 at three months and 12 months.  The factors that increased the 
risk of pain at 12 months following orthopaedic surgery included increased number of pre-
existing pain sites, pre-existing alcohol use, moderate-severe pain at 10 days and six weeks and 
a DN4 ≥3 at three months and 12 months.  The findings from these studies support the existing 
literature, with previous pain conditions and anxiety being identified as factors increasing the 
risk of PPP.  This study, however, adds substantial weight to the association between uncontrolled 
post-discharge pain and PPP, as well as neuropathic pain (DN4 ≥3) during the subacute period, 
following discharge and PPP.  Although younger age was associated with PPP, two risk factors, 
pre-existing pain and a reluctance to take analgesics (resulting in potentially uncontrolled post-
discharge pain), are associated with PPP and common in older people.  Consequently, it is 
important older patients are encouraged to manage their pain carefully and use analgesics as 
required following discharge to prevent uncontrolled pain.  The results from Chapters Three, 
Four and Five also clearly show that undermanagement of pain following hospital discharge is an 
issue. This is noteworthy, considering that uncontrolled post-discharge pain and neuropathic 
pain symptoms were associated with pain at 12 months. An increased emphasis on the 
importance of post-discharge pain management and increased pain specific follow-up is required 
to improve the management and potentially reduce the incidence and/or severity of PPP.   
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11.2.3 Objective 3: Identify QUM issues related to the management of pain 
QUM issues related to the management of pain were identified in a number of chapters.  The first 
key issue was the lack of concordance between practice and the available guidelines and 
recommendations regarding pain management, particularly in relation to the use of opioids.  The 
use of dangerous combinations of sedating agents, particularly benzodiazepines and opioids was 
common place and has significant potential to harm patients and potentially result in their death 
through respiratory depression or obliquely through increased fracture risk. The second key 
issue was the patient’s ability to safely and adequately self-manage their pain following surgery.  
Self-management of pain by patients was generally (although not always) characterised by the 
underutilisation of analgesics (resulting in under management of pain), often due to 
misconceptions about analgesics, how they work and their associated risk profile. There is a need 
to improve patient knowledge and capacity to self-manage pain adequately in order to improve 
patient outcomes. The third issue was the variability in counselling provided during the inpatient 
stay or at the point of discharge, regarding post-surgical pain management. This was found to 
vary in terms of which health care professionals were involved and the content of information 
provided.  Additionally, the actual supply of take-home analgesics following surgical procedures 
was often inadequate, with only 70% of patients receiving analgesics on discharge, despite 95.4% 
of patients reporting use of analgesics in their first week following surgery.   
 
11.2.4 Objective 4: Identify the barriers and enablers to pain management 
Barriers and enablers to pain management were mostly discussed in Chapters Eight, Nine and 
Ten, although some barriers, particularly patient-related barriers, were also identified in Chapter 
Three, Four and Five. In Chapter 8 GPs identified a number of barriers to optimal pain 
management including Healthcare system factors such as long waiting times for and access to 
pain clinics, limited government funding of allied health professions (psychologists and 
physiotherapists) and surgical waiting times.  Other barriers to pain management included 
patient factors such as unrealistic expectations, and a reluctance to use non-pharmacological or 
self-management strategies.  The risks and current lack of good quality evidence were also noted 
as barriers to optimal pain management.   Particularly noting that the evidence regarding 
analgesic use in the elderly and/or frail is even more uncertain than general adult guidelines, 
coupled with a patients’ reluctance to use non-pharmacological management strategies, it creates 
a very difficult position for the GP to be in and to manage. 
In Chapter 9, anaesthetists identified a number of barriers to optimal acute pain management 
including under and overusing medications, staffing resources, conflicting priorities and minimal 
involvement of pain specialists.  They also noted that communication was often poor or slow 
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communication between hospital and general practice and this coupled with a lack of post-
discharge resources were reasons they believed worsened post-discharge pain outcomes.  A 
number of barriers to the pharmacological management of pain and assessment of pain were 
identified in ACF in chapter 10. These included resident factors such as reluctance to report pain 
or take analgesics and stoicism; the ability for nursing staff to adequately assess pain in those 
unable to communicate; insufficient documentation of pain in nursing notes, and challenges in 
the communication between the ACF and staff.  Based on these findings, and noted below in Table 
25 and Table 26, which summarise the barriers and enablers to the pharmacological pain 
management, there are a number of overlapping factors found in the different studies, 
particularly in relation to education, challenges with the wider health system and patient-related 
barriers. 
Table 25 Barriers to the optimal management of pain 
Patient factors 
 
- Poor patient reporting of pain;  
- Difficulty in identifying pain in patients with cognitive 
impairment; 
- Patient stoicism and reluctance to take analgesics; 
- Patient knowledge, health literacy and expectations; 
- The influence of family on pain and its management; 
- The usefulness and validity of pain scales. 
Communication 
factors 
- Poor and slow communication between hospitals and GPs 
regarding post-discharge care; 
- Variable discharge counselling to patients on discharge 
following a surgical procedure; 
- Poor communication and management agreement between 
ACF and GPs; 
- Lack of post discharge resources and follow-up for surgical 
patients. 
Wider health  
system factors 
 
- Poor access and long waiting times for pain clinic services;  
- Poor access to Government funded allied health services for 
persistent pain management in the community; 
- Poor staffing on surgical wards, reducing acute pain 
management capacity and treatment modalities; 
- Underutilisation of anaesthetists, pain specialists or APS in the 
post-surgical period; 
- Conflicting priorities and goals following surgery influencing 
the management of pain. 
Education - Limited training as part of the undergraduate medical degree 
in pain and its management despite its prevalence within 
society. 
ACF: aged care facilities; GP: general practitioners 
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Table 26 Potential ways to overcome these barriers 
Education - Increased education of patients regarding expectations, 
management, analgesics, their side effects and how to take them;  
- Increased education of GPs regarding pain management;  
- Increased education of allied health professions to allow for 
increased specialisation in the management of persistent pain 
conditions; 
- Increased education of hospital nursing staff regarding 
identification and management of pain; 
- Increased education of ACF nursing staff regarding identification 
and management of pain;  
- A systematic approach across all Australian universities to increase 
pain management training as part of all undergraduate medical, 
nursing and allied health care practitioner courses. 
Post-discharge 
management 
- Improved content and consistency of counselling and resources for 
patients regarding post-discharge pain management; 
- Improved discharge planning and provision of discharge 
medication;  
- Increased involvement of anaesthetists, pain specialists or APS in all 
post-surgical patients’ care; 
- Early identification of neuropathic pain following surgery; 
- Improved speed of post-discharge communication with GPs about 
patients. 
Wider health  
system factors 
- Increased funding and access to pain clinics; 
- Increased MBS funding of psychology and physiotherapy for 
persistent pain conditions; 
- Increased time available for GP appointments, particularly in regard 
to pain; 
- Increased hospital staffing to allow for increased access to 
analgesics, and treatment modalities and monitoring of pain. 
Further research 
and evaluation 
of initiatives 
- Increased APS and/or pain specialists services following surgery 
and discharge for all post-surgical patients (including neuropathic 
pain assessment); 
- The development of improved patient resources and discharge 
counselling for post-surgical patients; 
- The identification of the predictors of PPP and development of an 
associated assessment tool;  
- The development of pre-operative interventions to overcome 
psychological factors associated with PPP;  
- Improved documentation of pain and protocols regarding pain 
management and the reporting of pain in ACFs;  
- Reviews of the management of pain, documenting frequency of pain 
reports and management strategies incorporating both non-
pharmacological and pharmacological management; and 
- Increased pain management role for pharmacists within or 
associated with GP clinics.  
ACF: aged care facilities; GP: general practitioner; MBS: Medical Benefits Scheme; APS: Acute Pain 
Service; PPP: persistent post-operative pain 
Identification of these barriers and the resulting proposals regarding approaches to overcome 
them add greatly to the current literature, particularly in the Australian context.  However, a 
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number of these have been previously identified, including patient stoicism and reluctance to 
take analgesics (404, 437, 541, 543-545) in older people in particular, poor access to pain clinics 
(472), and the need for increased training of health professionals regarding pain at 
undergraduate and postgraduate level (492, 493).  Where this research significantly adds to the 
literature is in relation to the quality of post-discharge counselling and prescribing, and the 
resultant under management of post-discharge pain. Poor post-discharge pain management was 
identified by GPs, patients and anaesthetists as a problem and patient self-management was often 
suboptimal in the studies carried out.  Although high levels of post-discharge pain have been 
identified previously (204, 393-397), the findings of this thesis, associating uncontrolled post 
discharge pain with PPP, add weight to the argument for improving the management of post-
discharge pain. Another area where the results significantly add to the literature, is in the post-
surgical management of patients and lack of involvement by pain specialists in the care of all post-
surgical patients.  These two areas have the potential, if rectified, to facilitate improved 
management of pain and a subsequent increase in QOL for people following surgery, together 
with a potentially reduced incidence and severity of PPP.  In addition, Chapter 10 is the first study 
conducted in Australia evaluating the barriers and enablers to pain management in ACFs.  This 
provides Australian specific barriers and enablers to managing pain. Considering the number of 
QUM issues identified in chapters 6 and 7, it is an imperative that the way pain in ACFs is managed 
and addressed, is further researched so that these residents can experience the best possible 
quality of life.     
11.3 Implications and recommendations 
The first key implication of this research is the need to improve the management post-discharge 
pain following surgery. Post-discharge pain management is sub-optimal for a variety of reasons 
including patient reluctance to take analgesics, poor discharge counselling, inadequate provision 
of post-discharge analgesics and poor guidance around what patients should do if there is a 
problem.  These issues were identified from a number of perspectives including patients, GPs and 
anaesthetists.  From Chapter Five in particular, as well as previous studies (208, 388, 389, 395, 
396), there appears to be an association between moderate to severe post-discharge pain and the 
development of PPP.  Previous studies have clearly articulated the risk of PPP increasing if acute 
postoperative pain (within the first 48 hours) levels are high (82, 202, 203).  Consequently, the 
following question must be asked; why is there not more attention given to how patients manage 
pain when they go home? It is conceivable that the risk of peripheral and central sensitisation 
persists beyond 48 hours after surgery and optimal pain management following discharge may 
reduce the risk of sensitisation occurring.  Many of the factors previously identified as 
contributing to PPP such as psychological and biological factors are difficult to augment to reduce 
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the incidence, other than identifying those at risk and managing these patients more aggressively. 
Improving the way post-discharge pain is managed has the potential to reduce the incidence 
and/or severity of PPP and at a minimum improve patients’ QOL and physical function.   Further 
research is needed to assess any intervention aimed at improving post-discharge pain on the 
incidence and severity of PPP.  Any research should take into consideration older Australians in 
relation to predictors of PPP, as well as patient characteristics that may make these patients less 
likely to take analgesics following discharge.   
Unfortunately, the complex range of factors and influences on these, mean that rectifying 
deficiencies in pain management will be challenging. Increasing the reach and role of the APS to 
incorporate all post-surgical patients’ pain management and discharge counselling may assist in 
overcoming some of these barriers.  Hospitals also need to have clear policies in place as to whose 
responsibility it is to provide discharge counselling regarding pain management and in doing so, 
ensuring they have relevant and adequately trained staff to accommodate this process. This can 
clearly be seen in Chapter Three and is also supported by anaesthetists’ opinions in Chapter Nine, 
where so many different providers gave advice to patients with poor consistency in counselling, 
despite this study being conducted in just one hospital.    
Further research needs to be undertaken involving interviews with patients about the content 
and delivery of information provided regarding pain management, following surgical discharge. 
Attempts should be made to determine what patients believe would assist them with their self-
management of pain, particularly given the personal, family and societal influences on attitudes 
and perceptions to pain. This bottom-up approach needs to be adopted as there are so many 
misconceptions about pain and its management, especially in older patients.  
The second key implication of this research is the way in which pain is managed by GPs and their 
lack of concordance with guidelines and recommendations. As noted previously, GPs are time 
poor, they are often under supported in the community by pain specialists, waiting times for pain 
clinics are long, or there are not pain clinics in the geographic area, and access to allied health 
services, particularly physiotherapy and psychology, is poor. These pressures, however, do not 
release GPs from practicing in accordance with guidelines or undertaking harm minimisation 
activities such as opioid trials. How to improve the management of pain by GPs and increase the 
use of these harm minimisation strategies needs to be further researched.   
Although not ideal, there may be a requirement to put in place further administrative 
requirements regarding the prescribing of opioids to ensure that GPs commence these as a trial 
for patients, that they have optimised non-opioid analgesics before commencing opioids and that 
patients are not taking regular benzodiazepines in combination with opioids.  This is particularly 
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pertinent in older patients who are at greatest risk of this combination causing harm.  In the 
shorter term, trying to increase the level of CPD about pain management or a mandated minimum 
number of CPD points related to pain education is likely to benefit patients and GPs.  Additionally, 
increasing the reach of persistent pain clinics so that GPs feel more supported in the community, 
and increased access to allied health services are also likely to benefit patients. However, 
increased access to pain clinics and allied health services would require major policy and fiscal 
changes, and significant government intervention for this to occur, which could be a major barrier 
to change in the current economic climate.   Further research should be undertaken to assess the 
role of pharmacists in GP clinics and the effect that this increased collaboration may have on the 
management of pain and its management.   
The final major implication of this research is the need for more education of health care 
practitioners (at an undergraduate and post graduate level) and patients regarding pain and its 
management.  This has previously been suggested in the National Pain Strategy (35, 36) and is 
clearly an area where more work is required.  Low levels of knowledge in relation to pain was 
cited by patients, GPs, anaesthetists and ACF staff as a barrier to optimal pain management. 
Health care practitioners need to improve their knowledge across the board in relation to pain 
management.  This education should be firstly implemented at an undergraduate level in all 
health professional degrees. This would require a national and coordinated response to ensure 
all graduates have a similar level of knowledge and skills.  This is likely to be best achieved by the 
Councils overseeing university course accreditations mandating a specific amount of training 
regarding pain and persistent pain management in order for the course to remain accredited.   
Training for nursing staff already working is likely to have the best outcome if it is in person and 
on site.  Although the recent University of Tasmania MOOC on dementia care has had good uptake 
(7,909 completed of 23,347 enrolled) (554), it has also had substantial number of people not 
complete it. It is possible that face-to-face education may facilitate increased completion of, and 
engagement in, training. For those working with post-surgical pain, training on site, peer-learning 
from increased APS or anaesthetists’ involvement on the wards, or online training may all be 
useful tools in improving acute post-surgical pain management. 
Patients, particularly older patients, were found in this thesis to demonstrate a reluctance to 
report pain and take analgesics. However, there is also the converse situation where patients are 
reliant on or expecting analgesics to “fix” their pain.  A comprehensive patient education program 
is needed to improve patient knowledge, expectations and patient outcomes.  Potentially, the use 
of accredited pharmacists, with additional pain management training, providing medication 
reviews in the community or pharmacists working in general practice may be other helpful 
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strategies. Intervention by pharmacists could assist patients by providing information and 
establishing realistic expectations and assist GPs in providing optimised management strategies 
for those with persistent pain conditions.  This may relieve some pressure from GPs but still 
ensure patients are provided relevant, timely information to allow them to safely and effectively 
self-manage their pain.  For post-surgical patients and those with persistent pain in the 
community, further work would need to be undertaken to determine the best method of 
delivering education such as identifying whether face-to-face, one on one or as a group, online or 
other types of information provision provided the best patient outcomes.  For those in ACFs it is 
likely face-to-face information sessions, preferably including patients’ families would be most 
beneficial and likely to result in behaviour change.  Intervention studies should be conducted to 
identify the best way in which this information should be presented and it’s content. 
In summary, based on the work in this thesis, the main recommendations for improved pain 
management in Australia are: 
- Increased provision of education and training regarding pain and its management to 
undergraduate, graduate and qualified health care practitioners, particularly to those who 
will work closely with patients who experience pain; 
- Increased patient education regarding pain, analgesics and expectations; 
- Improved involvement by anaesthetists, pain specialists or the APS following a surgical 
procedure and at discharge; 
- Improved and consistent discharge counselling and post-discharge resources for patients 
who have undergone a surgical procedure;  
- Increased access for patients with persistent pain to funded multidisciplinary services, 
including pain clinics, psychologists, physiotherapists and pharmacist services; and 
- Further research evaluating the effectiveness of the interventions suggested in this thesis, 
including pharmacist education in GP clinics, increased patient education on surgical 
discharge, pain specific follow-up after surgery, and the development and validation of a PPP 
assessment tool.  
11.4 Limitations 
Although this research contributes significantly to the area of pain and its management in 
Australia, it is important to acknowledge some limitations.  Firstly, it is important to note that the 
pharmacological management of pain is only one treatment modality, and thus the results within 
this thesis only review this aspect.  Multimodality management of pain is required in order to 
demonstrate significant improvements and this is a limitation with this study.  In all studies an 
increased sample size would have been beneficial to improve the strength of the findings.  
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Nonetheless, the results were still convincing despite this.  There was the potential, albeit small, 
that recall bias may have affected the results of surveys. Only one week’s recall was required for 
the prospective studies included in this thesis, and for this reason, recall bias would be unlikely 
to influence the results.  It would be useful to repeat the work conducted as part of Chapter Three 
in other hospitals, to further investigate the management of post-discharge pain.  Nonetheless, 
the results of Chapter Three are consistent with Chapter Nine, an Australian-wide survey of 
anaesthetists.  In Chapters Three, Eight and Nine, there may have been some self-selection of 
participants, as those interested in the area or with specific concerns may have been more likely 
to respond. Potentially this may have influenced the findings, although the effect of this is likely 
to be small and the results are consistent with previous studies in the area.  
As noted in the text of Chapters Six and Seven, a number of potential limitations in the medical 
review data could exist, including the potential inaccurate or incomplete recording of data and 
being able to determine the frequency of “as required” analgesic dosing. Based on the responses 
of the ACF staff regarding pain management (Chapter Ten) “as required” analgesics dosing 
appears to be not overly common for chronic pain conditions.  The staff noted that if a patient is 
requiring frequent “as required” medication, the doctor would be contacted and the order 
changed to more regular dosing.  It would have been beneficial to conduct this research in parallel 
with an audit of ACFs to improve the generalisability of the results and conclusions drawn, in 
addition to tying it in with the non-pharmacological management strategies employed and 
nursing perspective.  However, this is an avenue for further research to add to the literature in 
this area.    
In hindsight, for the purposes of comparison it would have been beneficial to modify the surveys 
used in Chapter Four and Five.  The same depression and anxiety scales should have been used 
for both cohorts to allow for better comparisons between the groups.  It also would have been 
beneficial to have been able to include more intraoperative data and although efforts were made 
to try and obtain this, inconsistencies and poor recording of this data by surgeons (in accessible 
medical notes) meant that it was not possible to include it.  This would have allowed for a more 
comprehensive data collection and clearer outcomes.  In addition, the numerical rating scale was 
found to be difficult to administer, as patients struggled to rate their pain using this scale (this 
was also noted by the ACF staff in Chapter Ten) and consequently other questions using 
descriptors such as mild, moderate or severe pain or discomfort were often used to elicit a patient 
answer. When conducting further research in this area, more descriptive assessments of pain and 
its characteristics would be desirable and permit easier comprehension for patients regarding 
their pain and its management. 
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11.5 Conclusion 
This thesis significantly adds to the literature concerning the pharmacological management of 
pain in older Australia and the predictors of PPP, particularly the influence of undermanagement 
of pain following hospital discharge, which has been not been previously researched.  Overall the 
key findings of this thesis are that pain is often undermanaged following hospital discharge after 
surgery, with inconsistent discharge planning, counselling and prescribing, and a lack of 
concordance with guidelines and recommendations by GPs managing pain in the elderly leading 
to potentially deadly drug combinations being prescribed.  These findings led to a number of 
recommendations being made to improve pain management, including increased education of 
health professionals and patients, increased involvement of pain specialists following surgery, 
improved discharge counselling and resources for patients following surgery, and increased 
access to funded multidisciplinary services including pain clinics, psychologists and 
physiotherapists.  With improved management of post-discharge pain there is the potential to 
reduce the incidence of PPP in the future and at the very least improve the QOL and rehabilitation 
potential following discharge.  Additionally, increased GP knowledge and access to 
multidisciplinary resources may help reduce the severity of pain and improve physical function 
of those patients who do experience persistent pain to allow them to have an improved QOL.   It 
is clear that significant improvements to pharmacological pain management are required in order 
to optimise treatment outcomes for elderly Australians.  
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Provision of Pain Management Advice 
to Surgical Patients at the Royal Hobart Hospital 
 
Many thanks for completing this survey, please answer as many questions as you are able to.  If 
you find you need help to answer this survey, please feel free to ask a family member or a friend 
who was involved in your care during your hospital stay.  We do appreciate your honesty and all 
answers shall be kept strictly confidential.     
 
Name: ...............................................................................................................  
Date of Birth:................ ............      Gender: ☐ Male ☐  Female 
Today’s date:..............................  
 
 
1a) How would you describe your current employment situation? 
☐  Full time      ☐  Part time   ☐  Casual     ☐ Full time student 
☐  Unemployed        ☐  Retired     ☐  Other         ☐  Disability pension 
 
1b) What is the highest level of education you have completed? 
☐  Pre-year 10 ☐  Year 10   ☐  Year 12    ☐ Diploma 
☐  VET Certificate ☐  Bachelor’s degree   ☐  Post-graduate Qualification 
 
 
2a) In a pre-assessment clinic did you speak to a doctor (from the surgical team or anaesthetist) 
about your postoperative pain management before you were admitted to hospital to have your 
operation? 
☐Yes   ☐No (Please go to question 3a) 
 
2b) Did the doctor give you any written information at this session? 
☐ Yes ☐ No 
 
3a) Were you experiencing pain before you had surgery?     
 ☐ Yes            ☐ No (Please go to Question 4) 
 
3b) On average, how severe would you rate your level of pain before surgery?  
(0 being no pain and 10 being worst pain imaginable)?  
☐0   ☐1   ☐2   ☐3   ☐4   ☐5   ☐6   ☐7   ☐8   ☐9   ☐10 
 
3c) Was this pain (or the medical condition causing this pain) the reason you had surgery? 
☐ Yes            ☐ No 
 
3d) For how long had you been suffering with this pain? 
☐  Less than 3 months     ☐ 3-6 months ☐ 6-12 months ☐ More than 12 months 
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Appendix 1: Provision of pain management advice to surgical patients at the Royal 
Hobart Hospital – elective patients 
 
 
 
Provision of Pain Management Advice 
to Surgical Patients at the Royal Hobart Hospital 
 
Many thanks for completing this survey, please answer as many questions as you are able to.  If you 
find you need help to answer this survey, please feel free to ask a family member or a friend who 
was involved in your care during your hospital stay.  We do appreciate your honesty and all 
answers shall be kept strictly confidential.     
 
Date of Birth:............................      Gender: ☐ Male ☐  Female 
Today’s date:.............................. 
 
 
1a) How would you describe your current employment situation? 
☐  Full time      ☐  Part time   ☐  Casual     ☐ Full time student 
☐  Unemployed        ☐  Retired     ☐  Other         ☐  Disability pension 
 
1b) What is the highest level of education you have completed? 
☐  Pre-year 10  ☐  Year 10     ☐  Year 12    ☐ Diploma 
☐  VET Certificate ☐  Bachelor’s degree   ☐  Post-graduate Qualification 
 
 
2a) In a pre-assessment clinic did you speak to a doctor (from the surgical team or anaesthetist) 
about your postoperative pain management before you were admitted to hospital to have your 
operation? 
☐Yes   ☐No (Please go to question 3a) 
 
2b) Did the doctor give you any written information at this session? 
☐ Yes ☐ No 
 
3a) Were you experiencing pain before you had surgery?     
 ☐ Yes            ☐ No (Please go to Question 4) 
 
3b) On average, how severe would you rate your level of pain before surgery?  
(0 being no pain and 10 being worst pain imaginable)?  
☐ 0   ☐ 1   ☐ 2   ☐ 3   ☐ 4   ☐ 5   ☐ 6   ☐ 7   ☐ 8   ☐ 9   ☐ 10 
 
3c) Was this pain (or the medical condition causing this pain) the reason you had surgery? 
☐ Yes            ☐ No 
 
3d) For how long had you been suffering with this pain? 
☐  Less than 3 months     ☐ 3-6 months ☐ 6-12 months ☐ More than 12 months 
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4a) Following discharge from hospital after your operation, what medicine(s) have you been taking for your pain ?  
If not listed, please at the blank spaces provided. 
Drug Strength Number of tablets per 
day 
Provided by the hospital on 
discharge? (Yes/No) 
If no, where did you get these medicines from? 
Eg. Supermarket, pharmacy, GP prescription, 
friend/family, old medication of my own 
Paracetamol (Panadol, 
Panamax) 
    
Ibuprofen (Nurofen®, Brufen®)     
Paracetamol/codeine 
(Panadeine Forte®, Panadeine 
Extra®, Codalgin Forte®, 
Codapane Forte®) 
    
Ibuprofen/codeine (Nurofen 
Plus®) 
    
Naproxen (Naprosyn®, Inza®, 
Naprogesic®) 
    
Diclofenac (Voltaren®)     
Meloxicam (Mobic®)     
Celecoxib (Celebrex®)     
Codeine     
Oxycodone (Endone®, 
Oxynorm®) 
    
Buprenorphine patch 
(Norspan®) 
    
Fentanyl patch (Durogesic®, 
Fenpatch®) 
    
Morphine (MS Mono® MS 
Contin®, Kapanol®) 
    
Tramadol (Tramal®, Zydol®)     
Gabapentin (Neurontin®)     
Pregabalin (Lyrica®)     
Duloxetine (Cymbalta®, 
Andepra®) 
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4b) Apart from taking medicine(s), have you been doing anything else to reduce your pain? (e.g. 
heat/cold packs, massage, physiotherapy) 
………………………………………………………………………………………………………………………………………………
…………………………………… 
 
5a) Right now, how severe would you rate your level of pain? 
(0 being no pain and 10 being worst pain imaginable)?  
 
  ☐ 0   ☐ 1   ☐ 2   ☐ 3   ☐ 4   ☐ 5   ☐ 6   ☐ 7   ☐ 8   ☐ 9   ☐ 10 
 
5b) Thinking about the last 7 days since you were discharged from hospital, how severe would 
you rate your average level of pain? 
(0 being no pain and 10 being worst pain imaginable)?  
 
☐ 0   ☐ 1   ☐ 2   ☐ 3   ☐ 4   ☐ 5   ☐ 6   ☐ 7   ☐ 8   ☐ 9   ☐ 10 
 
5c) What level of pain severity did you expect to have 7 days after discharge from hospital?  
(0 being no pain and 10 being worst pain imaginable)?  
 
☐ 0   ☐ 1   ☐ 2   ☐ 3   ☐ 4   ☐ 5   ☐ 6   ☐ 7   ☐ 8   ☐ 9   ☐ 10 
  
6a) When you were admitted to hospital for your operation, what information was given to you 
(before your operation and at discharge) about how to manage your pain once you were at 
home?  (Tick all that apply) 
☐ Number of tablets to take 
☐ What medications to take 
☐ When to contact the hospital 
☐ What activities you can do after the surgery 
☐ Other 
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
……………………………………………………………………………… 
 
 
6b) Were you given any written information? 
 
☐Yes ☐No 
 
6c) Who provided you with this advice / information? (Tick all that apply) 
 
☐ Doctor ☐ Nurse ☐ Pharmacist ☐ Anaesthetist 
 
6d) Have you followed this advice about pain medicines?  
 
☐ Yes (If yes continue question 7)   ☐ No 
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6e) Please tell us why you have chosen not to follow this advice. 
☐ Side effects of medication 
☐ Did not understand 
☐ Too complicated 
☐ Not in pain 
☐ Cost of medication 
☐ Difficulty in obtaining supplies 
Other………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………….. 
 
7a) Have you been using your medication: 
☐ More than directed   
☐ As directed (go to question 8) 
☐ Less than directed 
 
7b) Please tell us why you have found it necessary to use more or less of the pain medicine(s) 
than advised 
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………… 
8) Please tell us any other information about your pain management that you think may be 
useful to our project  
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………… 
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Appendix 2: Provision of pain management advice to surgical patients at the Royal 
Hobart Hospital - emergency patients 
 
 
 
 
Provision of Pain Management Advice 
to Surgical Patients at the Royal Hobart Hospital 
Many thanks for completing this survey, please answer as many questions as you are able to.  If you 
find you need help to answer this survey, please feel free to ask a family member or a friend who 
was involved in your care during your hospital stay.  We do appreciate your honesty and all 
answers shall be kept strictly confidential.     
Name: ............................................................................................................... 
Date of Birth:................       Gender: ☐  Male ☐  Female 
Today’s Date: ……………………………… 
 
1a) How would you describe your current employment situation? 
☐  Full time      ☐  Part time   ☐  Casual     ☐ Full time student 
☐  Unemployed        ☐  Retired     ☐  Other         ☐  Disability pension 
 
1b) What is the highest level of education you have completed? 
☐  Pre-year 10 ☐  Year 10   ☐  Year 12    ☐ Diploma 
☐  VET Certificate ☐  Bachelor’s degree   ☐  Post-graduate Qualification 
 
2a) Did you speak to an anaesthetist or doctor from the surgical team about your postoperative 
pain management before your operation? 
 ☐Yes   ☐No (Please go to question 3a) 
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2b) Were you given written information at this time? 
☐ Yes ☐ No 
 
3a) Were you experiencing pain before you had surgery?     
☐ Yes            ☐ No (Please go to Question 4) 
 
3b) Where was this pain? 
………………………………………………………………………………………………………………………………………………
……………………………………………… 
 
3c) On average, how severe would you rate your level of pain before surgery?  
(0 being no pain and 10 being worst pain imaginable)?  
☐0   ☐1   ☐2   ☐3   ☐4   ☐5   ☐6   ☐7   ☐8   ☐9   ☐10 
 
3d) How long have you have this pain for? 
☐  <3 months     ☐ 3-6 months   ☐  6-9 months     ☐ 9-12 months  
☐  1-2 years       ☐ 2-5 years       ☐  5-10 years      ☐  >10 years 
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4a) Following discharge from hospital after your operation, what medicine(s) have you been taking for your pain?  
If not listed, please at the blank spaces provided. 
Drug Strength Number of tablets per 
day 
Provided by the hospital on 
discharge? (Yes/No) 
If no, where did you get these medicines from? 
Eg. Supermarket, pharmacy, GP prescription, 
friend/family, old medication of my own 
Paracetamol (Panadol, 
Panamax) 
    
Ibuprofen (Nurofen®, Brufen®)     
Paracetamol/codeine 
(Panadeine Forte®, Panadeine 
Extra®, Codalgin Forte®, 
Codapane Forte®) 
    
Ibuprofen/codeine (Nurofen 
Plus®) 
    
Naproxen (Naprosyn®, Inza®, 
Naprogesic®) 
    
Diclofenac (Voltaren®)     
Meloxicam (Mobic®)     
Celecoxib (Celebrex®)     
Codeine     
Oxycodone (Endone®, 
Oxynorm®) 
    
Buprenorphine patch 
(Norspan®) 
    
Fentanyl patch (Durogesic®, 
Fenpatch®) 
    
Morphine (MS Mono® MS 
Contin®, Kapanol®) 
    
Tramadol (Tramal®, Zydol®)     
Gabapentin (Neurontin®)     
Pregabalin (Lyrica®)     
Duloxetine (Cymbalta®, 
Andepra®) 
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4b) Apart from taking medicine(s), have you been doing anything else to reduce your pain? (e.g. 
heat/cold packs, massage, physiotherapy) 
………………………………………………………………………………………………………………………………………………
…………… 
5a) Right now, how severe would you rate your level of pain? 
(0 being no pain and 10 being worst pain imaginable)?  
 
  ☐0   ☐1   ☐2   ☐3   ☐4   ☐5   ☐6   ☐7   ☐8   ☐9   ☐10 
 
5b) Thinking about the last 7 days since you were discharged from hospital, how severe would 
you rate your average level of pain? 
(0 being no pain and 10 being worst pain imaginable)? 
 
  ☐0   ☐1   ☐2   ☐3   ☐4   ☐5        ☐6   ☐7   ☐8   ☐9   ☐10 
 
5c) What level of pain severity did you expect to have 7 days after discharge from hospital?  
(0 being no pain and 10 being worst pain imaginable)?  
 
  ☐0   ☐1   ☐2   ☐3   ☐4   ☐5        ☐6   ☐7   ☐8   ☐9   ☐10 
  
6a) What information was given to you in hospital (before and at discharge) about how to 
manage your pain once you were at home? 
☐ Number of tablets to take 
☐ What medications to take 
☐ When to contact the hospital 
☐ What activities you can do after the surgery 
☐ Other 
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………………… 
 
6b) Were you given any written information? 
☐Yes ☐No 
 
6c) Who provided you with this information? (Tick all that apply) 
☐Doctor ☐Nurse ☐Pharmacist ☐Anaesthetist 
 
6d) Have you followed the advice that was given to you?  
☐ Yes (If yes continue question 7)   ☐ No  
 
6e) Why have you chosen not to follow this advice?  
☐ Side effects of medication 
☐ Did not understand 
☐ Too complicated 
☐ Not in pain 
☐ Cost of medication 
☐ Difficulty in obtaining supplies 
Other:…………………………………………………………………………………………………………………………………… 
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7a) Are you using you medication: 
☐ More than directed   
☐ As directed (go to question 8) 
☐ Less than directed 
 
7b) Please tell us why you have found it necessary to use more or less of the pain medicine(s) 
than advised 
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………… 
8) Please tell us any other information about your pain management that you think may be 
useful to our project 
………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………
………………………… 
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Appendix 3: The management of postoperative pain - sternotomy 
 
Many thanks for completing this survey, please answer all of the questions.  We apologise if some of 
the questions seem too personal or confronting.  We do appreciate your honesty and all answers 
shall be kept strictly confidential.     
 
Name: ............................................................................................................... 
Age:................         Gender: ☐  Male ☐  Female 
Do you have any allergies: ……………………………………………………………. 
 
Postcode: ………………………………………………………………………………. 
Phone number: …………………………………………………………………………. 
 
1a) How would you describe your marital status: 
☐ Married      ☐ Divorced   ☐ De-facto relationship     ☐ Other       
☐ Widowed    ☐ Single   Prefer not to say 
 
1b) How would you describe your current employment situation? 
☐  Full time      ☐  Part time   ☐  Casual     ☐ Full time student 
☐  Unemployed        ☐  Retired     ☐  Other         ☐  Disability pension 
 
1c) Do you intend to return to work after your surgery? 
☐ Yes   ☐ No     ☐ Maybe     ☐  Not applicable      
 
1d) What is the highest level of education you have completed? 
☐  Pre-year 10 ☐  Year 10   ☐  Year 12    ☐ Diploma 
☐  VET Certificate ☐  Bachelor’s degree   ☐  Post-graduate Qualification 
 
1e) Are you a cigarette/pipe/cigar smoker?    ☐  Yes    ☐ No    
 
1f) In an average week how many standard drinks of alcohol do you drink?................. 
1 can/bottle beer = 1    1 glass of wine = 1.5 
1 nip (30mL) spirits = 1  pre-mix/redi-mix bottle/can = 1.5 
 
1g) Do you have support (either friends or family) that can assist you when you are discharged 
from hospital?   ☐ Yes   ☐ No     ☐ Maybe      
 
1h) On a scale of 1 to 10 (one being not positive/optimistic to 10 being very positive/optimistic) 
do you consider yourself to be a positive/optimistic person?   
 
1 2 3 4 5 6 7 8 9 10 
 
1i) On a scale of 1 to 10 (one being very unhealthy to 10 being very healthy) what level of health 
do you think you have? 
 
1 2 3 4 5 6 7 8 9 10 
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1j) On a scale of one to 10 (one being able to cope with pain very well and 10 being unable to 
cope with pain very well) what level of pain tolerance do you think you have?   
 
1 2 3 4 5 6 7 8 9 10 
 
1k) On a scale of 1 to 10 (one being not scared/concerned to 10 being very concerned/scared) 
how worried are you about postoperative pain? 
 
1 2 3 4 5 6 7 8 9 10 
 
1l) Did you speak to an anaesthetist or doctor about your pain management before you had 
your operation? 
           Yes  ☐            No ☐ 
 
2a) Are you currently experiencing any pain?     
           ☐ Yes            ☐ No (Please go to Question 3) 
 
2b) Is this pain the reason you are having surgery? 
          ☐ Yes            ☐ No 
 
2c) Where is the site(s) of your pain?..................................................................... 
.................................................................................................................................... 
.................................................................................................................................... 
 
2d) How long have you have this pain for? 
☐  <3 months     ☐ 3-6 months   ☐  6-9 months     ☐ 9-12 months  
☐  1-2 years       ☐ 2-5 years       ☐  5-10 years      ☐  >10 years  
 
2e) How many days a week do you experience this pain?......................................... 
 
2f) Is your pain worst at rest or when you were moving? ……………………….. 
.................................................................................................................................... 
 
2g) Do you know what caused your pain? (eg. Car accident, arthritis, cancer, previous 
surgery)..................................................................................................................... 
.................................................................................................................................... 
 
2h) What is the highest level of pain you experience during an average day on a scale of one to 
ten? (One being no pain and 10 being the worst pain you can imagine) 
 
1 2 3 4 5 6 7 8 9 10 
 
2i) What is the average pain level across a week on a scale of one to ten that you experience? 
(One being no pain and 10 being the worst pain you can imagine) 
 
1 2 3 4 5 6 7 8 9 10 
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2j) Does this pain affect any of the following: (on a scale of 1-10 with one being no effect and 10 
being extremely effected) 
Sleep  
Activities of daily living (dressing, personal hygiene, self feeding, toileting)  
Sit in a car for >30 minutes  
Walk 100m  
Hobbies  
 
2k) What do you take to treat your pain? (Please include any over-the-counter medications or 
prescription medications that you have been taking) 
Drug Strength Number of tablets per day 
Paracetamol   
Ibuprofen   
Paracetamol/codeine   
Ibuprofen/codeine   
Naproxen   
Diclofenac   
Piroxicam/meloxicam   
Codeine   
Oxycodone XR/IR   
Buprenorphine patch    
Fentanyl patch/tab   
Morphine XR/IR   
Tramadol   
Methadone   
Di-Gesic/Capadex   
Gabapentin   
Pregabalin   
Lamotrigine    
Topiramate    
Valproic Acid    
Amitriptyline    
Venlafaxine    
Desvenlafaxine   
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Question 3: For each statement please choose a number 0, 1, 2 or 3 which indicates how much 
the statement applied to you over the past week.  There are no right or wrong answers.  Do not 
spend too much time on any statement. 
 
The rating scale is as follows: 
0 -  Did not apply to me at all  
1 – Applied to me to some degree, or some of the time 
2 – Applied to me a considerable degree, or a good part of time 
3 – Applied to me very much, or most of the time   
 
1 I found it hard to wind down 0      1      2      3 
2 I was aware of dryness of my mouth 0      1      2      3 
3 I couldn't seem to experience any positive feeling at all 0      1      2      3 
4 I experienced breathing difficulty (eg, excessively rapid 
breathing, 
breathlessness in the absence of physical exertion) 
0      1      2      3 
5 I found it difficult to work up the initiative to do things 0      1      2      3 
6 I tended to over-react to situations 0      1      2      3 
7 I experienced trembling (eg, in the hands) 0      1      2      3 
8 I felt that I was using a lot of nervous energy 0      1      2      3 
9 I was worried about situations in which I might panic and make  
a fool of myself 
0      1      2      3 
10 I felt that I had nothing to look forward to 0      1      2      3 
11 I found myself getting agitated 0      1      2      3 
12 I found it difficult to relax 0      1      2      3 
13 I felt down-hearted and blue 0      1      2      3 
14 I was intolerant of anything that kept me from getting on with 
what I was doing 
0      1      2      3 
15 I felt I was close to panic 0      1      2      3 
16 I was unable to become enthusiastic about anything 0      1      2      3 
17 I felt I wasn't worth much as a person 0      1      2      3 
18 I felt that I was rather touchy 0      1      2      3 
19 I was aware of the action of my heart in the absence of physical 
exertion (eg, sense of heart rate increase, heart missing a beat) 
0      1      2      3 
20 I felt scared without any good reason 0      1      2      3 
21 I felt that life was meaningless 0      1      2      3 
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Everyone experiences painful situations at some point in their lives. Such experiences may 
include headaches, tooth pain, joint or muscle pain. People are often exposed to situations that 
may cause pain such as illness, injury, dental procedures or surgery.  
We are interested in the types of thoughts and feelings that you have when you are in pain. 
Listed below are thirteen statements describing different thoughts and feelings that may be 
associated with pain. Using the following scale, please indicate the degree to which you have 
these thoughts and feelings when you are experiencing pain.  
 
0 – not at all 1 – to a slight degree 2 – to a moderate degree 3 – to a great degree 4 – all the time  
 
When I’m in pain …  
I worry all the time about whether the pain will end.  0 1 2 3 4 
I feel I can’t go on. 0 1 2 3 4 
It’s terrible and I think it’s never going to get any better. 0 1 2 3 4 
I feel I can’t stand it anymore. 0 1 2 3 4 
I become afraid that the pain will get worse. 0 1 2 3 4 
I keep thinking of other painful events. 0 1 2 3 4 
It’s awful and I feel that it overwhelms me 0 1 2 3 4 
I anxiously want the pain to go away. 0 1 2 3 4 
I can’t seem to keep it out of my mind. 0 1 2 3 4 
I keep thinking about how much it hurts. 0 1 2 3 4 
I keep thinking about how badly I want the pain to stop. 0 1 2 3 4 
There’s nothing I can do to reduce the intensity of the pain. 0 1 2 3 4 
I wonder whether something serious may happen. 0 1 2 3 4 
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Appendix 4: Follow-up survey – 10 days and 2 months post-discharge 
 
Date: ......................... 
 
Patient Name: ............................................................................................................... 
 
Thinking about your surgery and the area that was operated on, please answer the following. 
 
1a) Are you currently experiencing any pain at the site of your operation? (one being no pain 
and 10 being the worst pain imaginable) 
 
1 2 3 4 5 6 7 8 9 10 
 
1b) At this site, what is the worst level of pain you have experienced in the past week? (one 
being no pain and 10 being the worst pain imaginable) 
 
1 2 3 4 5 6 7 8 9 10 
 
1c) On average, what level of pain have you had over the last week at the site of the operation? 
(one being no pain and 10 being worst pain imaginable) 
 
1 2 3 4 5 6 7 8 9 10 
 
1d) Does this pain affect any of the following: (on a scale of 1-10 with one being no effect and 10 
being extremely effected) 
Sleep  
Activities of daily living (dressing, personal hygiene, self-feeding, toileting)  
Sit in a car for >30 minutes  
Walk 100m  
Hobbies  
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2) What medications are you currently taking for your pain? 
Drug Strength Number of tablets 
per day 
Who is your 
prescriber? 
Paracetamol    
Ibuprofen    
Paracetamol/codeine    
Ibuprofen/codeine    
Naproxen    
Diclofenac    
Piroxicam/meloxicam    
Codeine    
Oxycodone XR/IR    
Buprenorphine patch     
Fentanyl patch/tab    
Morphine XR/IR    
Tramadol    
Methadone    
Di-gesic/Capadex    
Gabapentin    
Pregabalin    
Lamotrigine     
Topiramate     
Valproic Acid     
Amitriptyline     
Venlafaxine     
Desvenlafaxine    
    
    
If you were working or studying prior to surgery have you returned to work? 
☐  Yes    ☐ No     
Are you working the same number of hours as you were prior to surgery? 
☐  Yes    ☐ No – fewer hours    ☐ No – more hours 
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Appendix 5: Follow-up survey – 3 and 12 months after surgery 
 
Date: ......................... 
Patient Name: .............................................................................................................. 
1) Have you had any new medical conditions diagnosed in the last three months? 
…………………………………………………………………………………………….………………………………………………… 
 
2) Thinking about your surgery and the area that was operated on, please answer the 
following. 
 
2a) Are you currently experiencing any pain at the site of your operation? (one being no pain 
and 10 being the worst pain imaginable) 
 
1 2 3 4 5 6 7 8 9 10 
 
2b) At this site, what is the worst level of pain you have experienced in the past week? (one 
being no pain and 10 being the worst pain imaginable) 
 
1 2 3 4 5 6 7 8 9 10 
 
2c) On average, what level of pain have you had over the last week at the site of the operation? 
(one being no pain and 10 being worst pain imaginable) 
 
1 2 3 4 5 6 7 8 9 10 
 
2d) Does this pain affect any of the following: (on a scale of 1-10 with one being no effect and 10 
being extremely effected) 
Sleep  
Activities of daily living (dressing, personal hygiene, self-feeding, toileting)  
Sit in a car for >30 minutes  
Walk 100m  
Hobbies  
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Question 1: Does the pain have one or more of the following characteristics? 
 
 YES NO 
1 - Burning   
2 - Painful Cold   
3 - Electric Shocks   
 
 
Question 2: Is the pain associated with one or more of the following symptoms in the same area? 
 
 YES NO 
4 - Tingling   
5 - Pins and Needles   
6 - Numbness   
7 - Itching   
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3) What medications or supplements are you currently taking for your pain, including anything 
bought at a pharmacy, health food store or supermarket (if you are not sure what a medication 
is used for please write it down)? 
 
Drug Strength Number of tablets per day 
   
   
   
   
   
   
 
4) Have you got any other pain not at the site of the surgery? 
☐ yes – please continue onto question 4a 
☐ no – many thanks for your time and assistance in completing this form.   
 
4a) Where are the site(s) of your pain? 
.......................................................................................................................................................................................................
............................................................................................................................. 
4b) How long have you have this pain for? ................................................................... 
4c) How many days a week do you experience this pain?..............................................  
4d) Do you know what is causing your pain?................................................................. 
4e) Are you having any treatment for this pain? Eg physiotherapy, further surgery, pain killers? 
.......................................................................................................................................................................................................
............................................................................................................................. 
 
4f) At this site, which was not operated on, what is your current level of pain? (one being no 
pain and 10 being the worst pain imaginable) 
 
1 2 3 4 5 6 7 8 9 10 
 
4g) At this site not related to your operation, what is the worst level of pain you have 
experienced in the past week? (one being no pain and 10 being the worst pain imaginable) 
 
1 2 3 4 5 6 7 8 9 10 
 
4H) On average, what level of pain have you had over the last week at the site of pain not 
associated with your operation? (one being no pain at all and 10 being significant and constant 
pain) 
 
1 2 3 4 5 6 7 8 9 10 
 
 
4I) Does this pain effect: (on a scale of 1-10 with one being no effect and 10 being extremely 
effected) 
Sleep  
Activities of daily living (dressing, personal hygiene, self-feeding, toileting)  
Sit in a car for >30 minutes  
Walk 100m  
Hobbies  
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Appendix 6: The management of postoperative pain – orthopaedic initial survey 
 
Many thanks for completing this survey, please answer all of the questions.  We apologise if some of 
the questions seem too personal or confronting.  We do appreciate your honesty and all answers 
shall be kept strictly confidential.     
 
Name: ............................................................................................................... 
Age:................         Gender: ☐  Male ☐  Female 
Do you have any allergies: ……………………………………………………………. 
 
Postcode: ………………………………………………………………………………. 
Phone number: …………………………………………………………………………. 
 
1a) How would you describe your marital status: 
☐ Married      ☐ Divorced   ☐ De-facto relationship     ☐ Other       
☐ Widowed    ☐ Single   
 
1b) How would you describe your current employment situation? 
☐  Full time      ☐  Part time   ☐  Casual     ☐ Full time student 
☐  Unemployed        ☐  Retired     ☐  Other       ☐  Disability pension 
 
1c) What is the highest level of education you have completed? 
☐  Pre-year 10 ☐  Year 10   ☐  Year 12    ☐ Diploma 
☐  VET Certificate ☐  Bachelor’s degree   ☐  Post-graduate Qualification 
 
1d) Are you a cigarette/pipe/cigar smoker?    ☐  Yes    ☐ No    
 
1e) In an average week how many standard drinks of alcohol do you drink?................. 
1 can/bottle beer = 1    1 glass of wine = 1.5 
1 nip (30mL) spirits = 1  pre-mix/redi-mix bottle/can = 1.5 
 
1f) Do you have support (either friends or family) that can assist you when you are discharged 
from hospital?   ☐ Yes   ☐ No     ☐ Maybe      
 
1g) On a scale of 1 to 10 (one being not positive/optimistic to 10 being very positive/optimistic) 
do you consider yourself to be a positive/optimistic person?   
 
1 2 3 4 5 6 7 8 9 10 
 
1h) On a scale of 1 to 10 (one being very unhealthy to 10 being very healthy) what level of 
health do you think you had prior to your emergency surgery? 
 
1 2 3 4 5 6 7 8 9 10 
 
1i) On a scale of one to 10 (one being able to cope with pain very well and 10 being unable to 
cope with pain very well) what level of pain tolerance do you think you have?   
 
1 2 3 4 5 6 7 8 9 10 
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1j) On a scale of 1 to 10 (one being not scared/concerned to 10 being very concerned/scared) 
how worried were you about postoperative pain prior to your emergency surgery? 
 
1 2 3 4 5 6 7 8 9 10 
 
1k) Did you speak to an anaesthetist or doctor about your pain management before you had 
your operation? 
           Yes  ☐            No ☐ 
 
1l) On a scale of 1 to 10 (one being very positive and 10 being very negative) how would you 
rate your current mood? 
 
1 2 3 4 5 6 7 8 9 10 
 
2a) Prior to your accident/incident that brought you into hospital, were you experiencing any 
pain?     
           ☐ Yes            ☐ No (Please go to Question 3) 
2b) Where is the site(s) of your pain?..................................................................... 
.................................................................................................................................... 
.................................................................................................................................... 
 
2c) How long have you have this pain for? 
☐  <3 months     ☐ 3-6 months   ☐  6-9 months     ☐ 9-12 months  
☐  1-2 years       ☐ 2-5 years       ☐  5-10 years      ☐  >10 years  
 
2d) How many days a week do you experience this pain?......................................... 
 
2e) Is your pain worst at rest or when you were moving? ……………………….. 
.................................................................................................................................... 
 
2f) Do you know what caused your pain? (eg. Car accident, arthritis, cancer, previous 
surgery)..................................................................................................................... 
.................................................................................................................................... 
 
2g) What is the highest level of pain you experience during an average day on a scale of one to 
ten? (One being no pain and 10 being the worst pain you can imagine) 
 
1 2 3 4 5 6 7 8 9 10 
 
2h) What is the average pain level across a week on a scale of one to ten that you experience? 
(One being no pain and 10 being the worst pain you can imagine) 
 
1 2 3 4 5 6 7 8 9 10 
 
2i) Does this pain affect any of the following: (on a scale of 1-10 with one being no effect and 10 
being extremely effected) 
Sleep  
Activities of daily living (dressing, personal hygiene, self feeding, toileting)  
Sit in a car for >30 minutes  
Walk 100m  
Hobbies  
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2j) What do you take to treat your pain? (Please include any over-the-counter medications or 
prescription medications that you have been taking) 
Drug Strength Number of tablets per day 
Paracetamol   
Ibuprofen   
Paracetamol/codeine   
Ibuprofen/codeine   
Naproxen   
Diclofenac   
Piroxicam/meloxicam   
Codeine   
Oxycodone XR/IR   
Buprenorphine patch    
Fentanyl patch/tab   
Morphine XR/IR   
Tramadol   
Methadone   
Di-Gesic/Capadex   
Gabapentin   
Pregabalin   
Lamotrigine    
Topiramate    
Valproic Acid    
Amitriptyline    
Venlafaxine    
Desvenlafaxine   
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Everyone experiences painful situations at some point in their lives. Such experiences may 
include headaches, tooth pain, joint or muscle pain. People are often exposed to situations that 
may cause pain such as illness, injury, dental procedures or surgery.  
 
We are interested in the types of thoughts and feelings that you have when you are in pain. 
Listed below are thirteen statements describing different thoughts and feelings that may be 
associated with pain. Using the following scale, please indicate the degree to which you have 
these thoughts and feelings when you are experiencing pain.  
 
0 – not at all 1 – to a slight degree 2 – to a moderate degree 3 – to a great degree 4 – all the time  
 
When I’m in pain …  
I worry all the time about whether the pain will end.  0 1 2 3 4 
I feel I can’t go on. 0 1 2 3 4 
It’s terrible and I think it’s never going to get any better. 0 1 2 3 4 
I feel I can’t stand it anymore. 0 1 2 3 4 
I become afraid that the pain will get worse. 0 1 2 3 4 
It’s awful and I feel that it overwhelms me 0 1 2 3 4 
I keep thinking of other painful events. 0 1 2 3 4 
I anxiously want the pain to go away. 0 1 2 3 4 
I can’t seem to keep it out of my mind. 0 1 2 3 4 
I keep thinking about how much it hurts. 0 1 2 3 4 
I keep thinking about how badly I want the pain to stop. 0 1 2 3 4 
There’s nothing I can do to reduce the intensity of the pain. 0 1 2 3 4 
I wonder whether something serious may happen. 0 1 2 3 4 
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Appendix 7: Management of pain - a survey of general practitioners’ opinions 
 
Thank you for taking the time to do this survey.  As part of this research we are trying to identify 
what guidelines you use to manage patients with pain, how you would treat patients in a number 
of given scenarios and what barriers you think exist to the optimal management of pain and how 
these could be overcome.  
This survey should take no more than 10 minutes to complete.  If you decide that you do not want 
to complete this study, please exit the survey and your results will not be included in the final 
analysis.  There are five Coles-Myer vouchers available valued at $100 each, if you wish to put 
your name in to the draw for one of these vouchers, please include your name and email address 
at the end.  These details will not be linked with your response to the survey. 
If you have any questions regarding this study, please do not hesitate to contact: 
Felicity Veal (6226 2312; fveal@utas.edu.au) or 
Associate Professor Luke Bereznicki (Luke.Bereznicki@utas.edu.au). 
This project has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee. If you have concerns or complaints about the conduct of this project, please contact 
the Executive Officer of the HREC (Tasmania) Network on (03) 6226 6254 or email 
human.ethics@utas.edu.au. The Executive Officer is the person nominated to receive complaints 
from research participants. Please quote ethics reference number H0012833. 
 
What guides decision making about pain management in general practice? 
How many years have you been working in general practice? 
On average, how many patients would you see each week with the following types of pain? 
 Number of patients, on average, per week  
- Acute pain   
- Persistent non-malignant pain   
- Neuropathic pain   
- Persistent malignant pain   
- Palliative care   
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When managing patients with persistent/chronic pain which of the following guidelines do you 
use? 
 Therapeutic Guidelines 
 WHO analgesic ladder 
 Hunter New England Pain Guidelines 
 Quick Clinical Guideline for the use of opioids in chronic non-malignant pain (WA Govt) 
 RACGP guideline for the non-surgical management of hip and knee osteoarthritis 
 APSOC Pain in residential aged care facilities - Management strategies 2005 
 NSW Therapeutic Assessment Group - Low Back Pain 
 NSW Therapeutic Assessment Group - Preventing and managing problems with opioids 
prescribing for chronic non cancer pain 
 Other:   
 
Do you use any of the following strategies when prescribing opioids? 
 Discussion around pain management expectations 
 Opioid Trials of ~8 weeks 
 Urine drug screening to monitor compliance and inappropriate drug taking 
 Referral for cognitive behavioural therapy 
 Referral for physiotherapy 
 Regular reviews of the 5As (activity; adverse events; aberrant behaviour; affect; analgesia) 
 Other:   
 
Please indicate how you think patients generally take their prescribed analgesics for ACUTE 
pain 
  
Less than 
prescribed 
As prescribed 
More than 
prescribed 
Paracetamol    
NSAIDs    
Regularly prescribed 
opioids    
As required opioids    
 
Please indicate how you think patients generally take their prescribed analgesics for 
CHRONIC/PERSISTENT pain 
  Less than prescribed As prescribed More than prescribed 
Paracetamol    
NSAIDs    
Regularly prescribed 
opioids    
As required opioids    
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For those patients who are non-compliant with analgesics, what do you think are the major 
reasons for non-compliance? 
 Poor analgesic effect 
 Misuse/diversion 
 Tablet burden 
 Reserving the analgesics for severe pain 
 Fear of addiction 
 Fear that it won’t work if they use it too often 
 Fear of pain 
 Pain catastrophising 
 Other:   
Which of the following do you think are the major barriers to the management of persistent 
pain in general practice? 
 Guidelines are difficult to use 
 Lack of supporting evidence surrounding analgesics 
 Lack of drug efficacy 
 Side effect profile/risk of drugs 
 Concern regarding misuse/diversion of analgesia 
 Limited government funding of physiotherapy 
 Difficult access to psychologists 
 Waiting times to access pain clinics 
 Patient expectations of pain management 
 Diagnosis of pain causing condition 
 Limited options for neuropathic pain on the PBS 
 Other:   
 
How do you think these barriers to pain management could be overcome? 
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Appendix 8: Management of postoperative pain - a survey of anaesthetists’ opinions 
 
Thank you for taking the time to do this survey.  As part of this research we are trying to identify 
what factors affect your clinical decision making and what barriers you think exist to the optimal 
management of acute postoperative pain and how these could be overcome.  
This survey should take no more than 5-10 minutes to complete.  If you decide that you do not 
want to complete this study, please exit the study and your results will not be included in the final 
analysis.   There are five Coles-Myer vouchers available valued at $100 each, if you wish to put 
your name in to the draw for one of these vouchers, please include your name and email address 
at the end.  These details will not be linked with your response to the survey. 
If you have any questions regarding this study, please do not hesitate to contact: 
Felicity Veal (6226 2312; fveal@utas.edu.au) or 
Associate Professor Luke Bereznicki (Luke.Bereznicki@utas.edu.au). 
This project has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee. If you have concerns or complaints about the conduct of this project, please contact 
the Executive Officer of the HREC (Tasmania) Network on (03) 6226 6254 or email 
human.ethics@utas.edu.au. The Executive Officer is the person nominated to receive complaints 
from research participants. Please quote ethics reference number H0012833. 
 
There are 12 questions in this survey 
A survey of anaesthetists’ opinion about the management and barriers to optimal pain 
management 
 Where do you work? 
 Public Hospital - Consultant 
 Public Hospital - Registrar 
 Private Hospital - Consultant 
 Private Hospital - Registrar 
 Both a Public and Private Hospital - Consultant 
 Both a Public and Private Hospital - Registrar 
 
How long have you been working in anaesthetics? 
 
On average how many operations would you attend each week? 
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Which type of surgery do you most frequently attend? (please select all that apply) 
 Cardiothoracic 
 Vascular 
 Neurosurgery 
 General 
 Colorectal 
 OB/GYN 
 Orthopaedic 
 Plastic/reconstruction 
 Head/neck 
 Paediatric 
 Interventional radiological procedures 
 Day procedures 
 No specific area 
 Other:   
 
Which patient factor(s) do you consider increase the risk of ACUTE postoperative pain? 
 Depression 
 Anxiety 
 Pain catastrophising 
 Persistent pain - somatic 
 Persistent pain - visceral 
 Lower socioeconomic status 
 Lower educational status 
 Severity of pre-operative pain 
 Duration of pre-operative pain 
 Re-operation on the same site 
 Other:   
 
Which patient factor(s) do you consider increase the risk of PERSISTENT postoperative pain? 
 Depression 
 Anxiety 
 Pain catastrophising 
 Persistent pain - somatic 
 Persistent pain - visceral 
 Lower socioeconomic status 
 Lower educational status 
 Severity of pre-operative pain 
 Duration of pre-operative pain 
 Re-operation on the same site 
 Other:   
 
Which of following influences how you manage a patient during the perioperative period?  
 Hospital/department protocol 
 Australian guideline(s) 
 International guideline(s) 
 Patient factors 
 Operation factors 
 Clinical judgment 
 Other:   
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If you identify a patient as high risk for ACUTE postoperative pain, how does your management 
differ from your standard management? 
 Increased likelihood of using a regional anaesthesia 
 Increased likelihood of using an epidural 
 Increased likelihood of using a perioperative local anaesthetic 
 Increased likelihood of using perioperative ketamine 
 Increased likelihood of using perioperative parecoxib 
 Increased likelihood of prescribing a short course of gabapentin or pregabalin 
 Increased likelihood of prescribing patient controlled analgesia 
 Increased likelihood of prescribing postoperative ketamine infusion 
 Increased likelihood of prescribing postoperative local anaesthetic infusion 
 Other:   
 
If you identify a patient as high risk for PERSISTENT postoperative pain, how does your 
management differ from your standard management procedure? 
 Increased likelihood of using an epidural 
 Increased likelihood of using a regional anaesthesia 
 Increased likelihood of using perioperative parecoxib 
 Increased likelihood of using perioperative ketamine 
 Increased likelihood of using a perioperative local anaesthetic 
 Increased likelihood of prescribing a short course of gabapentin or pregabalin 
 Increased likelihood of prescribing postoperative ketamine infusion 
 Increased likelihood of prescribing postoperative local anaesthetic infusion 
 Increased likelihood of prescribing patient controlled analgesia 
 Other:   
 
Which, if any, of these measures do you think would assist in reducing the incidence 
of persistent postoperative pain? 
 Increased pre-surgical assessment to assess for psychological factors 
 Identification of predictors of persistent postoperative pain for use as in assessment tool 
 Pre-operative screening for pain catastrophising, anxiety and depression 
 Increased post-surgical assessment of neuropathic pain 
 Increased post-discharge follow-up 
 Other:   
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What do you think is the major barrier(s) to the management of acute pain following surgery?  
 Patients over using their analgesics 
 Patients under using their analgesics 
 Adverse events associated with medications 
 Other:   
 
What do you think is the major barrier(s) to the management of pain following hospital 
discharge? 
 Patients over using their analgesics 
 Patients under using their analgesics 
 Patients undertaking activities beyond recommendations 
 Slow/poor communication between hospital and GP regarding patient 
 Other:   
 
Many thanks for taking the time to complete this survey. 
We appreciate your assistance. 
If you wish enter the prize draw click the link below. 
 
